<SEC-DOCUMENT>0001564590-21-050582.txt : 20211012
<SEC-HEADER>0001564590-21-050582.hdr.sgml : 20211012
<ACCEPTANCE-DATETIME>20211012065044
ACCESSION NUMBER:		0001564590-21-050582
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20211012
DATE AS OF CHANGE:		20211012

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Relay Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001812364
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258768
		FILM NUMBER:		211316832

	BUSINESS ADDRESS:	
		STREET 1:		399 BINNEY STREET
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-370-8837

	MAIL ADDRESS:	
		STREET 1:		399 BINNEY STREET
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>rlay-424b5.htm
<DESCRIPTION>424B5
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-424b5.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed Pursuant to Rule 424(b)(5)</p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration Statement No. 333-258768</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.45%;text-indent:0%;color:#FF0000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FF0000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this preliminary prospectus supplement is not complete and may be changed.&nbsp;&nbsp;A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FF0000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#FF0000;font-size:10pt;">Subject To Completion</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FF0000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated October 12, 2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Prospectus Supplement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(to Prospectus dated August 12, 2021) </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$350,000,000</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gxr3kcgo1wwv000001.jpg" title="" alt="" style="width:243px;height:96px;"></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:39.71%;margin-right:39.62%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are offering $350,000,000 of shares of our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The Nasdaq Global Market under the symbol &#8220;RLAY&#8221;. The last sale price as reported on The Nasdaq Global Market on October 8, 2021, was $28.16 per share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company disclosure and reporting requirements. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:bold;letter-spacing:0.3pt;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves risks.&nbsp;&nbsp;See &#8220;<a href="#RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:bold;letter-spacing:0.3pt;font-style:normal;text-transform:none;font-variant: normal;">&#8221; on page S-8 of this prospectus supplement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Neither the Securities and Exchange Commission, any state securities commission nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete.&nbsp;&nbsp;Any representation to the contrary is a criminal offense.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:98.32%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial price to public</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underwriting discount<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds, before expenses, to us</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:481.45pt;;">
<tr>
<td style="width:9.8pt;"></td>
<td style="width:4.9pt;"></td>
<td style="width:466.75pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We refer you to &#8220;Underwriting&#8221; beginning on page S-24 of this prospectus supplement for additional information regarding underwriting compensation. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted the underwriters a 30-day option to purchase up to an additional $52,500,000 of shares of our common stock from us at the public offering price, less the underwriting discounts and commissions.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">______________________</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters expect to deliver the shares on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:26.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Goldman Sachs &amp; Co. LLC</p></td>
<td valign="top"  style="width:24.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">J.P. Morgan</p></td>
<td valign="top"  style="width:24.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cowen</p></td>
<td valign="top"  style="width:24.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guggenheim Securities</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">______________________</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prospectus Supplement dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman Bold;text-transform:uppercase;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman Bold;text-transform:uppercase;font-style:normal;font-variant: normal;">Table of Contents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS SUPPLEMENT</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ABOUT_THIS_PROSPECTUS_SUPPLEMENT"><font style="text-decoration:underline;">About This Prospectus Supplement</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PROSPECTUS_SUPPLEMENT_SUMMARY"><font style="text-decoration:underline;">Prospectus Supplement Summary</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-2</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FERING"><font style="text-decoration:underline;">The Offering</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-6</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"><font style="text-decoration:underline;">Cautionary Statement Regarding Forward-Looking Statements</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-14</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS"><font style="text-decoration:underline;">Use of Proceeds</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-16</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DIVIDEND_POLICY"><font style="text-decoration:underline;">Dividend Policy</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-17</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DILUTION"><font style="text-decoration:underline;">Dilution</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-18</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CERTAIN_MATERIAL_US_FEDERAL_INCOME_TAX_C"><font style="text-decoration:underline;">Certain Material U.S. Federal Income Tax Consequences for Non-U.S. Holders of Common Stock</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-20</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#UNDERWRITING"><font style="text-decoration:underline;">Underwriting</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-24</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS"><font style="text-decoration:underline;">Legal Matters</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-30</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS"><font style="text-decoration:underline;">Experts</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-30</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#WHERE_YOU_CAN_FIND_MORE_INFORMATION"><font style="text-decoration:underline;">Where You Can Find More Information</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-31</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INCORPORATION_BY_REFERENCE"><font style="text-decoration:underline;">Incorporation by Reference</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S-31</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ABOUT_THIS_PROSPECTUS"><font style="text-decoration:underline;">About This Prospectus</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS_1"><font style="text-decoration:underline;">Risk Factors</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"><font style="text-decoration:underline;">Cautionary Statement Regarding Forward-Looking Statements</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#COMPANY"><font style="text-decoration:underline;">The Company</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS_1"><font style="text-decoration:underline;">Use of Proceeds</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SECURITIES_WE_OR_SELLING_STOCKHOLDERS_M"><font style="text-decoration:underline;">Securities We and/or Selling Stockholders May Offer or Sell</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_CAPITAL_STOCK"><font style="text-decoration:underline;">Description of Capital Stock</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_DEBT_SECURITIES"><font style="text-decoration:underline;">Description of Debt Securities</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_WARRANTS"><font style="text-decoration:underline;">Description of Warrants</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_UNITS"><font style="text-decoration:underline;">Description of Units</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PLAN_DISTRIBUTION"><font style="text-decoration:underline;">Plan of Distribution</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS_1"><font style="text-decoration:underline;">Legal Matters</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS_1"><font style="text-decoration:underline;">Experts</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#WHERE_YOU_CAN_FIND_MORE_INFORMATION_1"><font style="text-decoration:underline;">Where You Can Find More Information</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INCORPORATION_BY_REFERENCE_1"><font style="text-decoration:underline;">Incorporation by Reference</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><a name="ABOUT_THIS_PROSPECTUS_SUPPLEMENT"></a><font style="font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="ABOUT_THIS_PROSPECTUS_SUPPLEMENT"></a>About This Prosp</font><font style="font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">ectus Supplement</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This document contains two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of common stock and also supplements and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus dated August 12, 2021, included in our registration statement on Form S-3ASR (File No. 333-258768), along with the documents incorporated by reference, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission, or the SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information contained in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in the accompanying prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement and the accompanying prospectus are part of a &#8220;shelf&#8221; registration statement that we filed with the SEC. Under the shelf registration process, we may offer from time to time various securities, of which this offering of shares of our common stock is a part. Such registration statement also includes exhibits that provide more detail on the matters discussed in this prospectus supplement and the accompanying prospectus. You should read this prospectus supplement, the accompanying prospectus, including the information incorporated by reference, the exhibits filed with the SEC, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. For investors outside the United States, we have not done anything that would permit this offering or possession or distribution of this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering outside the United States.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, along with the information contained in any free writing prospectus that we have authorized for use in connection with this offering. We have not, and the underwriters have not, authorized anyone to provide you with different or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the respective dates of those documents, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties and covenants were accurate only as of the date when made; therefore, such representations, warranties and covenants should not be relied on as accurate representations of the current state of our affairs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Unless otherwise indicated or the context suggests otherwise, references in this prospectus supplement and the accompanying prospectus to &#8220;Relay Therapeutics,&#8221; &#8220;Relay&#8221;, the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar designations refer to Relay Therapeutics, Inc. and, where appropriate, our consolidated subsidiaries.</font>&nbsp;&nbsp;When we refer to &#8220;you,&#8221; we mean the potential purchasers of our common stock in this offering. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:1.96%;padding-Right:1.96%;padding-Top:1.52%;padding-Bottom:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><a name="PROSPECTUS_SUPPLEMENT_SUMMARY"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="PROSPECTUS_SUPPLEMENT_SUMMARY"></a>Prospectus Supp</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">lement Summary</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This summary highlights certain information about us, this offering and selected information contained elsewhere in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including our financial statements and related notes and the other information incorporated by reference into this prospectus supplement and the accompanying prospectus, and the information included in any free writing prospectus that we have authorized for use in connection with this offering, including the information referred to under the heading &#8220;Risk Factors&#8221; in this prospectus supplement beginning on page S-<font style="color:#000000;">8</font> and in the documents incorporated herein by reference. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Company Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. We are among the first of a new breed of biotech created at the intersection of disparate disciplines. Our Dynamo&#8482; platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Our initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing a pipeline of medicines to address targets in precision oncology, including our lead product candidates, RLY-4008, RLY-2608 and RLY-1971. In the third quarter of 2020, we initiated a first-in-human clinical trial for RLY-4008, our inhibitor of fibroblast growth factor receptor 2, or FGFR2, focusing on patients with advanced solid tumors having oncogenic FGFR2 alterations. In October 2021, we announced initial clinical data from this trial, which is discussed below in &#8220;Recent Developments&#8212;RLY-4008.&#8221; In 2021, we initiated Investigational New Drug, or IND, enabling studies for RLY-2608, our inhibitor of cancer-associated mutant variants H1047X, E542X, and E545X of phosphoinostide 3-kinase alpha, or PI3K&#945;. RLY-2608 is the lead program of multiple preclinical efforts to discover and develop mutant selective inhibitors of PI3K&#945;. In October 2021, we also announced preclinical data for RLY-2608, which is discussed below in &#8220;Recent Developments&#8212;RLY-2608.&#8221; We initiated a Phase 1 clinical trial for RLY-1971, our inhibitor of Src homology region 2 domain-containing phosphatase-2, or SHP2, in patients with advanced solid tumors in the first quarter of 2020. In December 2020, we entered into a global collaboration and license agreement with Genentech, Inc., a member of the Roche Group, or Genentech, for the development and commercialization of RLY-1971. In July 2021, Genentech initiated the cohort of RLY-1971 in combination with GDC-6036, its KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> inhibitor, in a Phase 1b trial. While our initial focus is on precision oncology, we believe our Dynamo platform may also be broadly applied to other areas of precision medicine, such as genetic disease. In addition to the three product candidates described above, we have five discovery stage programs across both precision oncology and genetic disease indications. We are focused on using the novel insights derived from our approach to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of our therapies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision medicine emerged as an approach for disease treatment as the understanding of the links between genetic alterations, protein dysfunction and diseases evolved. Precision medicine aims to specifically and potently drug genetically validated target proteins (i.e., genetic variants potentially implicated in biology of disease). However, some target proteins thus far have been intractable or inadequately addressed using conventional drug discovery tools, such as structure-based drug design, or SBDD. While SBDD is well-suited to solving some drug discovery problems such as orthosteric site kinase inhibitors, its reliance on static images of protein fragments limits its ability to gain accurate insights into the dynamic behavior of proteins in their natural state, which in turn limits its ability to discover medicines with exquisite specificity. Our approach pivots the understanding of protein targets from the industry-standard, static view, to a novel paradigm based on fundamental insights into protein motion. We then apply these novel insights into protein motion to drug discovery and design, which we term Motion Based Drug Design<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font>, or MBDD. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>The confluence of three forces&#8212;the proliferation of readily available genomic data, the evolution of experimental techniques, and advancements in computational power and speed&#8212;led to the founding of Relay Therapeutics. We believe we are uniquely situated in our ability to consolidate these advances and, when combined with our world-</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:1.96%;padding-Right:1.96%;padding-Top:1.52%;padding-Bottom:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">class team of both experimental and computational experts, integrate these solutions into MBDD to create medicines that will make a </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transformative difference for patients. </font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Developments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RLY-2608</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 7, 2021, at the AACR-NCI-EORTC Molecular Targets Conference, we announced preclinical data for RLY-2608, our inhibitor of cancer-associated mutant PI3K&#945; variants H1047X, E542X and E545X. RLY-2608 is the lead program of our multiple preclinical efforts to discover and develop mutant selective inhibitors of PI3K&#945;. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The data show that in preclinical models, RLY-2608 preferentially binds mutant PI3K&#945; at a novel allosteric site discovered by our Dynamo platform. In biochemical and cellular assays, RLY-2608 inhibited the three major classes of PI3K&#945; oncogenic mutations (H1047X, E542X and E545X) while sparing wild-type PI3K&#945;. The data further suggest that RLY-2608 is also highly selective against other PI3K family members and exquisitely selective across the kinome. The data suggest that projected clinically relevant doses of RLY-2608 achieved tumor regression in PIK3CA mutant in vivo xenograft models representing H1047R and E545K mutations with significantly reduced impact on glucose metabolism compared to non-mutant selective active site inhibitors. In higher species, dosing of RLY-2608 resulted in exposures exceeding 90% inhibition of mutant PI3K&#945; in cells without resulting in elevated glucose levels or histopathological changes associated with dysregulation of glucose metabolism that are seen with non-mutant selective inhibitors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe these results support advancement of RLY-2608 into clinical development as a differentiated mechanism of mutant PI3K&#945; inhibition.&nbsp;&nbsp;In addition, we believe that due to the preclinical selectivity that RLY-2608 has shown against the PI3K&#945; mutant variants H1047X, E542X, and E545X, RLY-2608 could potentially address over 100,000 patients per year in the United States. We expect to initiate a first-in-human clinical trial of RLY-2608 in the first half of 2022, subject to submission and acceptance of an IND by the U.S. Food and Drug Administration, or FDA. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RLY-4008</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 8, 2021, at the AACR-NCI-EORTC Molecular Targets Conference, we also announced interim clinical data from our ongoing dose-escalation first-in-human clinical trial of RLY-4008, or the RLY-4008-101 Trial, in patients with FGFR2 altered tumors regardless of prior FGFR inhibitor treatment. The clinical trial is designed to determine the maximum tolerated dose and recommended Phase 2 dosing as well as assess initial safety and tolerability. Approximately 125 patients are planned to enroll in the trial, which is being conducted in two parts, a dose escalation (part 1) and a dose expansion (part 2). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the interim clinical data suggest robust inhibition of FGFR2 in the first 49 subjects that was not shown to be limited by off-target toxicities, including hyperphosphatemia and diarrhea. The initial toxicity data suggest that certain dose levels administered can achieve &gt;85% continuous inhibition of FGFR2. At those levels, acute toxicities that would limit dose intensity have generally not been observed to date. The interim clinical data included results from FGFR2-altered solid tumors, with approximately 80% of all patients treated having achieved reductions in tumor size as of September 9, 2021, or the Data Cut-off Date. In pan-FGFR inhibitor treatment-na&#239;ve cholangiocarcinoma patients, RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR treatment-na&#239;ve FGFR2 fusion positive cholangiocarcinoma patients, with three achieving confirmed partial responses. Three of these six patients remain on study and a fourth patient went on to surgery with curative intent. We plan to select a once daily recommended Phase 2 dose and initiate expansion cohorts of the RLY-4008-101 Trial prior to the end of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the Data Cut-off Date, 48 of the 49 patients enrolled had a primary FGFR2 alteration, of which a majority were FGFR2 fusion cholangiocarcinoma. Most patients had high disease burden with multiple prior treatments including pan-FGFR inhibitors, and several had FGFR2 resistance mutations detected by circulating tumor DNA, or ctDNA, at baseline. Patients were treated at nine different once daily, or QD, or twice daily, or BID, dose levels, ranging from 20 mg QD to 70 mg QD and 20 mg BID to 100 mg BID. As of the Data Cut-off Date, duration of treatment ranged from 4 to 45 weeks.</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:1.96%;padding-Right:1.96%;padding-Top:1.52%;padding-Bottom:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Initial Safety Analysis</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The interim clinical data of the RLY-4008-101 Trial indicate that RLY-4008 has generally been well tolerated in the 49 patients treated as of the Data Cut-Off Date. With regard to dosing, the QD dosing schedule has been prioritized due to its preferable tolerability (as only one dose limiting toxicity, or DLT, was observed across all dose levels) and high target coverage (lowest dose of 20 mg exceeded 85% receptor occupancy). Within the BID dosing schedule there were five DLTs observed, and receptor occupancy ranged from 90% to 98% across the BID doses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Across all QD doses only 16% of patients, all Grade 1 or 2, experienced hyperphosphatemia, a toxicity that has been shown to limit dose intensity for pan-FGFR inhibitors in other studies. These data indicate that RLY-4008 had little or no FGFR1 inhibition at the examined dose levels. Additionally, little or no diarrhea was observed with RLY-4008 treatment suggesting minimal or no FGFR4 inhibition in treated patients to date across dose levels. Together, the interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor in humans.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most treatment emergent adverse events were low-grade adverse events and manageable. There have been no Grade 4 or 5 adverse events. Given that retinal toxicity has been observed with FGFR inhibitor treatment, the trial is designed to assess retinopathy and retinal pigment epithelial dystrophy adverse events, which have been observed in seven patients (14%), three of which occurred in the QD dosing regimen. All seven of these events were Grade 1-2, which were self-limiting or resolved upon treatment interruption. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Initial Efficacy Analysis </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The interim clinical data of the RLY-4008-101 Trial indicate that RLY-4008 has the potential to provide tumor reduction across a number of FGFR2 alterations and lines of treatment. Key interim data include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Promising early activity in FGFR inhibitor na&#239;ve cholangiocarcinoma FGFR2 fusion patients, with confirmed RECISTv1.1 partial responses observed in 3 out of 6 patients with deep tumor regressions (-56% to -83%) and 3 out of 6 patients continuing on treatment and a fourth who went on to surgery with curative intent.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Radiographic tumor shrinkage and complete clearance of ctDNA in 70% of patients with acquired resistance mutations (N=10), including molecular brake (N550) and gatekeeper (V565) mutations, suggesting the potential for RLY-4008 to treat or prevent on-target acquired resistance. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk84432487"></a><a name="_Hlk84432470"></a><a name="_Hlk84432470"></a>Early signs of activity observed outside of FGFR2 fusion positive cholangiocarcinoma, including tumor reduction in 6 out of 8 evaluable patients with activating mutations (1 confirmed partial response, or PR, 1 unconfirmed PR, and 4 stable disease, or SD, (based on RECISTv1.1 criteria)) and 3 out of 3 patients with amplifications (all SD).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Approximately 80% of all patients treated achieved radiographic tumor regressions; this was observed across all dose levels, tumor types and FGFR2 alterations, and in patients with prior FGFR inhibitor treatment.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with the preclinical profile of RLY-4008, these early clinical data support our belief that RLY-4008 has broad therapeutic potential across FGFR2 alterations and tumor types.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate History </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the laws of the State of Delaware on May 4, 2015 under the name &#8220;Allostery, Inc.&#8221; Our principal corporate office is located at 399 Binney Street, 2nd Floor, Cambridge, MA 02139, and our telephone number is (617) 370-8837. Our website address is www.relaytx.com. We do not incorporate the information on or accessible through our website into this prospectus supplement, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus supplement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>We own various U.S. federal trademark applications and unregistered trademarks, including our company name. All other trademarks or trade names referred to in this prospectus supplement are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus supplement are referred to </p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:1.96%;padding-Right:1.96%;padding-Top:1.52%;padding-Bottom:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">without the &#174; and &#8482; symbols, but such references should not be constru</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. </font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Implications of Being an Emerging Growth Company and a Smaller Reporting Company</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">being permitted to only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reduced disclosure about our executive compensation arrangements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden parachute arrangements not previously approved; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of our initial public offering in July 2020, or IPO; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the last day of the fiscal year in which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th. We may choose to take advantage of some but not all of these exemptions. We will become a large accelerated filer for the fiscal year ending December 31, 2022, and as such we will lose emerging growth status on December 31, 2021. We have taken advantage of reduced reporting requirements in this prospectus supplement. Accordingly, the information contained herein and in the accompanying prospectus may be different from the information you receive from other public companies in which you hold stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. We will lose smaller reporting company status on December 31, 2021.</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:1.96%;padding-Right:1.96%;padding-Top:1.52%;padding-Bottom:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><a name="FERING"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="FERING"></a>The Of</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">fering</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:27%;"></td>
<td style="width:73%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.85%;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common stock offered by us </p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$350,000,000 of shares (or $402,500,000 of shares if the underwriters exercise their option to purchase additional shares in full).</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:0pt;;margin-right:3.85%;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common stock to be outstanding immediately after this offering </p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,428,977 shares (or 14,293,323 shares if the underwriters exercise their option to purchase additional shares in full), which is based on an aggregate offering of $350,000,000 of our common stock at an assumed public offering price of $28.16 per share (the last reported sale price of our common stock on The Nasdaq Global Market on October 8, 2021).</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.85%;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option to purchase additional shares </p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We have granted a&#160;30-day&#160;option to the underwriters to purchase up to an aggregate of </font>$52,500,000 of <font style="Background-color:#FFFFFF;">additional shares of common stock from us at the public offering price, less underwriting discounts and commissions on the same terms as set forth in this prospectus supplement.</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of proceeds </p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $332.0 million, or approximately $381.9 million if the underwriters exercise their option to purchase additional shares from us in full. We&#160;intend to use the net proceeds from this offering to fund research and clinical development of current or additional pipeline candidates, working capital, capital expenditures and other general corporate purposes. See &#8220;Use of Proceeds&#8221; on page S-16 of this prospectus supplement. </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;">Risk factors </font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page S-8 of this prospectus supplement, as well as &#8220;Risk Factors&#8221; in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, for a discussion of factors you should consider carefully before deciding to purchase any shares of our common stock. </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.85%;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global Market symbol </p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLAY </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All information in this prospectus supplement related to the number of shares of our common stock to be outstanding immediately after this offering is based on 92,552,645 shares of our common stock outstanding as of June 30, 2021. The number of shares outstanding as of June 30, 2021 as used throughout this prospectus supplement, unless otherwise indicated, excludes: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">8,906,194 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2021 under our 2020 Stock Option and Incentive Plan, or 2020 Plan, at a weighted-average exercise price of $13.16 per share; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">505,393 shares of common stock issuable upon the vesting and settlement of restricted stock units outstanding as of June 30, 2021 under our 2020 Plan; &#160;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">10,653,994 shares of common stock reserved for future issuance as of June 30, 2021 under our 2020 Plan; and&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">1,991,600 shares of common stock reserved for future issuance as of June 30, 2021 under our 2020 Employee Stock Purchase Plan. </p></td></tr></table></div></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div style="width:100%;border-top:Solid 0.75pt #000000;border-bottom:Solid 0.75pt #000000;border-left:Solid 0.75pt #000000;border-right:Solid 0.75pt #000000;">
<div style="padding-left:1.96%;padding-Right:1.96%;padding-Top:1.52%;padding-Bottom:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise indicated, all information in this prospectus supplement reflects and assumes the following:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">no exercise of outstanding stock options after June 30, 2021; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">no exercise by the underwriters of their option to purchase additional shares of our common stock. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the number of shares outstanding immediately after this offering does not include shares of common stock that we may offer and sell in the future pursuant to our sales agreement, or the Sales Agreement, with Cowen and Company, LLC, as sales agent. After the expiration or waiver of the 90-day lock-up period applicable to us and described under the section of this prospectus supplement entitled &#8220;Underwriting,&#8221; we may offer and sell shares of our common stock having an aggregate offering price of up to $300.0 million from time to time in &#8220;at-the-market&#8221; offerings pursuant to the Sales Agreement. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p></div></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><a name="RISK_FACTORS"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="RISK_FACTORS"></a>Risk F</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">actors</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Investing in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described below and in our most recent Annual Report on Form&#160;10-K&#160;and subsequent Quarterly Reports on Form&#160;10-Q&#160;and Current Reports on Form&#160;8-K,&#160;as well as any amendments thereto reflected in subsequent filings with the SEC, each of which are incorporated by reference in this prospectus supplement, and all of the other information in this prospectus supplement, including our financial statements and related notes incorporated by reference herein, </font>and in any free writing prospectus that we have authorized for use in connection with this offering before acquiring any of our common stock<font style="Background-color:#FFFFFF;">. These risks could result in material and adverse impact on our business, financial condition, results of operations and prospects, which could cause the trading price of our common stock to decline, and you could lose part or all of your investment. Additional risks and uncertainties that are not yet identified or that we currently believe to be immaterial may also materially harm our business, financial condition, results of operations and prospects and could result in a complete loss of your investment.</font> The risks discussed below also include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements. See &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of Material Risks Associated with Our Business</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Positive data from preclinical or early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive data from our preclinical or early clinical studies of our product candidates in our future clinical trials, we will be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our current or future clinical trials may reveal significant adverse events not seen in our preclinical or nonclinical studies or early clinical trial data and may result in a safety profile that would inhibit regulatory approval or market acceptance of any of our product candidates.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Although we intend to explore other therapeutic opportunities in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we are not able to obtain, or if delays occur in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be materially impaired.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Under our Amended and Restated Collaboration and License Agreement, or the DESRES Agreement, with D. E. Shaw Research, LLC, or D. E. Shaw Research, we collaborate with D. E. Shaw Research to rapidly develop various protein models, a process that depends on D. E. Shaw Research&#8217;s use of their proprietary supercomputer, Anton 2. A termination of the DESRES Agreement could have a material adverse effect on our business, financial condition, results of operations and prospects.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties to conduct our ongoing clinical trials of RLY-1971 and RLY-4008 and expect to rely on third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of our pro</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">duct candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d our business could be substantially harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have and may enter into other collaborations with third parties for the research, development, manufacture and commercialization of one or more of our programs or product candidates. If these collaborations are not successful, our business could be adversely affected.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We are a biopharmaceutical company with a limited operating history. We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. We have no products approved for commercial sale and have not generated any revenue from product sales.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we are unable to adequately protect our proprietary technology or obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours and our ability to successfully commercialize our technology and products will be impaired.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to this Offering and Our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The trading price of our common stock historically has been volatile, which may affect the price at which you could sell any shares of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price for our common stock historically has been volatile and could continue to be subject to wide fluctuations in response to various factors. <font style="Background-color:#FFFFFF;">Since shares of our common stock were sold in our IPO in July 2020 at a price of $20.00 per share, our stock price has fluctuated significantly, ranging from an intraday low of $25.72 to an intraday high of $64.37 through October 8, 2021. This volatility may affect the price at which you could resell the common stock. Our stock price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and other factors, including the factors described below. </font>The stock market in general and Nasdaq and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated or disproportionate to the operating performance of these companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price for our common stock may be influenced by many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of competitive products or technologies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">results of clinical trials of our product candidates or those of our competitors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory or legal developments in the United States and other countries; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the recruitment or departure of key personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the level of expenses related to any of our product candidates or clinical development programs; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:5pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:5pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:5pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in the structure of healthcare payment systems; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">market conditions in the pharmaceutical and biotechnology sectors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">general economic, industry and market conditions; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the other factors described in this &#8220;Risk Factors&#8221; section as well as the &#8220;Risk Factors&#8221; section in the documents incorporated by reference into this prospectus supplement. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our executive officers, directors, principal stockholders and their affiliates exercise significant control over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021, the holdings of our executive officers, directors, principal stockholders and their affiliates, including entities affiliated with SoftBank Vision Fund and FMR LLC represented beneficial ownership, in the aggregate, of approximately 40.1% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and control the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These stockholders may have interests, with respect to their common stock, that are different from those of our public market investors and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delaying, deferring or preventing a change of control of us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">impeding a merger, consolidation, takeover or other business combination involving us; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have broad discretion in the use of the net proceeds from this offering as well as our cash, cash equivalents and investments and may invest or spend the proceeds in ways with which you do not agree or in ways that ultimately may not increase the value of your investment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section entitled &#8220;Use of Proceeds,&#8221; as well as our existing cash, cash equivalents and investments, and you will be relying on the judgment of our management regarding such application. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds from this offering and our existing cash, cash equivalents or investments are being used effectively. Our management might not apply the net proceeds or our existing cash, cash equivalents or investments in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from this offering or our existing cash, cash equivalents or investments in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. <font style="Background-color:#FFFFFF;">Pending their use, we may invest the net proceeds from this offering in </font>short- and intermediate-term, interest-bearing obligations, investment-grade </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government</font><font style="Background-color:#FFFFFF;">. These investments may not yield a favorable retur</font><font style="Background-color:#FFFFFF;">n to our stockholders.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors purchasing shares of common stock in this offering will pay a price per share that substantially exceeds the net tangible book value per share of our common stock before giving effect to this offering. As a result, investors purchasing shares of common stock in this offering will incur immediate dilution of $19.13 per share based on an assumed public offering price of $28.16 per share, which was the last reported sale price of our common stock on The Nasdaq Global Market on October 8, 2021. For information on how the foregoing amounts were calculated, see &#8220;Dilution.&#8221; </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This dilution is due to the substantially lower price paid by some of our investors who purchased shares prior to this offering as compared to the price offered to the public in this offering. In addition, we have a significant number of stock options and unvested restricted stock units outstanding. The exercise of any of these outstanding options and vesting and settlement of these restricted stock units would result in further dilution. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately after this offering, see the section titled &#8220;Dilution.&#8221;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the&#160;percentage ownership of our stockholders and could cause our stock price to fall.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional capital will be needed in the future to continue our planned operations. To the extent we issue additional equity securities to raise capital or pursuant to our equity incentive plans or other contractual obligations, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell or issue common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, sales of a substantial number of shares of our outstanding common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Persons who were our stockholders prior to our initial public offering continue to hold a substantial number of shares of our common stock that many of them are now able to sell in the public market. Significant portions of these shares are held by a relatively small number of stockholders. Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, because we expect we will need to raise additional capital to fund our future activities, we may in the future sell substantial amounts of common stock or securities convertible into or exchangeable for common stock. Future issuances of common stock or common stock-related securities, together with the exercise of outstanding stock options, the vesting and settlement of outstanding restricted stock units, and new equity awards granted under our equity incentive plans, if any, may result in further dilution. Pursuant to the Sales Agreement, we may offer and sell up to an aggregate amount of $300.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings, subject to the limitations thereof. As of October 8, 2021, no shares of common stock have been sold under the Sales Agreement. To the extent that we sell shares of our common stock in the future pursuant to the Sales Agreement, after the expiration or waiver of the 90-day lock-up period applicable to us and described under the section of this prospectus supplement entitled &#8220;Underwriting,&#8221; investors purchasing shares of common stock in this offering could experience further dilution.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">An active trading market for our common stock may not be sustained. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">If an active market for our common stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at the time they would like to sell. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration</font>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Commencing December 31, 2021, we will no longer be an &#8220;emerging growth company&#8221; or a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to emerging growth companies will no longer apply to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;letter-spacing:0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently an emerging growth company but because as of June&#160;30, 2021, the market value of our common stock that was held by non-affiliates exceeded $700 million, we will no longer qualify for such status commencing December 31, 2021. As a large-accelerated filer, we will be subject to certain disclosure requirements that are applicable to other public companies that have not been applicable to us as an emerging growth company. These requirements include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">compliance with the auditor attestation requirements in the assessment of our internal control over financial reporting;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">compliance with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">full disclosure obligations regarding executive compensation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">compliance with the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also currently a smaller reporting company, but based on the market value of our common stock that was held by non-affiliates as of June&#160;30, 2021, we have determined that we will no longer be a smaller reporting company as of January 1, 2022. However, for so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not smaller reporting companies. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors. After January 1, 2022, we will no longer be able to rely on these reduced requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional Risks Related to Clinical Development</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. We have two product candidates, RLY-1971 and RLY-4008, in first-in-human clinical development. For RLY-2608, we initiated IND-enabling studies in 2021 and plan to initiate a first-in-human clinical study in the first half of 2022, subject to submission and acceptance of an IND by the FDA. We may not be able to file such IND or INDs for any of our other product candidates on the timelines we expect, if at all. For example, we may experience manufacturing delays with IND-enabling studies. Moreover, we cannot be sure that once we have submitted an IND, the FDA will allow clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. The FDA may impose a clinical hold before or after a trial begins for a number of reasons outlined in FDA regulations, including if the FDA believes the study drug raises a significant risk of illness or injury. If the FDA imposes a clinical hold, trials may not commence or recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, the submission of an IND does not mean the FDA will allow clinical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials to begin and, if and when clinical trials do commence under an active IND, issues may arise that requ</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ire suspension or termination of such trials. Further, commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regu</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">latory authorities is subject to change. Regulatory authorities could change their position, including, on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or impose stri</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting a new drug application, or NDA, to the FDA and a Marketing Authorization Application, or MAA, to the European Medicines Agency, </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or EMA, for each product candidate and, consequently, the ultimate approval and commercial marketing of each product candidate. Our RLY-1971 and RLY-4008 first-in-human clinical trials are ongoing, but we do not know whether any of our future clinical tria</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ls, including the</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> planned</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> first-in-human clinical trial for RLY-2608, will begin on time or ever be completed on schedule, if at all.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be delayed in obtaining marketing approval for our product candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">not obtain marketing approval at all;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be subject to post-marketing testing requirements; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#231F20;">have the product</font> removed from the market after obtaining marketing approval.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:5pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Positive results from preclinical or early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive results from our preclinical or earlier clinical studies of our product candidates in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any positive results from our preclinical or early clinical studies of our product candidates may not necessarily be predictive of the results of later clinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical and clinical studies or any future clinical trials of our product candidates according to our current development timeline, the positive results from such preclinical or earlier clinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or EMA approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><a name="CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"></a>Cautionary STATEMENT Regardin</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">g Forward-Looking Statements</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, and any free writing prospectus that we have authorized for use in connection with this offering, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act of 1934, as amended, or the Exchange Act. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking. These statements are often, but are not always, made through the use of words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; and similar expressions, or the negative of these terms, or similar expressions. Accordingly, these statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus supplement, and in particular those factors referenced in the section &#8220;Risk Factors.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement contains forward-looking statements that relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical and clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the identification of research priorities and application of a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential safety and efficacy of our product candidates and the implications of clinical and preclinical data;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the manufacture of our drug substances, delivery vehicles, and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our relationships with our third-party strategic collaborators and their ability to continue research and development activities relating to our development candidates and product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the funding for our operations necessary to complete further development and commercialization of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our plans to seek regulatory approval of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the pricing and reimbursement of our product candidates, if approved; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the implementation of our business model and strategic plans for our business, product candidates and technology; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope of protection for intellectual property rights covering our product candidates and technology; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">estimates of our future expenses, revenues and capital requirements and our needs for additional financing; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential benefits of strategic collaboration agreements with collaborators with development, regulatory and commercialization expertise; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">future agreements with third parties in connection with the commercialization of product candidates and any other approved product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the size and growth potential of the markets for our product candidates and our ability to serve those markets; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our financial performance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the rate and degree of market acceptance of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory developments in the United States and foreign countries; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of competing therapies that are or may become available; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to attract and retain key scientific or management personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact of laws and regulations on our business and programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developments relating to our competitors and our industry; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking statements are neither promises nor guarantees of future performance due to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those indicated by these forward-looking statements, including, without limitation the risk factors and cautionary statements described in other documents that we file from time to time with the SEC, specifically under &#8220;Item 1A: Risk Factors&#8221; and elsewhere in our most recent Annual Report on Form 10-K for the period ended December 31, 2020 and our most recent Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021, and our Current Reports on Form 8-K, and in this prospectus supplement under the heading &#8220;Risk Factors.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we may elect to update forward-looking statements at some point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement and the documents incorporated by reference also contain estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><a name="USE_PROCEEDS"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="USE_PROCEEDS"></a>Use of P</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">roceeds</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that we will receive net proceeds from this offering of approximately $332.0 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, or approximately $381.9 million if the underwriters exercise their option to purchase additional shares from us in full. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We&#160;intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, to fund research and clinical development of current or additional pipeline candidates, working capital, capital expenditures and other general corporate purposes.&nbsp;&nbsp;<font style="Background-color:#FFFFFF;">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve.&#160; </font>The amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under &#8220;Risk Factors&#8221; in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference herein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><a name="DIVIDEND_POLICY"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="DIVIDEND_POLICY"></a>Dividend</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"> Policy</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><a name="DILUTION"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="DILUTION"></a>Dilu</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">tion</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per share of our common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after this offering. The net tangible book value of our common stock as of June 30, 2021 was approximately $616.2 million, or approximately $6.66 per share of common stock based upon 92,552,645 shares outstanding. Net tangible book value per share is equal to our total tangible assets (total assets less intangible assets), less our total liabilities, divided by the total number of shares of common stock outstanding as of June 30, 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net tangible book value dilution per share to investors participating in this offering represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the as adjusted net tangible book value per share of common stock immediately after completion of this offering. After giving effect to the issuance and sale by us of 12,428,977 shares of our common stock at an assumed public offering price of $28.16 per share, which was the last reported sale price of our common stock on The Nasdaq Global Market on October 8, 2021, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2021 would have been $948.2 million, or $9.03 per share of our common stock. This represents an immediate increase in net tangible book value of $2.37 per share to our existing stockholders and an immediate dilution in as adjusted net tangible book value of $19.13 per share to new investors in this offering. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table illustrates this calculation on a per share basis without giving effect to the option to purchase additional shares granted to the underwriters:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumed public offering price per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.16  </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net tangible book value per share as of June 30, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.66  </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in net tangible book value per share attributable to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; this offering</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As adjusted net tangible book value per share after giving effect to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; this offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.03</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilution in net tangible book value per share to new investors in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; this offering</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each $1.00 increase in an assumed public offering price of $28.16&#160;per share, the last reported sale price of our common stock on The Nasdaq Global Market on October 8, 2021, would increase dilution per share to new investors by approximately $0.96 after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, to $20.09. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each $1.00 decrease in an assumed public offering price of $28.16 per share, the last reported sale price of our common stock on The Nasdaq Global Market on October 8, 2021, would decrease dilution per share to new investors by approximately $0.96 after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, to $18.17.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the underwriters exercise in full their option to purchase additional shares of common stock, the as adjusted net tangible book value after this offering would be $9.34 per share of our common stock, representing an increase of as adjusted net tangible book value of $2.68 per share to our existing stockholders and an immediate dilution of $18.82 per share to new investors purchasing shares in this offering. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information above and in the foregoing table is based upon 92,552,645 shares of our common stock outstanding as of June 30, 2021. The information above and in the foregoing table excludes:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">8,906,194 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2021 at a weighted-average exercise price of $13.16 per share; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">505,393 shares of common stock issuable upon the vesting and settlement of restricted stock units outstanding as of June 30, 2021; &#160;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-18</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,653,994 shares of common stock r</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eserved for future issuance as of June 30, 2021 under our 2020 Plan; and&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">1,991,600 shares of common stock reserved for future issuance as of June 30, 2021 under our 2020 Employee Stock Purchase Plan. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In addition, we may choose to raise additional capital in the future through the sale of equity or convertible debt securities due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.&#160;</font>To the extent that any of our outstanding options are exercised, shares of common stock are issued upon the vesting and settlement of our restricted stock units outstanding, new equity awards are granted under our equity incentive plans, additional shares of common stock are issued pursuant to the Sales Agreement with Cowen and Company, LLC or we otherwise issue additional shares of common stock or other equity or convertible debt securities in the future, there may be further dilution to investors participating in this offering. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-19</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><a name="CERTAIN_MATERIAL_US_FEDERAL_INCOME_TAX_C"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="CERTAIN_MATERIAL_US_FEDERAL_INCOME_TAX_C"></a>CERTAIN Material U.S. Federal Income Tax Consid</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">erations For Non-U.S. Holders OF COMMON STOCK</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following discussion is a summary of certain material U.S. federal income tax considerations applicable to non-U.S. holders (as defined below) with respect to their ownership and disposition of shares of our common stock. For purposes of this discussion, a non-U.S. holder means a beneficial owner of our common stock that is, for U.S. federal income tax purposes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a non-resident alien individual; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax purposes; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion does not address the tax treatment of partnerships or other entities or arrangements that are treated as pass-through entities for U.S. federal income tax purposes or persons that hold their shares of our common stock through partnerships or such other pass-through entities. The tax treatment of a partner in a partnership or other entity or arrangement that is treated as a pass-through entity for U.S. federal income tax purposes generally will depend upon the status of the partner and the activities of the partnership. A partner in a partnership or an investor in any other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus supplement and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax consequences to non-U.S. holders described in this prospectus supplement. There can be no assurance that the Internal Revenue Service, or the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion that a non-U.S. holder holds shares of our common stock as a capital asset, which is generally property held for investment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#8217;s individual circumstances, including the alternative minimum tax, the Medicare tax on net investment income or the rules relating to &#8220;qualified small business stock.&#8221; Any U.S. federal tax other than the income tax (including, for example, the estate tax), and it does not nor does it address any aspects of U.S. state, local or non-U.S. taxes. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">insurance companies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">tax-exempt or governmental organizations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">financial institutions; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">brokers or dealers in securities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulated investment companies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">pension plans; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#8220;qualified foreign pension funds,&#8221; or entities wholly owned by one or more &#8220;qualified foreign pension funds&#8221;; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-20</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and partners and investors therein); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">persons that have a functional currency other than the U.S. dollar; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">persons deemed to sell our common stock under the constructive sale provisions of the Code; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">persons that hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">investors in pass-through entities (or entities that are treated as disregarded entities for U.S. federal income tax purposes); and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">U.S. expatriates. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This discussion is for general information only and is not tax advice. Accordingly, all prospective non-U.S. holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local, estate and non-U.S. tax consequences of the purchase, ownership and disposition of our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Distributions on our common stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in the &#8220;Dividend Policy&#8221; section above, we do not intend to pay any cash dividends on our common stock in the foreseeable future. Distributions, if any, on shares of our common stock generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#8217;s investment, up to such holder&#8217;s tax basis in the shares of common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &#8220;Gain on sale or other taxable disposition of our shares of common stock.&#8221; Any such distributions will also be subject to the discussion below under the section titled &#8220;Withholding and information reporting requirements&#8212;FATCA.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussion in the following two paragraphs in this section, dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A non-U.S. holder of shares of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#8217;s country of residence generally will be required to provide a properly executed IRS Form W-8BEN or W-8BEN-E (or a successor form) to the applicable withholding agent and satisfy applicable certification and other requirements. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-21</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale, exchange or other taxable disposition of shares of our common</font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> stock </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussion below under &#8220;Withholding and information reporting requirements&#8212;FATCA,&#8221; a non-U.S. holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder&#8217;s sale, exchange or other taxable disposition of shares of our common stock unless: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the gain is effectively connected with the non-U.S. holder&#8217;s conduct of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such non-U.S. holder in the United States, in which case the non-U.S. holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the non-U.S. holder is a foreign corporation, the branch profits tax described above in &#8220;Distributions on our common stock&#8221; also may apply; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the non-U.S. holder is a nonresident alien individual who is present in the United States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the non-U.S. holder, if any (even though the individual is not considered a resident of the United States), provided that the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the non-U.S. holder&#8217;s holding period, if shorter) a &#8220;U.S. real property holding corporation,&#8221; unless our common stock is regularly traded on an established securities market, within the meaning of the relevant provisions of the Code, and the non-U.S. holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the five-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock. Generally, a corporation is a &#8220;U.S. real property holding corporation&#8221; only if the fair market value of its &#8220;U.S. real property interests&#8221; (as defined in the Code and applicable U.S. Treasury regulations) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. </p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Backup withholding and information reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on shares of our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on shares of our common stock. Generally, a non-U.S. holder will comply with such procedures if it provides a properly executed IRS Form W-8BEN or W-8BEN-E (or other applicable IRS Form W-8), or otherwise meets documentary evidence requirements for establishing that it is a non-U.S. holder, or otherwise establishes an exemption. Dividends paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above in &#8220;Distributions on our common stock,&#8221; generally will be exempt from U.S. backup withholding. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>Information reporting and backup withholding will generally apply to the proceeds of a disposition of shares of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or non-U.S., unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from a payment to a non-U.S. holder can be refunded or credited against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Withholding and information reporting requirements&#8212;FATCA </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax at a rate of 30% on payments of dividends on our common stock paid to a foreign entity unless (i) if the foreign entity is a &#8220;foreign financial institution,&#8221; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii) if the foreign entity is not a &#8220;foreign financial institution,&#8221; such foreign entity identifies certain of its U.S. investors, if any, or (iii) the foreign entity is otherwise exempt under FATCA. Such withholding may also apply to payments of gross proceeds of sales or other dispositions of shares of our common stock, although under proposed U.S. Treasury regulations (the preamble to which specifies that taxpayers, including withholding agents, are generally permitted to rely on them pending finalization), no withholding will apply to payments of gross proceeds. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our shares of common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA.<font style="font-weight:bold;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-23</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><a name="UNDERWRITING"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="UNDERWRITING"></a>Underwr</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">iting</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Guggenheim Securities, LLC are the representatives of the underwriters.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Underwriters</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goldman Sachs &amp; Co. LLC</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">J.P. Morgan Securities LLC</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cowen and Company, LLC</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guggenheim Securities, LLC</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the shares covered by the option described below unless and until this option is exercised.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters have an option to buy up to an additional $52,500,000 of shares from us. They may exercise that option for 30 days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase $52,500,000 of additional shares from us.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Paid by Relay Therapeutics, Inc.</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Full Exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares sold by the underwriters to the public will initially be offered at the public offering price set forth on the cover of this prospectus supplement. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the public offering price. After the initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any order in whole or in part.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<font style="font-style:italic;">&#160;</font>have agreed that, subject to certain limited exceptions, we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the&#160;Securities Act&#160;relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of Goldman Sachs &amp; Co. LLC and J.P. Morgan Securities LLC for a period of 90 days after the date of this prospectus supplement, other than the shares of our common stock to be sold in this offering.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a>Our directors and executive officers (such persons, the&#160;&#8220;lock-up&#160;parties&#8221;) have entered into&#160;lock-up&#160;agreements with the underwriters prior to the commencement of this offering pursuant to which each&#160;lock-up&#160;party, with limited exceptions, for a period of 90 days after the date of this prospectus supplement (such period, the &#8220;restricted period&#8221;), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of Goldman Sachs &amp; Co. LLC and J.P. Morgan Securities LLC, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may b</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e deemed to be beneficially owned by such&#160;lock-up&#160;parties in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the&#160;&#8220;lock-up&#160;securities&#8221;)),</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the&#160;lock-up&#160;securities, whether any such transaction described in clause (1) or (2) above is to be set</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tled by delivery of&#160;lock-up&#160;securities, in cash or otherwise, (3) make any demand for, or exercise any right with respect to, the registration of any&#160;lock-up&#160;securities, or (4) publicly disclose the intention to do any of the foregoing. Such persons or ent</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or co</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mbination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (by any person or entit</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any&#160;lock-up&#160;securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> settled by delivery of&#160;lock-up&#160;securities, in cash or otherwise.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restrictions described in the immediately preceding paragraph and contained in the&#160;lock-up&#160;agreements between the underwriters and the&#160;lock-up&#160;parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a) transfers of&#160;lock-up&#160;securities: (i) as a bona fide gift or gifts, or for bona fide estate planning purposes, (ii) by will or intestacy, (iii) to any trust for the direct or indirect benefit of the&#160;lock-up&#160;party or any immediate family member of the&#160;lock-up&#160;party, or, if the&#160;lock-up&#160;party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, (iv) to a partnership, limited liability company or other entity of which the&#160;lock-up&#160;party and its immediate family members are the legal and beneficial owner of all of the outstanding equity securities or similar interests, (v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv), (vi) in the case of a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate of the&#160;lock-up&#160;party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the&#160;lock-up&#160;party or its affiliates or (B) as part of a distribution to members or stockholders of the&#160;lock-up&#160;party; (vii) by operation of law, (viii) to us from an employee upon death, disability or termination of employment of such employee, (ix) as part of a sale of&#160;lock-up&#160;securities acquired in open market transactions after the completion of this offering, (x) to us in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of our common stock (including &#8220;net&#8221; or &#8220;cashless&#8221; exercise), including for the payment of exercise price and tax and remittance payments, or (xi) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction approved by our board of directors and made to all stockholders involving a change in control, provided that if such transaction is not completed, all such&#160;lock-up&#160;securities would remain subject to the restrictions in the immediately preceding paragraph; (b) exercise of the options, settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to our equity incentive plans (including &#8220;net&#8221; or &#8220;cashless&#8221; exercise, vesting or settlement), provided that any&#160;lock-up&#160;securities received upon such exercise, vesting or settlement would be subject to restrictions similar to those in the immediately preceding paragraph; (c) the conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible securities into shares of our common stock or warrants to acquire shares of our common stock, provided that any common stock or warrant received upon such conversion would be subject to restrictions similar to those in the immediately preceding paragraph; (d) the establishment by&#160;lock-up&#160;parties of trading plans under Rule&#160;10b5-1&#160;under the&#160;Exchange Act, provided that such plan does not provide for the transfer of&#160;lock-up&#160;securities during the restricted period; and (e) the sale of lock-up securities (including following the exercise of options to purchase common stock) pursuant to existing trading plans under Rule&#160;10b5-1&#160;under the&#160;Exchange Act .</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">J.P. Morgan Securities LLC and Goldman Sachs &amp; Co. LLC, in their sole discretion, may release the securities subject to any of the&#160;lock-up&#160;agreements with the underwriters described above, in whole or in part at any time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#8220;covered short position&#8221; is a short</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> position that is not greater than the amount of additional shares for which the underwriters&#8217; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> purchasing shares in the open market. In determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at wh</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ich they may purchase additional shares pursuant to the option described above. &#8220;Naked&#8221; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The und</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">erwriters must cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the op</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">en market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offerin</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on The Nasdaq Global Market, in the over-the-counter market or otherwise.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into derivative transactions with third parties, or sell securities not covered by this prospectus supplement to third parties in privately negotiated transactions. In connection with those derivatives, the third parties may sell securities covered by this prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter or will be identified in a post-effective amendment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $500,000. We have also agreed to reimburse the underwriters for certain of their expenses in an amount up to $35,000.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or will receive customary fees and expenses. For example, Cowen and Company, LLC is the sales agent under the Sales Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or short positions in such assets, securities and instruments.&nbsp;&nbsp;</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">European Economic Area and the United Kingdom </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In relation to each Member State of the European Economic Area and the United Kingdom (each a &#8220;Member State&#8221;), no common shares (the &#8220;Shares&#8221;) have been offered or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the Shares which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation), except that offers of Shares may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the Representatives for any such offer; or </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of Shares shall require the company or any Representative to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">United Kingdom</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each underwriter has represented and agreed that: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section&#160;21 of the Financial Services and Markets Act 2000 (FSMA)) received by it in connection with the issue or sale of the shares in circumstances in which Section&#160;21(1) of the FSMA does not apply to the company; and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares in, from or otherwise involving the United Kingdom.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Canada</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory of these rights or consult with a legal advisor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-27</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hong </font><font style="font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Kong</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares may not be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (&#8220;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#8221;) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (&#8220;Securities and Futures Ordinance&#8221;), or (ii) to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Singapore</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore.&nbsp;&nbsp;Accordingly, this prospectus supplement and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined under Section 4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#8220;SFA&#8221;)) under Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section 239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer in that corporation&#8217;s securities pursuant to Section 275(1A) of the SFA, (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (&#8220;Regulation 32&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section 4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>Singapore SFA Product Classification&#8212;In connection with Section 309B of the SFA and the Securities and Futures (Capital Markets Products) Regulations 2018 (the &#8220;CMP Regulations 2018&#8221;), the Company has determined, and hereby notifies all relevant persons (as defined in the CMP Regulations 2018), that the shares are &#8220;prescribed capital markets products&#8221; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-28</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Japan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (the &#8220;FIEA&#8221;) (Act No. 25 of 1948, as amended). The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-29</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><a name="LEGAL_MATTERS"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="LEGAL_MATTERS"></a>Legal M</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">atters</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain legal matters in connection with this offering will be passed upon for the underwriters by Ropes &amp; Gray LLP, Boston, Massachusetts. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="EXPERTS"></a><a name="EXPERTS"></a>Experts</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, as set forth in their report, which is incorporated by reference in this prospectus supplement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.85%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-30</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION"></a>Where You Can Find</font><font style="font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"> More Information</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at<font style="font-style:italic;"> www.sec.gov</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our web site address is<font style="font-style:italic;"> www.relaytx.com</font>. The information on our web site, however, is not, and should not be deemed to be, a part of this prospectus supplement or the accompanying prospectus. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement and the accompanying prospectus is part of a registration statement on Form S-3 that we filed with the SEC and does not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided above. Statements in this prospectus supplement and the accompanying prospectus about any documents filed as exhibits to the registration statement are summaries, and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC&#8217;s website, as provided above. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="INCORPORATION_BY_REFERENCE"></a><a name="INCORPORATION_BY_REFERENCE"></a>Incorporation By Reference</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we file later with the SEC will automatically update and supersede the information already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC (SEC File No. 001-39385), and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including all filings made after the date of this prospectus supplement, except as to any portion of any future report or document that is not deemed filed under such provisions until we sell all of the securities: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Annual Report on <a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021015518/rlay-10k_20201231.htm"><font style="text-decoration:underline;color:#000000;">Form 10-K</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the year ended December 31, 2020, filed with the SEC on March 25, 2021; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information specifically incorporated by reference into our Annual Report on <a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021015518/rlay-10k_20201231.htm"><font style="text-decoration:underline;color:#000000;">Form 10-K</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the year ended December 31, 2020 from our definitive proxy statement on </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021015518/rlay-10k_20201231.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021018016/rlay-def14a_20210519.htm"><font style="text-decoration:underline;color:#000000;">Schedule 14A</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (other than information furnished rather than filed), which was filed with the SEC on April 7, 2021; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quarterly Reports on Form 10-Q filed with the SEC for the quarters ended March 31, 2021 and June 30, 2021, filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021027601/rlay-10q_20210331.htm"><font style="text-decoration:underline;color:#000000;">May 13, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021027601/rlay-10q_20210331.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021043999/rlay-10q_20210630.htm"><font style="text-decoration:underline;color:#000000;">August 12, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Current Reports on Form 8-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312521118438/d110953d8k.htm"><font style="text-decoration:underline;color:#000000;">April 16, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312521118438/d110953d8k.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021028867/rlay-8k_20210519.htm"><font style="text-decoration:underline;color:#000000;">May 19, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312521118438/d110953d8k.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021028867/rlay-8k_20210519.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021030437/rlay-8k_20210518.htm"><font style="text-decoration:underline;color:#000000;">May 27, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312521118438/d110953d8k.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021028867/rlay-8k_20210519.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021030437/rlay-8k_20210518.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312521294713/d228629d8k.htm"><font style="text-decoration:underline;color:#000000;">October 8, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, excluding, in each case, information &#8220;furnished&#8221; pursuant to Items 2.02, 7.01 or 9.01; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The description of our common stock contained in our Registration Statement on <a href="http://www.sec.gov/Archives/edgar/data/1812364/000119312520191867/d948089d8a12b.htm"><font style="text-decoration:underline;color:#000000;">Form 8-A</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (File No. 001-39385) as filed with the SEC on July 13, 2020, including any amendments or reports filed for the purpose of updating this description, including Exhibit 4.3 to our Annual Report on </font><a href="http://www.sec.gov/Archives/edgar/data/1812364/000119312520191867/d948089d8a12b.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021015518/rlay-10k_20201231.htm"><font style="text-decoration:underline;color:#000000;">Form 10-K</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the year ended December 31, 2020, as filed with the SEC on March 25, 2021. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus supplement is delivered, a copy of the documents incorporated by reference into this prospectus supplement but not delivered with the prospectus supplement. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus supplement, at no cost by writing or telephoning us at the following address: Relay Therapeutics, Inc., 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139, telephone: (617) 370-8837. You may also access these documents, free of charge on the SEC&#8217;s website at <font style="font-style:italic;">www.sec.gov</font> or on our website at <font style="font-style:italic;">www.relaytx.com</font>. Information contained on our website is not incorporated by reference into this prospectus supplement, and you should not consider any information on, or that can be accessed from, our website as part of this prospectus supplement or any accompanying prospectus supplement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-31</a>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, unless specifically stated to the contrary, information that we furnish (and that is not deemed &#8220;filed&#8221; w</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ith the SEC) under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, is not incorporated by reference into this prospectus supplement or the registration statement of which this prospectus supplement is </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a part. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus supplement and the accompanying prospectus are part of a registration statement we filed with the SEC. We have incorporated exhibits into the registration statement. You should read the exhibits carefully for provisions that may be important to you. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should rely only on the information incorporated by reference or provided in this prospectus supplement and the accompanying prospectus. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement, the accompanying prospectus or in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus supplement or those documents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Any statement contained in a document that is incorporated by reference will be modified or superseded for all purposes to the extent that a statement contained in this prospectus, or in any other document that is subsequently filed with the SEC and incorporated by reference into this prospectus supplement and the accompanying prospectus, modifies or is contrary to that previous statement. Any statement so modified or superseded will not be deemed a part of this prospectus supplement and the accompanying prospectus, except as so modified or superseded. Since information that we later file with the SEC will update and supersede previously incorporated information, you should look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any documents previously incorporated by reference have been modified or superseded.</font></p>
<p style="margin-top:36pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:18pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-32</a>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gxr3kcgo1wwv000002.jpg" title="" alt="" style="width:244px;height:93px;"></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:20.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred<font style="letter-spacing:-0.8pt;"> </font>Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Debt Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="text-align:center;line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Units</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time<font style="letter-spacing:0.05pt;"> </font>issue,<font style="letter-spacing:0.05pt;"> </font>in one or more<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>or classes,<font style="letter-spacing:0.05pt;"> </font>our common<font style="letter-spacing:0.05pt;"> </font>stock, preferred<font style="letter-spacing:0.1pt;"> </font>stock, debt<font style="letter-spacing:0.05pt;"> </font>securities,<font style="letter-spacing:0.05pt;"> </font>warrants and/or<font style="letter-spacing:0.05pt;"> </font>units. We may<font style="letter-spacing:-0.05pt;"> </font>offer these<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.05pt;"> </font>separately<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>together in units. We will<font style="letter-spacing:-0.05pt;"> </font>specify in the applicable<font style="letter-spacing:0.1pt;"> </font>accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>the terms<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>being offered.<font style="letter-spacing:0.05pt;"> </font>We<font style="letter-spacing:0.05pt;"> </font>may sell these securities<font style="letter-spacing:0.1pt;"> </font>to or through underwriters<font style="letter-spacing:0.1pt;"> </font>and also to other<font style="letter-spacing:0.05pt;"> </font>purchasers<font style="letter-spacing:0.05pt;"> </font>or through agents.<font style="letter-spacing:0.05pt;"> </font>We will set forth<font style="letter-spacing:0.05pt;"> </font>the names<font style="letter-spacing:0.05pt;"> </font>of any underwriters<font style="letter-spacing:0.1pt;"> </font>or agents,<font style="letter-spacing:0.05pt;"> </font>and any fees,<font style="letter-spacing:0.05pt;"> </font>conversions<font style="letter-spacing:0.05pt;"> </font>or discount<font style="letter-spacing:0.05pt;"> </font>arrangements,<font style="letter-spacing:0.1pt;"> </font>in the applicable<font style="letter-spacing:0.05pt;"> </font>accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>We may not sell<font style="letter-spacing:0.05pt;"> </font>any securities<font style="letter-spacing:0.1pt;"> </font>under this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>without delivery<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this document and any prospectus supplement or amendment carefully before you invest in our securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;RLAY.&#8221; On August 9, 2021, the closing price<font style="letter-spacing:0.05pt;"> </font>for our common<font style="letter-spacing:0.05pt;"> </font>stock, as reported<font style="letter-spacing:0.05pt;"> </font>on the Nasdaq Global Market,<font style="letter-spacing:0.05pt;"> </font>was $33.50 per share.<font style="letter-spacing:0.05pt;"> </font>Our<font style="letter-spacing:0.05pt;"> </font>principal<font style="letter-spacing:0.1pt;"> </font>executive<font style="letter-spacing:0.05pt;"> </font>office<font style="letter-spacing:0.05pt;"> </font>is located<font style="letter-spacing:0.05pt;"> </font>at 399 Binney Street,<font style="letter-spacing:0.05pt;"> </font>2nd Floor, Cambridge,<font style="letter-spacing:0.05pt;"> </font>MA<font style="letter-spacing:-0.05pt;"> </font>02139.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading &#8220;<a href="#RISK_FACTORS_1"><font style="text-decoration:underline;color:#000000;">Risk Factors</font></a><font style="font-weight:bold;color:#231F20;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8221; contained in this</font><font style="letter-spacing:0.05pt;"> </font>prospectus beginning on page 2 and any applicable prospectus supplement, and under<font style="letter-spacing:0.05pt;"> </font>similar headings in the other documents that are incorporated by reference into this<font style="letter-spacing:0.05pt;"> </font>prospectus.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Neither the Securities<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>Exchange<font style="letter-spacing:-0.05pt;"> </font>Commission<font style="letter-spacing:0.05pt;"> </font>nor any<font style="letter-spacing:-0.05pt;"> </font>state<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>commission<font style="letter-spacing:0.1pt;"> </font>has approved<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal<font style="letter-spacing:0.05pt;"> </font>offense.</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:-0.1pt;"> </font>date of this Prospectus is August<font style="letter-spacing:-0.05pt;"> </font>12, 2021.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF CONTENTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:96.21%;"></td>
<td style="width:3.79%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#231F20;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ABOUT_THIS_PROSPECTUS"><font style="text-decoration:underline;">About This Prospectus</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RISK_FACTORS_1"><font style="text-decoration:underline;">Risk Factors</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"><font style="text-decoration:underline;">Cautionary</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Statement</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Regarding Forward-Looking</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Statements</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#COMPANY"><font style="text-decoration:underline;">The Company</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#USE_PROCEEDS_1"><font style="text-decoration:underline;">Use of Proceeds</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SECURITIES_WE_OR_SELLING_STOCKHOLDERS_M"><font style="text-decoration:underline;">Securities</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">We and/or</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Selling</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Stockholders</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">May Offer</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">or Sell</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_CAPITAL_STOCK"><font style="text-decoration:underline;">Description</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of Capital</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Stock</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_DEBT_SECURITIES"><font style="text-decoration:underline;">Description</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of Debt Securities</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_WARRANTS"><font style="text-decoration:underline;">Description</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of Warrants</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DESCRIPTION_UNITS"><font style="text-decoration:underline;">Description</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of Units</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PLAN_DISTRIBUTION"><font style="text-decoration:underline;">Plan of Distribution</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LEGAL_MATTERS_1"><font style="text-decoration:underline;">Legal Matters</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#EXPERTS_1"><font style="text-decoration:underline;">Experts</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#WHERE_YOU_CAN_FIND_MORE_INFORMATION_1"><font style="text-decoration:underline;">Where</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">You</font><font style="letter-spacing:-0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Can</font><font style="letter-spacing:-0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Find More Information</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INCORPORATION_BY_REFERENCE_1"><font style="text-decoration:underline;">Incorporation</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">by Reference</font></a><font style="text-decoration:none;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><a name="ABOUT_THIS_PROSPECTUS"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ABOUT</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ABOUT_THIS_PROSPECTUS"></a>THIS </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROSPECTUS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus<font style="letter-spacing:0.05pt;"> </font>is part<font style="letter-spacing:0.05pt;"> </font>of an automatic<font style="letter-spacing:0.1pt;"> </font>shelf<font style="letter-spacing:0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>on Form S-3 that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>filed<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>the Securities<font style="letter-spacing:0.05pt;"> </font>and Exchange Commission,<font style="letter-spacing:0.05pt;"> </font>or the SEC,<font style="letter-spacing:-0.05pt;"> </font>as a &#8220;well-known seasoned<font style="letter-spacing:0.05pt;"> </font>issuer&#8221;<font style="letter-spacing:0.05pt;"> </font>as defined<font style="letter-spacing:0.05pt;"> </font>in Rule 405 under the<font style="letter-spacing:0.05pt;"> </font>Securities<font style="letter-spacing:0.1pt;"> </font>Act. Under the shelf<font style="letter-spacing:0.05pt;"> </font>registration,<font style="letter-spacing:0.15pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>and/or<font style="letter-spacing:0.05pt;"> </font>selling<font style="letter-spacing:0.05pt;"> </font>stockholders<font style="letter-spacing:0.1pt;"> </font>may offer<font style="letter-spacing:0.05pt;"> </font>or sell<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of our<font style="letter-spacing:0.05pt;"> </font>common stock<font style="letter-spacing:-0.05pt;"> </font>and preferred<font style="letter-spacing:0.05pt;"> </font>stock,<font style="letter-spacing:-0.05pt;"> </font>various<font style="letter-spacing:0.05pt;"> </font>series of warrants to<font style="letter-spacing:-0.05pt;"> </font>purchase<font style="letter-spacing:0.05pt;"> </font>common stock<font style="letter-spacing:-0.05pt;"> </font>or preferred<font style="letter-spacing:0.05pt;"> </font>stock, debt <font style="letter-spacing:-2.35pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>or any combination<font style="letter-spacing:0.1pt;"> </font>thereof,<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time<font style="letter-spacing:0.05pt;"> </font>in one or more<font style="letter-spacing:0.05pt;"> </font>offerings.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus<font style="letter-spacing:0.05pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>you with a general<font style="letter-spacing:0.05pt;"> </font>description<font style="letter-spacing:0.1pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>and/or<font style="letter-spacing:0.05pt;"> </font>selling<font style="letter-spacing:0.05pt;"> </font>stockholders<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>or sell. Each time<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>sell<font style="letter-spacing:0.05pt;"> </font>securities,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>one or more<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplements<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>will contain<font style="letter-spacing:0.05pt;"> </font>specific<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>about the terms<font style="letter-spacing:0.05pt;"> </font>of the offering.<font style="letter-spacing:0.05pt;"> </font>The applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>may also<font style="letter-spacing:0.05pt;"> </font>add, update <font style="letter-spacing:-2.35pt;"> </font>or change information contained in this prospectus. You should read both this prospectus and any accompanying <font style="letter-spacing:-2.35pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>with the additional<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>under the heading &#8220;Where<font style="letter-spacing:0.05pt;"> </font>You<font style="letter-spacing:-0.05pt;"> </font>Can<font style="letter-spacing:0.05pt;"> </font>Find More Information&#8221;<font style="letter-spacing:0.1pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>on page 26 of this<font style="letter-spacing:0.05pt;"> </font>prospectus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You<font style="letter-spacing:-0.05pt;"> </font>should rely<font style="letter-spacing:0.05pt;"> </font>only on the information<font style="letter-spacing:0.1pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>in or incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>or in any related<font style="letter-spacing:0.05pt;"> </font>free<font style="letter-spacing:0.05pt;"> </font>writing<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>filed<font style="letter-spacing:0.05pt;"> </font>by us with the SEC.<font style="letter-spacing:-0.05pt;"> </font>We<font style="letter-spacing:0.05pt;"> </font>have not authorized<font style="letter-spacing:0.05pt;"> </font>anyone to provide<font style="letter-spacing:0.05pt;"> </font>you with different<font style="letter-spacing:0.1pt;"> </font>information.<font style="letter-spacing:0.1pt;"> </font>This prospectus<font style="letter-spacing:0.05pt;"> </font>and the accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>do not constitute<font style="letter-spacing:0.1pt;"> </font>an offer<font style="letter-spacing:0.05pt;"> </font>to sell<font style="letter-spacing:0.05pt;"> </font>or the solicitation<font style="letter-spacing:0.15pt;"> </font>of an offer<font style="letter-spacing:0.05pt;"> </font>to buy any securities<font style="letter-spacing:0.15pt;"> </font>other <font style="letter-spacing:-2.35pt;"> </font>than the securities<font style="letter-spacing:0.1pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in the accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>or an offer<font style="letter-spacing:0.05pt;"> </font>to sell<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>the solicitation<font style="letter-spacing:0.15pt;"> </font>of <font style="letter-spacing:-2.35pt;"> </font>an offer<font style="letter-spacing:0.05pt;"> </font>to buy such securities<font style="letter-spacing:0.1pt;"> </font>in any circumstances<font style="letter-spacing:0.15pt;"> </font>in which such offer<font style="letter-spacing:0.05pt;"> </font>or solicitation<font style="letter-spacing:0.15pt;"> </font>is unlawful.<font style="letter-spacing:0.05pt;"> </font>You<font style="letter-spacing:-0.05pt;"> </font>should<font style="letter-spacing:0.05pt;"> </font>assume<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the information<font style="letter-spacing:0.1pt;"> </font>appearing<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus,<font style="letter-spacing:0.05pt;"> </font>any prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>the documents<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>and any related<font style="letter-spacing:0.05pt;"> </font>free<font style="letter-spacing:0.05pt;"> </font>writing<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>is accurate<font style="letter-spacing:0.05pt;"> </font>only as of their<font style="letter-spacing:0.05pt;"> </font>respective<font style="letter-spacing:0.1pt;"> </font>dates.<font style="color:#000000;"> </font>Our<font style="letter-spacing:-0.05pt;"> </font>business, financial<font style="letter-spacing:0.05pt;"> </font>condition, results<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>operations and<font style="letter-spacing:-0.05pt;"> </font>prospects<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:-0.05pt;"> </font>have<font style="letter-spacing:-0.05pt;"> </font>changed<font style="letter-spacing:-0.05pt;"> </font>materially<font style="letter-spacing:0.15pt;"> </font>since those <font style="letter-spacing:-2.35pt;"> </font>dates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the context suggests otherwise, all references to &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Relay Therapeutics,&#8221; &#8220;we,&#8221; the &#8220;Company&#8221;<font style="letter-spacing:-2.35pt;"> </font>and similar<font style="letter-spacing:0.1pt;"> </font>designations<font style="letter-spacing:0.1pt;"> </font>refer<font style="letter-spacing:0.05pt;"> </font>to Relay Therapeutics,<font style="letter-spacing:0.1pt;"> </font>Inc. and, where appropriate,<font style="letter-spacing:0.1pt;"> </font>our consolidated<font style="letter-spacing:0.1pt;"> </font>subsidiaries.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><a name="RISK_FACTORS_1"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RISK</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="RISK_FACTORS_1"></a>FA</font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CTORS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing<font style="letter-spacing:0.05pt;"> </font>in our securities<font style="letter-spacing:0.1pt;"> </font>involves<font style="letter-spacing:0.05pt;"> </font>a high degree<font style="letter-spacing:0.05pt;"> </font>of risk.<font style="letter-spacing:0.05pt;"> </font>You<font style="letter-spacing:-0.05pt;"> </font>should carefully<font style="letter-spacing:0.1pt;"> </font>consider<font style="letter-spacing:0.05pt;"> </font>the risks<font style="letter-spacing:0.05pt;"> </font>referenced<font style="letter-spacing:0.05pt;"> </font>below and described in the documents incorporated by reference in this prospectus and any applicable prospectus supplement,<font style="letter-spacing:0.05pt;"> </font>as well as other<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>include<font style="letter-spacing:0.05pt;"> </font>or incorporate<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>into this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>and any<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>making<font style="letter-spacing:0.05pt;"> </font>an investment<font style="letter-spacing:0.1pt;"> </font>decision.<font style="letter-spacing:0.05pt;"> </font>Our business,<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>condition<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>of operations<font style="letter-spacing:0.05pt;"> </font>could be materially<font style="letter-spacing:0.15pt;"> </font>adversely<font style="letter-spacing:0.05pt;"> </font>affected<font style="letter-spacing:0.1pt;"> </font>by the materialization<font style="letter-spacing:0.2pt;"> </font>of any of these<font style="letter-spacing:0.05pt;"> </font>risks.<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:0.05pt;"> </font>trading<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of our securities<font style="letter-spacing:0.1pt;"> </font>could decline<font style="letter-spacing:0.05pt;"> </font>due to the materialization<font style="letter-spacing:0.2pt;"> </font>of any of these<font style="letter-spacing:0.05pt;"> </font>risks,<font style="letter-spacing:0.1pt;"> </font>and you may lose all<font style="letter-spacing:0.05pt;"> </font>or part<font style="letter-spacing:0.05pt;"> </font>of your investment.<font style="letter-spacing:0.1pt;"> </font>This prospectus<font style="letter-spacing:0.05pt;"> </font>and the documents<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>herein<font style="letter-spacing:0.05pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>also contain<font style="letter-spacing:0.05pt;"> </font>forward-looking<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>involve<font style="letter-spacing:0.05pt;"> </font>risks<font style="letter-spacing:0.05pt;"> </font>and uncertainties.<font style="letter-spacing:0.15pt;"> </font>Actual results<font style="letter-spacing:0.05pt;"> </font>could differ<font style="letter-spacing:0.05pt;"> </font>materially<font style="letter-spacing:0.15pt;"> </font>from<font style="letter-spacing:0.1pt;"> </font>those<font style="letter-spacing:0.05pt;"> </font>anticipated<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>forward-looking<font style="letter-spacing:0.05pt;"> </font>statements<font style="letter-spacing:0.05pt;"> </font>as a<font style="letter-spacing:-0.05pt;"> </font>result<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>certain factors,<font style="letter-spacing:0.05pt;"> </font>including the risks referenced<font style="letter-spacing:0.05pt;"> below and</font> described<font style="letter-spacing:0.05pt;"> </font>in the documents<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>herein<font style="letter-spacing:0.05pt;"> </font>by reference,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>our annual report<font style="letter-spacing:0.05pt;"> </font>on Form 10-K<font style="letter-spacing:0.05pt;"> </font>for the fiscal<font style="letter-spacing:0.05pt;"> </font>year ended December<font style="letter-spacing:0.05pt;"> </font>31, 2020, which is on file<font style="letter-spacing:0.05pt;"> </font>with the SEC<font style="letter-spacing:-0.05pt;"> </font>and is incorporated<font style="letter-spacing:0.1pt;"> </font>herein<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>reference,<font style="letter-spacing:0.1pt;"> </font>(ii)<font style="letter-spacing:0.05pt;"> </font>our quarterly<font style="letter-spacing:0.1pt;"> </font>reports<font style="letter-spacing:0.05pt;"> </font>on Form 10-Q for the quarters<font style="letter-spacing:0.05pt;"> </font>ended March<font style="letter-spacing:0.05pt;"> </font>31, 2021 and June 30, 2021,<font style="letter-spacing:0.05pt;"> </font>which are on file<font style="letter-spacing:0.05pt;"> </font>with the SEC<font style="letter-spacing:-0.05pt;"> </font>and incorporated<font style="letter-spacing:0.1pt;"> </font>herein<font style="letter-spacing:0.05pt;"> </font>by reference,<font style="letter-spacing:0.1pt;"> </font>and (iii)<font style="letter-spacing:0.1pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>documents<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>file<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>SEC<font style="letter-spacing:-0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are deemed<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>into this<font style="letter-spacing:0.05pt;"> </font>prospectus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><a name="CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CAUTIONARY</font><font style="letter-spacing:-0.2pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REGARDING</font><font style="letter-spacing:-0.1pt;"><a name="CAUTIONARY_NOTE_REGARDING_FORWARDLOOKING"></a> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus,<font style="letter-spacing:0.05pt;"> </font>any applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>any related<font style="letter-spacing:0.05pt;"> </font>free<font style="letter-spacing:0.05pt;"> </font>writing<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>and the documents<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>incorporate<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>herein<font style="letter-spacing:0.05pt;"> </font>or therein<font style="letter-spacing:0.05pt;"> </font>contain<font style="letter-spacing:0.05pt;"> </font>forward-looking<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>within the meaning<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>Section<font style="letter-spacing:0.05pt;"> </font>27A<font style="letter-spacing:-0.05pt;"> </font>of the Securities<font style="letter-spacing:0.1pt;"> </font>Act, and Section<font style="letter-spacing:0.05pt;"> </font>21E<font style="letter-spacing:-0.05pt;"> </font>of the Securities<font style="letter-spacing:0.1pt;"> </font>Exchange Act of 1934, as amended,<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>Exchange<font style="letter-spacing:-0.05pt;"> </font>Act.<font style="letter-spacing:-0.05pt;"> </font>Any<font style="letter-spacing:-0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>about<font style="letter-spacing:-0.05pt;"> </font>our<font style="letter-spacing:-0.05pt;"> </font>expectations,<font style="letter-spacing:0.1pt;"> </font>beliefs, plans,<font style="letter-spacing:-0.05pt;"> </font>objectives,<font style="letter-spacing:0.05pt;"> </font>assumptions<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>future events<font style="letter-spacing:0.05pt;"> </font>or <font style="letter-spacing:-2.35pt;"> </font>performance<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:-0.05pt;"> </font>not historical<font style="letter-spacing:0.05pt;"> </font>facts<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>may be<font style="letter-spacing:-0.05pt;"> </font>forward-looking.<font style="letter-spacing:0.1pt;"> </font>These<font style="letter-spacing:-0.05pt;"> </font>statements<font style="letter-spacing:0.05pt;"> </font>are often, but are<font style="letter-spacing:-0.05pt;"> </font>not always,<font style="letter-spacing:-2.35pt;"> </font>made through the use of words or phrases<font style="letter-spacing:0.05pt;"> </font>such as &#8220;may,&#8221;<font style="letter-spacing:0.05pt;"> </font>&#8220;will,&#8221;<font style="letter-spacing:0.05pt;"> </font>&#8220;could,&#8221;<font style="letter-spacing:0.05pt;"> </font>&#8220;should,&#8221;<font style="letter-spacing:0.05pt;"> </font>&#8220;expects,&#8221;<font style="letter-spacing:0.05pt;"> </font>&#8220;intends,&#8221;<font style="letter-spacing:0.05pt;"> </font>&#8220;plans,&#8221;<font style="letter-spacing:0.05pt;"> </font>&#8220;anticipates,&#8221;<font style="letter-spacing:0.15pt;"> </font>&#8220;believes,&#8221;<font style="letter-spacing:0.1pt;"> </font>&#8220;estimates,&#8221;<font style="letter-spacing:0.15pt;"> </font>&#8220;predicts,&#8221;<font style="letter-spacing:0.1pt;"> </font>&#8220;projects,&#8221;<font style="letter-spacing:0.1pt;"> </font>&#8220;potential,&#8221;<font style="letter-spacing:0.1pt;"> </font>&#8220;continue,&#8221;<font style="letter-spacing:0.05pt;"> </font>and similar<font style="letter-spacing:0.05pt;"> </font>expressions,<font style="letter-spacing:0.05pt;"> </font>or the negative<font style="letter-spacing:0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>or similar<font style="letter-spacing:0.1pt;"> </font>expressions.<font style="letter-spacing:0.05pt;"> </font>Accordingly,<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>involve<font style="letter-spacing:0.05pt;"> </font>estimates,<font style="letter-spacing:0.1pt;"> </font>assumptions,<font style="letter-spacing:0.1pt;"> </font>risks<font style="letter-spacing:0.05pt;"> </font>and uncertainties<font style="letter-spacing:0.15pt;"> </font>which could cause actual<font style="letter-spacing:0.05pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>to differ<font style="letter-spacing:0.05pt;"> </font>materially<font style="letter-spacing:0.15pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>those<font style="letter-spacing:0.05pt;"> </font>expressed<font style="letter-spacing:0.05pt;"> </font>in them.<font style="letter-spacing:0.05pt;"> </font>Any<font style="letter-spacing:-0.05pt;"> </font>forward-looking<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>are qualified<font style="letter-spacing:0.1pt;"> </font>in their<font style="letter-spacing:0.05pt;"> </font>entirety<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>to the factors<font style="letter-spacing:0.05pt;"> </font>discussed<font style="letter-spacing:0.05pt;"> </font>throughout<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>prospectus,<font style="letter-spacing:0.05pt;"> </font>and in particular<font style="letter-spacing:0.1pt;"> </font>those factors<font style="letter-spacing:0.05pt;"> </font>referenced<font style="letter-spacing:0.1pt;"> </font>in the section<font style="letter-spacing:0.05pt;"> </font>&#8220;Risk Factors.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus contains forward-looking statements that are based on our management&#8217;s belief and assumptions and on information<font style="letter-spacing:0.1pt;"> </font>currently<font style="letter-spacing:0.1pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>to our management.<font style="letter-spacing:0.1pt;"> </font>These statements<font style="letter-spacing:0.1pt;"> </font>relate<font style="letter-spacing:0.05pt;"> </font>to future<font style="letter-spacing:0.1pt;"> </font>events<font style="letter-spacing:0.05pt;"> </font>or our future<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>performance,<font style="letter-spacing:0.1pt;"> </font>and involve<font style="letter-spacing:0.05pt;"> </font>known<font style="letter-spacing:-0.05pt;"> </font>and unknown<font style="letter-spacing:-0.05pt;"> </font>risks,<font style="letter-spacing:0.05pt;"> </font>uncertainties<font style="letter-spacing:0.15pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>factors<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>may cause<font style="letter-spacing:0.05pt;"> </font>our actual<font style="letter-spacing:0.05pt;"> </font>results,<font style="letter-spacing:0.05pt;"> </font>levels<font style="letter-spacing:0.05pt;"> </font>of activity,<font style="letter-spacing:0.1pt;"> </font>performance<font style="letter-spacing:0.1pt;"> </font>or achievements<font style="letter-spacing:0.1pt;"> </font>to be materially<font style="letter-spacing:0.15pt;"> </font>different<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.1pt;"> </font>any future<font style="letter-spacing:0.05pt;"> </font>results,<font style="letter-spacing:0.05pt;"> </font>levels<font style="letter-spacing:0.05pt;"> </font>of activity,<font style="letter-spacing:0.1pt;"> </font>performance<font style="letter-spacing:0.1pt;"> </font>or achievements<font style="letter-spacing:0.1pt;"> </font>expressed<font style="letter-spacing:0.05pt;"> </font>or implied<font style="letter-spacing:0.05pt;"> </font>by these<font style="letter-spacing:0.05pt;"> </font>forward-looking<font style="letter-spacing:0.1pt;"> </font>statements.<font style="color:#000000;"> </font>Forward-looking<font style="letter-spacing:0.05pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>include,<font style="letter-spacing:0.05pt;"> </font>but are not limited<font style="letter-spacing:0.1pt;"> </font>to, statements<font style="letter-spacing:0.1pt;"> </font>about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the initiation,<font style="letter-spacing:0.1pt;"> </font>timing,<font style="letter-spacing:0.05pt;"> </font>progress,<font style="letter-spacing:0.05pt;"> </font>results,<font style="letter-spacing:0.05pt;"> </font>and cost of our research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>and our<font style="letter-spacing:0.05pt;"> </font>current<font style="letter-spacing:0.05pt;"> </font>and future<font style="letter-spacing:0.05pt;"> </font>preclinical<font style="letter-spacing:0.1pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>studies,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>regarding<font style="letter-spacing:0.05pt;"> </font>the timing<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>initiation and completion of studies or trials and related preparatory work, the period during which the <font style="letter-spacing:-2.35pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>of the trials<font style="letter-spacing:0.1pt;"> </font>will become<font style="letter-spacing:0.05pt;"> </font>available,<font style="letter-spacing:0.1pt;"> </font>and our research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>programs;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the identification<font style="letter-spacing:0.15pt;"> </font>of research<font style="letter-spacing:0.05pt;"> </font>priorities<font style="letter-spacing:0.1pt;"> </font>and application<font style="letter-spacing:0.1pt;"> </font>of a risk-mitigated<font style="letter-spacing:0.15pt;"> </font>strategy<font style="letter-spacing:0.05pt;"> </font>to efficiently<font style="letter-spacing:0.05pt;"> </font>discover and develop product candidates, including by applying learnings from one program to other <font style="letter-spacing:-2.35pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>and from<font style="letter-spacing:0.05pt;"> </font>one modality<font style="letter-spacing:0.05pt;"> </font>to our other<font style="letter-spacing:0.05pt;"> </font>modalities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the manufacture<font style="letter-spacing:0.1pt;"> </font>of our drug substances,<font style="letter-spacing:0.05pt;"> </font>delivery<font style="letter-spacing:0.05pt;"> </font>vehicles,<font style="letter-spacing:0.05pt;"> </font>and product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>for preclinical<font style="letter-spacing:0.15pt;"> </font>use, <font style="letter-spacing:-2.35pt;">  </font>for clinical<font style="letter-spacing:0.1pt;"> </font>trials<font style="letter-spacing:0.1pt;"> </font>and on a larger<font style="letter-spacing:0.05pt;"> </font>scale<font style="letter-spacing:0.05pt;"> </font>for commercial<font style="letter-spacing:0.1pt;"> </font>use, if approved;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our<font style="letter-spacing:-0.05pt;"> </font>relationships<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>our third-party<font style="letter-spacing:0.05pt;"> </font>strategic<font style="letter-spacing:0.05pt;"> </font>collaborators<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>their ability<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>continue research<font style="letter-spacing:0.05pt;"> </font>and development<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to our development<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>and product<font style="letter-spacing:0.05pt;"> </font>candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the funding for our operations<font style="letter-spacing:0.05pt;"> </font>necessary<font style="letter-spacing:0.05pt;"> </font>to complete<font style="letter-spacing:0.05pt;"> </font>further<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>and commercialization<font style="letter-spacing:0.25pt;"> </font>of <font style="letter-spacing:-2.35pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our plans to seek regulatory<font style="letter-spacing:0.1pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>of our product<font style="letter-spacing:0.05pt;"> </font>candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the pricing<font style="letter-spacing:0.05pt;"> </font>and reimbursement<font style="letter-spacing:0.15pt;"> </font>of our product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>if approved;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the implementation of our business model and strategic plans for our business, product candidates and technology;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope of protection<font style="letter-spacing:0.1pt;"> </font>for intellectual<font style="letter-spacing:0.15pt;"> </font>property<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>covering<font style="letter-spacing:0.05pt;"> </font>our product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.05pt;"> </font>and technology;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">estimates of our future expenses, revenues and capital requirements and our needs for additional <font style="letter-spacing:-2.35pt;"> </font>financing;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<font style="letter-spacing:-0.05pt;"> </font>potential<font style="letter-spacing:0.05pt;"> </font>benefits of<font style="letter-spacing:-0.05pt;"> </font>strategic<font style="letter-spacing:0.05pt;"> </font>collaboration<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>collaborators<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>development, <font style="letter-spacing:-2.35pt;"> </font>regulatory<font style="letter-spacing:0.1pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>expertise;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">future agreements<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>third parties in connection with<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>commercialization<font style="letter-spacing:0.15pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>product candidates <font style="letter-spacing:-2.35pt;"> </font>and any other<font style="letter-spacing:0.05pt;"> </font>approved product;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the size</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and growth potential</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the markets</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for our product</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and our ability</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to serve</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tho</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">se </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our financial<font style="letter-spacing:0.1pt;"> </font>performance;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the rate<font style="letter-spacing:0.05pt;"> </font>and degree<font style="letter-spacing:0.05pt;"> </font>of market<font style="letter-spacing:0.05pt;"> </font>acceptance<font style="letter-spacing:0.05pt;"> </font>of our product<font style="letter-spacing:0.05pt;"> </font>candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory<font style="letter-spacing:0.1pt;"> </font>developments<font style="letter-spacing:0.1pt;"> </font>in the United States<font style="letter-spacing:0.05pt;"> </font>and foreign<font style="letter-spacing:0.05pt;"> </font>countries;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability<font style="letter-spacing:0.05pt;"> </font>to contract<font style="letter-spacing:0.05pt;"> </font>with third-party<font style="letter-spacing:0.1pt;"> </font>suppliers<font style="letter-spacing:0.05pt;"> </font>and manufacturers<font style="letter-spacing:0.15pt;"> </font>and their<font style="letter-spacing:0.05pt;"> </font>ability<font style="letter-spacing:0.05pt;"> </font>to perform<font style="letter-spacing:-2.35pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>adequately;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing<font style="letter-spacing:0.1pt;"> </font>cost;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success<font style="letter-spacing:0.05pt;"> </font>of competing<font style="letter-spacing:0.05pt;"> </font>therapies<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are or may become<font style="letter-spacing:0.05pt;"> </font>available;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability<font style="letter-spacing:0.05pt;"> </font>to attract<font style="letter-spacing:0.1pt;"> </font>and retain<font style="letter-spacing:0.05pt;"> </font>key scientific<font style="letter-spacing:0.1pt;"> </font>or management<font style="letter-spacing:0.1pt;"> </font>personnel;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact<font style="letter-spacing:0.05pt;"> </font>of laws and regulations<font style="letter-spacing:0.1pt;"> </font>on our business<font style="letter-spacing:0.05pt;"> </font>and programs;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developments<font style="letter-spacing:0.1pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to our competitors<font style="letter-spacing:0.1pt;"> </font>and our industry;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>aspects<font style="letter-spacing:0.05pt;"> </font>of our business<font style="letter-spacing:0.05pt;"> </font>operations,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>but not limited<font style="letter-spacing:0.1pt;"> </font>to our preclinical<font style="letter-spacing:0.05pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and future<font style="letter-spacing:0.05pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trials;<font style="letter-spacing:0.1pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221; in our Annual <font style="letter-spacing:-2.35pt;"> </font>Report on Form 10-K for the year ended December<font style="letter-spacing:0.05pt;"> </font>31, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>are neither<font style="letter-spacing:0.05pt;"> </font>promises<font style="letter-spacing:0.05pt;"> </font>nor guarantees<font style="letter-spacing:0.05pt;"> </font>of future<font style="letter-spacing:0.05pt;"> </font>performance<font style="letter-spacing:0.1pt;"> </font>due to a variety<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>risks<font style="letter-spacing:0.05pt;"> </font>and uncertainties,<font style="letter-spacing:0.15pt;"> </font>many of which are beyond our control,<font style="letter-spacing:0.05pt;"> </font>which could cause actual<font style="letter-spacing:0.05pt;"> </font>results<font style="letter-spacing:0.05pt;"> </font>to differ<font style="letter-spacing:0.05pt;"> </font>materially<font style="letter-spacing:0.2pt;"> </font>from<font style="letter-spacing:0.1pt;"> </font>those<font style="letter-spacing:0.1pt;"> </font>indicated<font style="letter-spacing:0.1pt;"> </font>by<font style="letter-spacing:0.1pt;"> </font>these<font style="letter-spacing:0.1pt;"> </font>forward-looking<font style="letter-spacing:0.2pt;"> </font>statements,<font style="letter-spacing:0.15pt;"> </font>including,<font style="letter-spacing:0.15pt;"> </font>without<font style="letter-spacing:0.05pt;"> </font>limitation<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>risk<font style="letter-spacing:0.05pt;"> </font>factors<font style="letter-spacing:0.05pt;"> </font>and cautionary<font style="letter-spacing:0.05pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in other<font style="letter-spacing:0.05pt;"> </font>documents<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>file<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time<font style="letter-spacing:0.05pt;"> </font>with the SEC,<font style="letter-spacing:0.05pt;"> </font>specifically<font style="letter-spacing:0.15pt;"> </font>under &#8220;Item<font style="letter-spacing:0.1pt;"> </font>1A: Risk<font style="letter-spacing:0.05pt;"> </font>Factors&#8221;<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>elsewhere<font style="letter-spacing:0.05pt;"> </font>in our<font style="letter-spacing:0.05pt;"> </font>most<font style="letter-spacing:0.05pt;"> </font>recent<font style="letter-spacing:0.1pt;"> </font>Annual Report<font style="letter-spacing:0.05pt;"> </font>on Form 10-K<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the period ended December 31, 2020 and our most recent Quarterly Reports on Form 10-Q for the quarters ended <font style="letter-spacing:-2.35pt;"> </font>March<font style="letter-spacing:0.05pt;"> </font>31, 2021 and June 30, 2021, and our Current<font style="letter-spacing:0.05pt;"> </font>Reports on Form 8-K, and the section<font style="letter-spacing:0.05pt;"> </font>of any accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>&#8220;Risk Factors.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>and the documents<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>represent<font style="letter-spacing:0.1pt;"> </font>our<font style="letter-spacing:0.05pt;"> </font>views<font style="letter-spacing:-0.05pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>of their respective<font style="letter-spacing:0.05pt;"> </font>dates.<font style="letter-spacing:0.05pt;"> </font>We<font style="letter-spacing:-0.05pt;"> </font>anticipate<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>subsequent events<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>developments<font style="letter-spacing:0.05pt;"> </font>will cause<font style="letter-spacing:-0.05pt;"> </font>our<font style="letter-spacing:-0.05pt;"> </font>views to <font style="letter-spacing:-2.35pt;"> </font>change. However, while we<font style="letter-spacing:-0.05pt;"> </font>may elect<font style="letter-spacing:0.05pt;"> </font>to update these<font style="letter-spacing:0.05pt;"> </font>forward-looking<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>at some point in the future,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:0.05pt;"> </font>assume<font style="letter-spacing:0.05pt;"> </font>no obligation<font style="letter-spacing:0.05pt;"> </font>to update or revise<font style="letter-spacing:0.05pt;"> </font>any forward-looking<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>except<font style="letter-spacing:0.05pt;"> </font>to the extent<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>law. You<font style="letter-spacing:-0.05pt;"> </font>should, therefore,<font style="letter-spacing:0.1pt;"> </font>not rely<font style="letter-spacing:0.05pt;"> </font>on these<font style="letter-spacing:0.05pt;"> </font>forward-looking<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>as representing<font style="letter-spacing:0.1pt;"> </font>our views as<font style="letter-spacing:0.05pt;"> </font>of any date subsequent<font style="letter-spacing:0.05pt;"> </font>to the dates<font style="letter-spacing:0.05pt;"> </font>on which they were made.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus<font style="letter-spacing:0.05pt;"> </font>and the documents<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>also contain<font style="letter-spacing:0.05pt;"> </font>estimates,<font style="letter-spacing:0.1pt;"> </font>projections<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>concerning<font style="letter-spacing:0.05pt;"> </font>our industry,<font style="letter-spacing:0.05pt;"> </font>our business,<font style="letter-spacing:0.05pt;"> </font>and the markets<font style="letter-spacing:0.05pt;"> </font>for certain<font style="letter-spacing:0.05pt;"> </font>diseases,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>data regarding<font style="letter-spacing:0.05pt;"> </font>the estimated<font style="letter-spacing:0.1pt;"> </font>size<font style="letter-spacing:0.05pt;"> </font>of those markets,<font style="letter-spacing:0.05pt;"> </font>and the incidence<font style="letter-spacing:0.05pt;"> </font>and prevalence<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>medical<font style="letter-spacing:0.05pt;"> </font>conditions.<font style="letter-spacing:0.05pt;"> </font>Information<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>based<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:0.05pt;"> </font>estimates,<font style="letter-spacing:0.15pt;"> </font>forecasts,<font style="letter-spacing:0.15pt;"> </font>projections,<font style="letter-spacing:0.15pt;"> </font>market<font style="letter-spacing:0.1pt;"> </font>research<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>similar<font style="letter-spacing:0.15pt;"> </font>methodologies<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>inherently<font style="letter-spacing:0.15pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>uncertainties<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>actual events or<font style="letter-spacing:-0.05pt;"> </font>circumstances<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:-0.05pt;"> </font>differ<font style="letter-spacing:0.05pt;"> </font>materially<font style="letter-spacing:0.1pt;"> </font>from events and<font style="letter-spacing:-0.05pt;"> </font>circumstances<font style="letter-spacing:0.1pt;"> </font>reflected <font style="letter-spacing:-2.35pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>information.<font style="letter-spacing:0.1pt;"> </font>Unless otherwise<font style="letter-spacing:0.05pt;"> </font>expressly<font style="letter-spacing:0.05pt;"> </font>stated,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>obtained<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>industry,<font style="letter-spacing:0.05pt;"> </font>business,<font style="letter-spacing:0.05pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>data<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>reports,<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>surveys,<font style="letter-spacing:0.05pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>and similar<font style="letter-spacing:0.1pt;"> </font>data prepared<font style="letter-spacing:0.05pt;"> </font>by market<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>firms<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>third<font style="letter-spacing:0.05pt;"> </font>parties, industry,<font style="letter-spacing:0.05pt;"> </font>medical<font style="letter-spacing:0.05pt;"> </font>and general<font style="letter-spacing:0.05pt;"> </font>publications,<font style="letter-spacing:0.1pt;"> </font>government<font style="letter-spacing:0.05pt;"> </font>data and similar<font style="letter-spacing:0.1pt;"> </font>sources.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><a name="COMPANY"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="COMPANY"></a>CO</font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MPANY</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage<font style="letter-spacing:0.15pt;"> </font>precision<font style="letter-spacing:0.05pt;"> </font>medicines<font style="letter-spacing:0.1pt;"> </font>company transforming<font style="letter-spacing:0.1pt;"> </font>the drug discovery<font style="letter-spacing:0.05pt;"> </font>process<font style="letter-spacing:0.05pt;"> </font>with the goal of<font style="letter-spacing:0.05pt;"> </font>bringing<font style="letter-spacing:0.05pt;"> </font>life-changing<font style="letter-spacing:0.1pt;"> </font>therapies<font style="letter-spacing:0.1pt;"> </font>to patients.<font style="letter-spacing:0.05pt;"> </font>We are among the first<font style="letter-spacing:0.05pt;"> </font>of a new<font style="letter-spacing:-0.05pt;"> </font>breed of biotech<font style="letter-spacing:0.05pt;"> </font>created<font style="letter-spacing:0.05pt;"> </font>at the<font style="letter-spacing:0.05pt;"> </font>intersection<font style="letter-spacing:0.1pt;"> </font>of disparate<font style="letter-spacing:0.1pt;"> </font>disciplines.<font style="letter-spacing:0.1pt;"> </font>Our Dynamo&#8482; <font style="letter-spacing:0.2pt;"> </font>platform<font style="letter-spacing:0.1pt;"> </font>integrates<font style="letter-spacing:0.1pt;"> </font>an array<font style="letter-spacing:0.05pt;"> </font>of leading-edge<font style="letter-spacing:0.1pt;"> </font>computational and<font style="letter-spacing:-0.05pt;"> </font>experimental<font style="letter-spacing:0.05pt;"> </font>approaches to effectively<font style="letter-spacing:0.05pt;"> </font>drug<font style="letter-spacing:-0.05pt;"> </font>protein<font style="letter-spacing:0.05pt;"> </font>targets that have previously been<font style="letter-spacing:-0.05pt;"> </font>intractable.<font style="letter-spacing:0.1pt;"> </font>Our initial <font style="letter-spacing:-2.35pt;"> </font>focus is on enhancing<font style="letter-spacing:0.05pt;"> </font>small<font style="letter-spacing:0.05pt;"> </font>molecule<font style="letter-spacing:0.05pt;"> </font>therapeutic<font style="letter-spacing:0.1pt;"> </font>discovery<font style="letter-spacing:0.05pt;"> </font>in targeted<font style="letter-spacing:0.05pt;"> </font>oncology and genetic<font style="letter-spacing:0.05pt;"> </font>disease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing<font style="letter-spacing:0.05pt;"> </font>a pipeline<font style="letter-spacing:0.05pt;"> </font>of medicines<font style="letter-spacing:0.1pt;"> </font>to address<font style="letter-spacing:0.05pt;"> </font>targets<font style="letter-spacing:0.05pt;"> </font>in precision<font style="letter-spacing:0.05pt;"> </font>oncology, including<font style="letter-spacing:0.05pt;"> </font>our lead product<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>RLY4008,<font style="letter-spacing:-0.05pt;"> </font>RLY-2608<font style="letter-spacing:-0.05pt;"> </font>and RLY-1971.<font style="letter-spacing:-0.05pt;"> </font>We initiated<font style="letter-spacing:0.1pt;"> </font>a first-in-human<font style="letter-spacing:0.15pt;"> </font>clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>for RLY-4008,<font style="letter-spacing:-0.05pt;"> </font>our<font style="letter-spacing:0.05pt;"> </font>inhibitor<font style="letter-spacing:0.1pt;"> </font>of fibroblast<font style="letter-spacing:0.1pt;"> </font>growth factor<font style="letter-spacing:0.05pt;"> </font>receptor<font style="letter-spacing:0.05pt;"> </font>2, or FGFR2,<font style="letter-spacing:-0.1pt;"> </font>enriched<font style="letter-spacing:0.05pt;"> </font>for patients<font style="letter-spacing:0.05pt;"> </font>with advanced solid<font style="letter-spacing:0.05pt;"> </font>tumors<font style="letter-spacing:0.05pt;"> </font>having oncogenic<font style="letter-spacing:0.05pt;"> </font>FGFR2<font style="letter-spacing:-0.1pt;"> </font>alterations<font style="letter-spacing:0.1pt;"> </font>in the third<font style="letter-spacing:0.05pt;"> </font>quarter<font style="letter-spacing:0.05pt;"> </font>of 2020. In 2021, we<font style="letter-spacing:-0.05pt;"> </font>initiated<font style="letter-spacing:0.1pt;"> </font>Investigational<font style="letter-spacing:0.15pt;"> </font>New<font style="letter-spacing:-0.05pt;"> </font>Drug, or IND,<font style="letter-spacing:-0.05pt;"> </font>enabling<font style="letter-spacing:0.05pt;"> </font>studies<font style="letter-spacing:0.05pt;"> </font>for RLY-2608,<font style="letter-spacing:-0.05pt;"> </font>our inhibitor<font style="letter-spacing:0.1pt;"> </font>of cancer-associated<font style="letter-spacing:0.15pt;"> </font>mutant<font style="letter-spacing:0.05pt;"> </font>variants<font style="letter-spacing:0.05pt;"> </font>H1047X,<font style="letter-spacing:-0.05pt;"> </font>E542X,<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>E545X<font style="letter-spacing:-0.1pt;"> </font>of phosphoinostide<font style="letter-spacing:0.05pt;"> </font>3-kinase<font style="letter-spacing:0.05pt;"> </font>alpha, or PI3K<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font>. RLY-2608<font style="letter-spacing:-0.05pt;"> </font>is the lead program<font style="letter-spacing:0.05pt;"> </font>of multiple<font style="letter-spacing:0.1pt;"> </font>preclinical<font style="letter-spacing:0.05pt;"> </font>efforts<font style="letter-spacing:0.05pt;"> </font>to discover<font style="letter-spacing:0.05pt;"> </font>and develop mutant<font style="letter-spacing:0.05pt;"> </font>selective<font style="letter-spacing:0.1pt;"> </font>inhibitors<font style="letter-spacing:0.1pt;"> </font>of PI3K<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">a</font></font>. We initiated<font style="letter-spacing:0.1pt;"> </font>a Phase 1 clinical<font style="letter-spacing:0.1pt;"> </font>trial<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>RLY-1971,<font style="letter-spacing:-0.05pt;"> </font>our inhibitor<font style="letter-spacing:0.1pt;"> </font>of Src homology region<font style="letter-spacing:0.05pt;"> </font>2 domain-containing<font style="letter-spacing:0.15pt;"> </font>phosphatase-2,<font style="letter-spacing:0.05pt;"> </font>or SHP2,<font style="letter-spacing:-0.05pt;"> </font>in patients<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>advanced solid<font style="letter-spacing:0.05pt;"> </font>tumors<font style="letter-spacing:0.05pt;"> </font>in the first<font style="letter-spacing:0.05pt;"> </font>quarter<font style="letter-spacing:0.05pt;"> </font>of 2020. In December<font style="letter-spacing:0.05pt;"> </font>2020, we<font style="letter-spacing:-0.05pt;"> </font>entered<font style="letter-spacing:0.05pt;"> </font>into a global<font style="letter-spacing:0.05pt;"> </font>collaboration<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>license<font style="letter-spacing:0.05pt;"> </font>agreement,<font style="letter-spacing:0.1pt;"> </font>or the Genentech Agreement,<font style="letter-spacing:0.05pt;"> </font>with Genentech, Inc., a member<font style="letter-spacing:0.05pt;"> </font>of the Roche Group, or<font style="letter-spacing:0.05pt;"> </font>Genentech, for the development<font style="letter-spacing:0.05pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>of RLY-1971.<font style="letter-spacing:-0.05pt;"> </font>In July 2021, Genentech initiated<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>cohort<font style="letter-spacing:0.15pt;"> </font>of<font style="letter-spacing:0.15pt;"> </font>RLY-1971<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.15pt;"> </font>combination<font style="letter-spacing:0.2pt;"> </font>with<font style="letter-spacing:0.15pt;"> </font>GDC-6036,<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>KRASG12C<font style="letter-spacing:1pt;"> </font>inhibitor,<font style="letter-spacing:0.25pt;"> </font>in<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.1pt;"> </font>phase<font style="letter-spacing:0.15pt;"> </font>1b<font style="letter-spacing:0.15pt;"> </font>trial.<font style="letter-spacing:0.2pt;"> </font>While<font style="letter-spacing:0.15pt;"> </font>our<font style="letter-spacing:0.05pt;"> </font>initial<font style="letter-spacing:0.1pt;"> </font>focus is on<font style="letter-spacing:0.05pt;"> </font>precision<font style="letter-spacing:0.05pt;"> </font>oncology, we believe<font style="letter-spacing:0.05pt;"> </font>our Dynamo<font style="letter-spacing:0.05pt;"> </font>platform<font style="letter-spacing:0.1pt;"> </font>may also<font style="letter-spacing:0.05pt;"> </font>be broadly<font style="letter-spacing:0.05pt;"> </font>applied<font style="letter-spacing:0.1pt;"> </font>to other<font style="letter-spacing:0.05pt;"> </font>areas<font style="letter-spacing:0.05pt;"> </font>of precision<font style="letter-spacing:0.05pt;"> </font>medicine,<font style="letter-spacing:0.05pt;"> </font>such as genetic<font style="letter-spacing:0.05pt;"> </font>disease.<font style="letter-spacing:0.05pt;"> </font>In addition<font style="letter-spacing:0.05pt;"> </font>to the three<font style="letter-spacing:0.05pt;"> </font>product<font style="letter-spacing:0.05pt;"> </font>candidates<font style="letter-spacing:0.1pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>above,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have five<font style="letter-spacing:0.05pt;"> </font>discovery<font style="letter-spacing:0.05pt;"> </font>stage<font style="letter-spacing:0.05pt;"> </font>programs<font style="letter-spacing:0.05pt;"> </font>across<font style="letter-spacing:0.05pt;"> </font>both precision<font style="letter-spacing:0.05pt;"> </font>oncology and genetic<font style="letter-spacing:0.05pt;"> </font>disease.<font style="letter-spacing:0.05pt;"> </font>We are focused<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:0.05pt;"> </font>using the novel insights<font style="letter-spacing:0.05pt;"> </font>derived<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>our approach<font style="letter-spacing:0.05pt;"> </font>to transform<font style="letter-spacing:0.1pt;"> </font>the lives<font style="letter-spacing:0.05pt;"> </font>of patients<font style="letter-spacing:0.05pt;"> </font>suffering<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>debilitating<font style="letter-spacing:0.05pt;"> </font>and life-threatening<font style="letter-spacing:0.2pt;"> </font>diseases<font style="letter-spacing:0.05pt;"> </font>through the discovery,<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>and commercialization<font style="letter-spacing:0.2pt;"> </font>of our therapies.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision<font style="letter-spacing:0.05pt;"> </font>medicine<font style="letter-spacing:0.05pt;"> </font>emerged<font style="letter-spacing:0.05pt;"> </font>as an approach<font style="letter-spacing:0.05pt;"> </font>for disease<font style="letter-spacing:0.05pt;"> </font>treatment<font style="letter-spacing:0.1pt;"> </font>as the understanding<font style="letter-spacing:0.05pt;"> </font>of the link between<font style="letter-spacing:0.05pt;"> </font>genetic<font style="letter-spacing:0.05pt;"> </font>alterations,<font style="letter-spacing:0.1pt;"> </font>protein<font style="letter-spacing:0.05pt;"> </font>dysfunction<font style="letter-spacing:0.05pt;"> </font>and diseases<font style="letter-spacing:0.05pt;"> </font>evolved. Precision<font style="letter-spacing:0.05pt;"> </font>medicine<font style="letter-spacing:0.05pt;"> </font>aims<font style="letter-spacing:0.05pt;"> </font>to specifically<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>potently<font style="letter-spacing:0.05pt;"> </font>drug genetically<font style="letter-spacing:0.1pt;"> </font>validated<font style="letter-spacing:0.05pt;"> </font>target<font style="letter-spacing:0.05pt;"> </font>proteins<font style="letter-spacing:0.05pt;"> </font>(i.e.,<font style="letter-spacing:0.05pt;"> </font>genetic<font style="letter-spacing:0.05pt;"> </font>variants<font style="letter-spacing:0.05pt;"> </font>potentially<font style="letter-spacing:0.1pt;"> </font>implicated<font style="letter-spacing:0.1pt;"> </font>in biology<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>disease).<font style="letter-spacing:0.05pt;"> </font>However, some target<font style="letter-spacing:0.05pt;"> </font>proteins<font style="letter-spacing:0.05pt;"> </font>thus far<font style="letter-spacing:0.05pt;"> </font>have been intractable<font style="letter-spacing:0.1pt;"> </font>using conventional<font style="letter-spacing:0.05pt;"> </font>drug discovery<font style="letter-spacing:0.05pt;"> </font>tools, <font style="letter-spacing:-2.35pt;"> </font>such as structure-based<font style="letter-spacing:0.15pt;"> </font>drug design, or SBDD.<font style="letter-spacing:-0.1pt;"> </font>While<font style="letter-spacing:0.05pt;"> </font>SBDD<font style="letter-spacing:-0.1pt;"> </font>is well-suited<font style="letter-spacing:0.1pt;"> </font>to solving<font style="letter-spacing:0.05pt;"> </font>some drug discovery<font style="letter-spacing:0.05pt;"> </font>problems<font style="letter-spacing:0.05pt;"> </font>such as orthosteric<font style="letter-spacing:0.1pt;"> </font>site<font style="letter-spacing:0.05pt;"> </font>kinase<font style="letter-spacing:0.05pt;"> </font>inhibitors,<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>reliance<font style="letter-spacing:0.1pt;"> </font>on static<font style="letter-spacing:0.05pt;"> </font>images<font style="letter-spacing:0.05pt;"> </font>of protein<font style="letter-spacing:0.05pt;"> </font>fragments<font style="letter-spacing:0.1pt;"> </font>limits<font style="letter-spacing:0.1pt;"> </font>its<font style="letter-spacing:0.05pt;"> </font>ability<font style="letter-spacing:0.05pt;"> </font>to gain accurate<font style="letter-spacing:0.05pt;"> </font>insights<font style="letter-spacing:0.05pt;"> </font>into the dynamic<font style="letter-spacing:0.05pt;"> </font>behavior<font style="letter-spacing:0.05pt;"> </font>of proteins<font style="letter-spacing:0.05pt;"> </font>in their<font style="letter-spacing:0.05pt;"> </font>natural<font style="letter-spacing:0.05pt;"> </font>state,<font style="letter-spacing:0.1pt;"> </font>which in turn limits its<font style="letter-spacing:0.05pt;"> </font>ability<font style="letter-spacing:0.05pt;"> </font>to discover<font style="letter-spacing:0.05pt;"> </font>medicines<font style="letter-spacing:0.1pt;"> </font>with exquisite<font style="letter-spacing:0.05pt;"> </font>specificity.<font style="letter-spacing:0.1pt;"> </font>Our approach<font style="letter-spacing:0.05pt;"> </font>pivots<font style="letter-spacing:0.05pt;"> </font>the understanding<font style="letter-spacing:0.05pt;"> </font>of protein<font style="letter-spacing:0.05pt;"> </font>targets<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the industry-standard,<font style="letter-spacing:0.15pt;"> </font>static<font style="letter-spacing:0.05pt;"> </font>view, to a novel paradigm<font style="letter-spacing:0.05pt;"> </font>based on fundamental<font style="letter-spacing:0.1pt;"> </font>insights<font style="letter-spacing:0.05pt;"> </font>into protein<font style="letter-spacing:0.05pt;"> </font>motion.<font style="letter-spacing:0.05pt;"> </font>We then apply these<font style="letter-spacing:0.05pt;"> </font>novel insights<font style="letter-spacing:0.05pt;"> </font>into protein<font style="letter-spacing:0.05pt;"> </font>motion<font style="letter-spacing:0.05pt;"> </font>to drug discovery<font style="letter-spacing:0.05pt;"> </font>and design, which we<font style="letter-spacing:-0.05pt;"> </font>term<font style="letter-spacing:0.05pt;"> </font>Motion<font style="letter-spacing:0.05pt;"> </font>Based Drug DesignTM, or<font style="letter-spacing:-0.05pt;"> </font>MBDD.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The confluence<font style="letter-spacing:0.05pt;"> </font>of three<font style="letter-spacing:0.05pt;"> </font>forces&#8212;the<font style="letter-spacing:0.1pt;"> </font>proliferation<font style="letter-spacing:0.15pt;"> </font>of readily<font style="letter-spacing:0.05pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>genomic<font style="letter-spacing:0.05pt;"> </font>data, the evolution<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>experimental<font style="letter-spacing:0.1pt;"> </font>techniques,<font style="letter-spacing:0.05pt;"> </font>and advancements<font style="letter-spacing:0.1pt;"> </font>in computational<font style="letter-spacing:0.1pt;"> </font>power and speed&#8212;led<font style="letter-spacing:0.05pt;"> </font>to the founding<font style="letter-spacing:0.05pt;"> </font>of Relay<font style="letter-spacing:0.05pt;"> </font>Therapeutics.<font style="letter-spacing:0.1pt;"> </font>We believe<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>are uniquely<font style="letter-spacing:0.05pt;"> </font>situated<font style="letter-spacing:0.05pt;"> </font>in our ability<font style="letter-spacing:0.05pt;"> </font>to consolidate<font style="letter-spacing:0.1pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>advances<font style="letter-spacing:0.05pt;"> </font>and, when<font style="letter-spacing:0.05pt;"> </font>combined with<font style="letter-spacing:-0.05pt;"> </font>our<font style="letter-spacing:-0.05pt;"> </font>world-class<font style="letter-spacing:0.05pt;"> </font>team of<font style="letter-spacing:-0.05pt;"> </font>both<font style="letter-spacing:-0.05pt;"> </font>experimental<font style="letter-spacing:0.05pt;"> </font>and computational<font style="letter-spacing:0.05pt;"> </font>experts, integrate<font style="letter-spacing:0.05pt;"> </font>these solutions <font style="letter-spacing:-2.35pt;"> </font>into MBDD<font style="letter-spacing:-0.05pt;"> </font>to create<font style="letter-spacing:0.05pt;"> </font>medicines<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>will make a transformative<font style="letter-spacing:0.15pt;"> </font>difference<font style="letter-spacing:0.1pt;"> </font>for patients.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate history</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated<font style="letter-spacing:0.1pt;"> </font>under the laws of the State<font style="letter-spacing:0.05pt;"> </font>of Delaware on May 4, 2015 under the name &#8220;Allostery,<font style="letter-spacing:0.05pt;"> </font>Inc.&#8221; Our principal corporate office is located at 399 Binney Street, 2nd<font style="letter-spacing:0.05pt;"> </font>Floor, Cambridge, MA 02139, and our<font style="letter-spacing:0.05pt;"> </font>telephone<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>is (617) 370-8837. Our website<font style="letter-spacing:0.05pt;"> </font>address<font style="letter-spacing:0.05pt;"> </font>is www.relaytx.com.<font style="letter-spacing:0.05pt;"> </font>We do not incorporate<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>on or accessible<font style="letter-spacing:0.1pt;"> </font>through our website<font style="letter-spacing:0.05pt;"> </font>into this<font style="letter-spacing:0.05pt;"> </font>prospectus,<font style="letter-spacing:0.05pt;"> </font>and you should not consider<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>on, or that<font style="letter-spacing:0.05pt;"> </font>can be accessed<font style="letter-spacing:0.05pt;"> </font>through, our website<font style="letter-spacing:0.05pt;"> </font>as part<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>prospectus.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own various U.S. federal trademark applications and unregistered trademarks, including our company name</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="letter-spacing:-2.35pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trademarks</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or trade</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">names</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">referred</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to in this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are the property</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of their</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respective</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">owners. Solely for convenience,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the trademarks</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and trade</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">names</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are referred</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to without the symbols</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font><font style="letter-spacing:0.6pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#8482;</sup></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, but such references</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">should not be construed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any indicator</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respective</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">owners </font><font style="letter-spacing:-0.15pt;">will</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not assert,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the fullest</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extent</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under applicable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">law, their</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereto</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><a name="USE_PROCEEDS_1"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">USE</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="USE_PROCEEDS_1"></a>OF P</font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ROCEEDS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend<font style="letter-spacing:0.05pt;"> </font>to use the net proceeds<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the sale<font style="letter-spacing:0.05pt;"> </font>of any securities<font style="letter-spacing:0.1pt;"> </font>offered<font style="letter-spacing:0.05pt;"> </font>under this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>for general<font style="letter-spacing:0.05pt;"> </font>corporate<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>otherwise<font style="letter-spacing:0.05pt;"> </font>indicated<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>General<font style="letter-spacing:0.05pt;"> </font>corporate<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>may include<font style="letter-spacing:0.05pt;"> </font>research<font style="letter-spacing:0.05pt;"> </font>and clinical<font style="letter-spacing:0.1pt;"> </font>development<font style="letter-spacing:0.05pt;"> </font>of current<font style="letter-spacing:0.05pt;"> </font>or additional<font style="letter-spacing:0.1pt;"> </font>pipeline<font style="letter-spacing:0.05pt;"> </font>candidates,<font style="letter-spacing:0.05pt;"> </font>working<font style="letter-spacing:0.05pt;"> </font>capital,<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>expenditures<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>general<font style="letter-spacing:0.05pt;"> </font>corporate<font style="letter-spacing:0.05pt;"> </font>purposes.<font style="letter-spacing:0.05pt;"> </font>We may temporarily<font style="letter-spacing:0.15pt;"> </font>invest<font style="letter-spacing:0.05pt;"> </font>the net proceeds in a variety of<font style="letter-spacing:-0.05pt;"> </font>capital preservation instruments,<font style="letter-spacing:0.05pt;"> </font>including short-term,<font style="letter-spacing:0.05pt;"> </font>investment-grade,<font style="letter-spacing:0.1pt;"> </font>interest-bearing<font style="letter-spacing:0.1pt;"> </font>instruments and U.S. government<font style="letter-spacing:0.05pt;"> </font>securities,<font style="letter-spacing:0.1pt;"> </font>or may hold such proceeds<font style="letter-spacing:0.05pt;"> </font>as cash, until<font style="letter-spacing:0.05pt;"> </font>they are used for their<font style="letter-spacing:0.05pt;"> </font>stated<font style="letter-spacing:0.05pt;"> </font>purpose.<font style="letter-spacing:0.05pt;"> </font>We have not determined<font style="letter-spacing:0.1pt;"> </font>the amount<font style="letter-spacing:0.05pt;"> </font>of net proceeds<font style="letter-spacing:0.05pt;"> </font>to be used specifically<font style="letter-spacing:0.15pt;"> </font>for such purposes.<font style="letter-spacing:0.05pt;"> </font>As<font style="letter-spacing:-0.05pt;"> </font>a result,<font style="letter-spacing:0.05pt;"> </font>management<font style="letter-spacing:0.1pt;"> </font>will retain<font style="letter-spacing:0.05pt;"> </font>broad discretion<font style="letter-spacing:0.1pt;"> </font>over the allocation<font style="letter-spacing:0.1pt;"> </font>of net proceeds.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><a name="SECURITIES_WE_OR_SELLING_STOCKHOLDERS_M"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES</font><font style="letter-spacing:-0.2pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WE</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND/OR</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SELLING</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SECURITIES_WE_OR_SELLING_STOCKHOLDERS_M"></a>S</font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOCKHOLDERS</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAY</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OFFER</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR SELL</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This<font style="letter-spacing:-0.05pt;"> </font>prospectus contains<font style="letter-spacing:0.05pt;"> </font>summary descriptions<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:-0.05pt;"> </font>securities<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>and/or selling stockholders<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:-0.05pt;"> </font>offer or sell from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time.<font style="letter-spacing:0.05pt;"> </font>These summary<font style="letter-spacing:0.05pt;"> </font>descriptions<font style="letter-spacing:0.1pt;"> </font>are not meant<font style="letter-spacing:0.05pt;"> </font>to be complete<font style="letter-spacing:0.05pt;"> </font>descriptions<font style="letter-spacing:0.1pt;"> </font>of each security.<font style="letter-spacing:0.1pt;"> </font>The<font style="letter-spacing:0.05pt;"> </font>particular<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of any security<font style="letter-spacing:0.05pt;"> </font>will be described<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>This prospectus<font style="letter-spacing:0.05pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>you with a general<font style="letter-spacing:0.05pt;"> </font>description<font style="letter-spacing:0.1pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may offer.<font style="letter-spacing:0.05pt;"> </font>Each time<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>sell<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>herein,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will provide<font style="letter-spacing:0.05pt;"> </font>prospective<font style="letter-spacing:0.1pt;"> </font>investors<font style="letter-spacing:0.05pt;"> </font>with a supplement<font style="letter-spacing:0.05pt;"> </font>to this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>will contain<font style="letter-spacing:0.05pt;"> </font>specific<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>about the terms<font style="letter-spacing:0.05pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>offering,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the specific<font style="letter-spacing:0.1pt;"> </font>amounts,<font style="letter-spacing:0.05pt;"> </font>prices<font style="letter-spacing:0.05pt;"> </font>and terms<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.05pt;"> </font>offered.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may sell<font style="letter-spacing:0.05pt;"> </font>the securities<font style="letter-spacing:0.1pt;"> </font>to or through underwriters,<font style="letter-spacing:0.1pt;"> </font>dealers<font style="letter-spacing:0.05pt;"> </font>or agents,<font style="letter-spacing:0.05pt;"> </font>directly<font style="letter-spacing:0.1pt;"> </font>to purchasers<font style="letter-spacing:0.05pt;"> </font>or through a<font style="letter-spacing:0.05pt;"> </font>combination<font style="letter-spacing:0.1pt;"> </font>of any of these<font style="letter-spacing:0.05pt;"> </font>methods<font style="letter-spacing:0.05pt;"> </font>of sale<font style="letter-spacing:0.05pt;"> </font>or as otherwise<font style="letter-spacing:0.05pt;"> </font>set forth<font style="letter-spacing:0.05pt;"> </font>below under &#8220;Plan of Distribution.&#8221;<font style="letter-spacing:0.1pt;"> </font>We, as<font style="letter-spacing:0.05pt;"> </font>well as any agents<font style="letter-spacing:0.05pt;"> </font>acting<font style="letter-spacing:0.05pt;"> </font>on our behalf,<font style="letter-spacing:0.05pt;"> </font>reserve<font style="letter-spacing:0.05pt;"> </font>the sole right<font style="letter-spacing:0.05pt;"> </font>to accept<font style="letter-spacing:0.05pt;"> </font>and to reject<font style="letter-spacing:0.05pt;"> </font>in whole or in part<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>proposed purchase of securities. Any prospectus supplement will set forth the names of any underwriters, dealers, <font style="letter-spacing:-2.35pt;"> </font>agents<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>entities<font style="letter-spacing:0.1pt;"> </font>involved<font style="letter-spacing:0.05pt;"> </font>in the sale<font style="letter-spacing:0.05pt;"> </font>of securities<font style="letter-spacing:0.1pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in that<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>and any<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>fee, commission<font style="letter-spacing:0.1pt;"> </font>or discount<font style="letter-spacing:0.05pt;"> </font>arrangements<font style="letter-spacing:0.1pt;"> </font>with them.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><a name="DESCRIPTION_CAPITAL_STOCK"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_CAPITAL_STOCK"></a>OF </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CAPITAL</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOCK</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>description<font style="letter-spacing:0.1pt;"> </font>of our common<font style="letter-spacing:-0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>and preferred<font style="letter-spacing:0.05pt;"> </font>stock,<font style="letter-spacing:0.05pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>with the additional<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.05pt;"> </font>we include<font style="letter-spacing:0.05pt;"> </font>in any applicable<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplements,<font style="letter-spacing:0.05pt;"> </font>summarizes the material<font style="letter-spacing:0.05pt;"> </font>terms and provisions<font style="letter-spacing:0.05pt;"> </font>of the common stock<font style="letter-spacing:0.05pt;"> </font>and preferred<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>that we<font style="letter-spacing:-0.05pt;"> </font>may<font style="letter-spacing:-0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>under this<font style="letter-spacing:0.05pt;"> </font>prospectus.<font style="letter-spacing:0.05pt;"> </font>The following<font style="letter-spacing:0.05pt;"> </font>description<font style="letter-spacing:0.1pt;"> </font>of our capital<font style="letter-spacing:0.05pt;"> </font>stock does not purport to be complete and is subject to, and qualified in its entirety by, our certificate of incorporation and bylaws, which are exhibits<font style="letter-spacing:0.05pt;"> </font>to the registration<font style="letter-spacing:0.1pt;"> </font>statement<font style="letter-spacing:0.05pt;"> </font>of which this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>forms a part, and by<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.05pt;"> </font>law. The terms of our common<font style="letter-spacing:-0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>and preferred<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>may<font style="letter-spacing:-0.05pt;"> </font>also be affected<font style="letter-spacing:0.05pt;"> </font>by Delaware law.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized<font style="letter-spacing:0.05pt;"> </font>capital<font style="letter-spacing:0.05pt;"> </font>stock consists<font style="letter-spacing:0.05pt;"> </font>of One<font style="letter-spacing:-0.05pt;"> </font>Hundred Fifty<font style="letter-spacing:0.05pt;"> </font>Million<font style="letter-spacing:0.05pt;"> </font>(150,000,000) shares<font style="letter-spacing:0.05pt;"> </font>of common stock, par value $0.001 per share<font style="letter-spacing:0.05pt;"> </font>and Ten Million<font style="letter-spacing:0.05pt;"> </font>(10,000,000) shares<font style="letter-spacing:0.05pt;"> </font>of undesignated<font style="letter-spacing:0.05pt;"> </font>preferred<font style="letter-spacing:0.1pt;"> </font>stock, par value $0.001<font style="letter-spacing:0.05pt;"> </font>per share.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common<font style="letter-spacing:-0.05pt;"> </font>stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders<font style="letter-spacing:0.05pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock are entitled<font style="letter-spacing:0.1pt;"> </font>to one vote for each share<font style="letter-spacing:0.05pt;"> </font>held on all<font style="letter-spacing:0.05pt;"> </font>matters<font style="letter-spacing:0.1pt;"> </font>submitted<font style="letter-spacing:0.15pt;"> </font>to a vote of the stockholders.<font style="letter-spacing:0.1pt;"> </font>The holders<font style="letter-spacing:0.05pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock do not have any cumulative<font style="letter-spacing:0.1pt;"> </font>voting rights.<font style="letter-spacing:0.05pt;"> </font>Holders of our<font style="letter-spacing:0.05pt;"> </font>common stock are<font style="letter-spacing:-0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>receive<font style="letter-spacing:0.05pt;"> </font>ratably any dividends declared<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>our board<font style="letter-spacing:-0.05pt;"> </font>of directors<font style="letter-spacing:0.05pt;"> </font>out of<font style="letter-spacing:-0.05pt;"> </font>funds legally available<font style="letter-spacing:0.1pt;"> </font>for that<font style="letter-spacing:0.05pt;"> </font>purpose, subject<font style="letter-spacing:0.05pt;"> </font>to any preferential<font style="letter-spacing:0.15pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>of any outstanding<font style="letter-spacing:0.05pt;"> </font>preferred<font style="letter-spacing:0.1pt;"> </font>stock. Our<font style="letter-spacing:0.05pt;"> </font>common<font style="letter-spacing:0.05pt;"> </font>stock has no preemptive<font style="letter-spacing:0.1pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>conversion<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or redemption<font style="letter-spacing:0.1pt;"> </font>or sinking<font style="letter-spacing:0.05pt;"> </font>fund provisions.<font style="letter-spacing:0.05pt;"> </font>In the event of our liquidation,<font style="letter-spacing:0.1pt;"> </font>dissolution<font style="letter-spacing:0.1pt;"> </font>or winding up, holders<font style="letter-spacing:0.05pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock will be<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to share<font style="letter-spacing:0.05pt;"> </font>ratably<font style="letter-spacing:0.05pt;"> </font>in all<font style="letter-spacing:0.05pt;"> </font>assets<font style="letter-spacing:0.05pt;"> </font>remaining<font style="letter-spacing:0.1pt;"> </font>after<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>of all<font style="letter-spacing:0.05pt;"> </font>debts<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>liabilities<font style="letter-spacing:0.15pt;"> </font>and any liquidation<font style="letter-spacing:0.05pt;"> </font>preference<font style="letter-spacing:0.1pt;"> </font>of any outstanding<font style="letter-spacing:0.05pt;"> </font>preferred<font style="letter-spacing:0.1pt;"> </font>stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common<font style="letter-spacing:0.05pt;"> </font>stock is listed<font style="letter-spacing:0.05pt;"> </font>on the Nasdaq Global Market<font style="letter-spacing:0.05pt;"> </font>under the trading<font style="letter-spacing:0.05pt;"> </font>symbol<font style="letter-spacing:0.05pt;"> </font>&#8220;RLAY.&#8221;<font style="letter-spacing:0.05pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:-0.05pt;"> </font>transfer<font style="letter-spacing:0.05pt;"> </font>agent<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>registrar<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:-0.05pt;"> </font>our<font style="letter-spacing:-0.05pt;"> </font>common stock is<font style="letter-spacing:-0.05pt;"> </font>Computershare<font style="letter-spacing:0.05pt;"> </font>Trust<font style="letter-spacing:-0.05pt;"> </font>Company,<font style="letter-spacing:-0.05pt;"> </font>N.A.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred<font style="letter-spacing:0.05pt;"> </font>stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors<font style="letter-spacing:0.1pt;"> </font>has the authority,<font style="letter-spacing:0.05pt;"> </font>without further<font style="letter-spacing:0.05pt;"> </font>action<font style="letter-spacing:0.05pt;"> </font>by our stockholders,<font style="letter-spacing:0.1pt;"> </font>to issue<font style="letter-spacing:0.05pt;"> </font>up to 10,000,000<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock in one or more<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>and to fix the rights,<font style="letter-spacing:0.05pt;"> </font>preferences,<font style="letter-spacing:0.1pt;"> </font>privileges<font style="letter-spacing:0.1pt;"> </font>and restrictions<font style="letter-spacing:0.05pt;"> </font>thereof.<font style="letter-spacing:0.05pt;"> </font>These rights,<font style="letter-spacing:0.05pt;"> </font>preferences<font style="letter-spacing:0.1pt;"> </font>and privileges<font style="letter-spacing:0.1pt;"> </font>could include<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>conversion<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>voting rights,<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of redemption,<font style="letter-spacing:0.1pt;"> </font>liquidation<font style="letter-spacing:0.1pt;"> </font>preferences,<font style="letter-spacing:0.1pt;"> </font>sinking<font style="letter-spacing:0.05pt;"> </font>fund terms<font style="letter-spacing:0.05pt;"> </font>and the number<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>constituting,<font style="letter-spacing:0.1pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>designation<font style="letter-spacing:0.05pt;"> </font>of, such series,<font style="letter-spacing:0.05pt;"> </font>any or all<font style="letter-spacing:0.05pt;"> </font>of which may be greater<font style="letter-spacing:0.05pt;"> </font>than the rights<font style="letter-spacing:0.05pt;"> </font>of common<font style="letter-spacing:0.05pt;"> </font>stock. The issuance<font style="letter-spacing:0.05pt;"> </font>of our preferred<font style="letter-spacing:0.1pt;"> </font>stock could adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the voting power of holders<font style="letter-spacing:0.05pt;"> </font>of common<font style="letter-spacing:0.05pt;"> </font>stock and the likelihood<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>such holders<font style="letter-spacing:0.05pt;"> </font>will receive<font style="letter-spacing:0.05pt;"> </font>dividend<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>and payments<font style="letter-spacing:0.05pt;"> </font>upon our liquidation.<font style="letter-spacing:0.1pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>the issuance<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>preferred<font style="letter-spacing:0.1pt;"> </font>stock could have the effect<font style="letter-spacing:0.05pt;"> </font>of delaying,<font style="letter-spacing:0.05pt;"> </font>deferring<font style="letter-spacing:0.1pt;"> </font>or preventing<font style="letter-spacing:0.05pt;"> </font>a change in control<font style="letter-spacing:0.05pt;"> </font>of our<font style="letter-spacing:0.05pt;"> </font>company or<font style="letter-spacing:-2.35pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>corporate<font style="letter-spacing:0.05pt;"> </font>action.<font style="letter-spacing:0.05pt;"> </font>No<font style="letter-spacing:-0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock are outstanding,<font style="letter-spacing:0.05pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>have no present<font style="letter-spacing:0.05pt;"> </font>plan to issue<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration<font style="letter-spacing:0.05pt;"> </font>rights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock are entitled<font style="letter-spacing:0.1pt;"> </font>to rights<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to the registration<font style="letter-spacing:0.15pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.05pt;"> </font>under the Securities Act. These rights are provided under the terms of a second amended and restated investors&#8217; <font style="letter-spacing:-2.35pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>between us and the holders<font style="letter-spacing:0.05pt;"> </font>of our preferred<font style="letter-spacing:0.1pt;"> </font>stock at the time<font style="letter-spacing:0.05pt;"> </font>of the agreement.<font style="letter-spacing:0.1pt;"> </font>The second<font style="letter-spacing:0.05pt;"> </font>amended<font style="letter-spacing:0.05pt;"> </font>and restated<font style="letter-spacing:0.1pt;"> </font>investors&#8217;<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>includes<font style="letter-spacing:0.05pt;"> </font>demand registration<font style="letter-spacing:0.15pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>short-form<font style="letter-spacing:0.1pt;"> </font>registration<font style="letter-spacing:0.05pt;"> </font>rights,<font style="letter-spacing:0.05pt;"> </font>and piggyback registration<font style="letter-spacing:0.15pt;"> </font>rights.<font style="letter-spacing:0.05pt;"> </font>All fees,<font style="letter-spacing:0.05pt;"> </font>costs<font style="letter-spacing:0.05pt;"> </font>and expenses<font style="letter-spacing:0.05pt;"> </font>of underwritten<font style="letter-spacing:0.1pt;"> </font>registrations<font style="letter-spacing:0.15pt;"> </font>under this<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>will be borne by us and all<font style="letter-spacing:0.05pt;"> </font>selling<font style="letter-spacing:0.05pt;"> </font>expenses,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>underwriting<font style="letter-spacing:0.05pt;"> </font>discounts<font style="letter-spacing:0.05pt;"> </font>and selling<font style="letter-spacing:0.05pt;"> </font>commissions,<font style="letter-spacing:0.1pt;"> </font>will be borne by the holders<font style="letter-spacing:0.05pt;"> </font>of the shares<font style="letter-spacing:0.05pt;"> </font>being registered.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Demand registration<font style="letter-spacing:0.1pt;"> </font>rights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock, are entitled<font style="letter-spacing:0.1pt;"> </font>to demand registration<font style="letter-spacing:0.15pt;"> </font>rights.<font style="letter-spacing:0.05pt;"> </font>Under the terms<font style="letter-spacing:0.05pt;"> </font>of the second<font style="letter-spacing:0.05pt;"> </font>amended and<font style="letter-spacing:-0.05pt;"> </font>restated<font style="letter-spacing:0.1pt;"> </font>investors&#8217;<font style="letter-spacing:0.05pt;"> </font>rights agreement,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.1pt;"> </font>will<font style="letter-spacing:-0.05pt;"> </font>be required, upon<font style="letter-spacing:-0.05pt;"> </font>the written request<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>of holders<font style="letter-spacing:0.05pt;"> </font>of the registrable<font style="letter-spacing:0.1pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>then outstanding<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>would result<font style="letter-spacing:0.05pt;"> </font>in an aggregate<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of at least $7.5<font style="letter-spacing:-0.05pt;"> </font>million,<font style="letter-spacing:0.05pt;"> </font>to file a<font style="letter-spacing:-0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>statement<font style="letter-spacing:0.05pt;"> </font>and to<font style="letter-spacing:-0.05pt;"> </font>use<font style="letter-spacing:-0.05pt;"> </font>commercially<font style="letter-spacing:0.15pt;"> </font>reasonable efforts<font style="letter-spacing:0.05pt;"> </font>to effect the registration of all<font style="letter-spacing:0.05pt;"> </font>or a portion<font style="letter-spacing:0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>for public<font style="letter-spacing:0.05pt;"> </font>resale.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Short-Form registration<font style="letter-spacing:0.1pt;"> </font>rights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to<font style="letter-spacing:-0.05pt;"> </font>our second<font style="letter-spacing:-0.05pt;"> </font>amended<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>restated<font style="letter-spacing:0.05pt;"> </font>investors&#8217;<font style="letter-spacing:0.1pt;"> </font>rights agreement,<font style="letter-spacing:0.1pt;"> </font>if<font style="letter-spacing:-0.05pt;"> </font>we<font style="letter-spacing:-0.1pt;"> </font>are eligible<font style="letter-spacing:0.05pt;"> </font>to file a registration statement<font style="letter-spacing:0.1pt;"> </font>on Form S-3, upon the written<font style="letter-spacing:0.05pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>of at least<font style="letter-spacing:0.05pt;"> </font>10% in interest<font style="letter-spacing:0.1pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>to sell<font style="letter-spacing:0.05pt;"> </font>registrable<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>at an aggregate<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of at least<font style="letter-spacing:0.05pt;"> </font>$1.0 million,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will be required<font style="letter-spacing:0.05pt;"> </font>to use commercially<font style="letter-spacing:0.2pt;"> </font>reasonable<font style="letter-spacing:0.05pt;"> </font>efforts<font style="letter-spacing:0.1pt;"> </font>to effect<font style="letter-spacing:0.05pt;"> </font>a registration<font style="letter-spacing:0.15pt;"> </font>of such shares.<font style="letter-spacing:0.05pt;"> </font>We are required<font style="letter-spacing:0.05pt;"> </font>to effect<font style="letter-spacing:0.05pt;"> </font>only two registrations<font style="letter-spacing:0.15pt;"> </font>in any twelve-<font style="letter-spacing:0.05pt;"> </font>month period<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to this<font style="letter-spacing:0.05pt;"> </font>provision<font style="letter-spacing:0.05pt;"> </font>of the second amended<font style="letter-spacing:0.05pt;"> </font>and restated<font style="letter-spacing:0.1pt;"> </font>investors&#8217;<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>agreement.<font style="letter-spacing:0.1pt;"> </font>The<font style="letter-spacing:0.05pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>to have such shares<font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>on Form S-3 is further<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to other<font style="letter-spacing:0.05pt;"> </font>specified<font style="letter-spacing:0.1pt;"> </font>conditions<font style="letter-spacing:0.05pt;"> </font>and limitations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Piggyback registration<font style="letter-spacing:0.1pt;"> </font>rights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant<font style="letter-spacing:0.05pt;"> </font>to our second amended<font style="letter-spacing:0.05pt;"> </font>and restated<font style="letter-spacing:0.1pt;"> </font>investors&#8217;<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>agreement,<font style="letter-spacing:0.1pt;"> </font>if we<font style="letter-spacing:-0.05pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>any of our securities<font style="letter-spacing:0.05pt;"> </font>either<font style="letter-spacing:0.05pt;"> </font>for our own<font style="letter-spacing:-0.05pt;"> </font>account<font style="letter-spacing:0.05pt;"> </font>or for the account<font style="letter-spacing:0.05pt;"> </font>of other<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>holders,<font style="letter-spacing:0.05pt;"> </font>the holders<font style="letter-spacing:0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>are entitled<font style="letter-spacing:0.15pt;"> </font>to <font style="letter-spacing:-2.35pt;"> </font>include<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>in the registration.<font style="letter-spacing:0.15pt;"> </font>Subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.05pt;"> </font>exceptions<font style="letter-spacing:0.05pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>in the second amended<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>restated<font style="letter-spacing:0.1pt;"> </font>investors&#8217;<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>agreement,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>and the underwriters<font style="letter-spacing:0.1pt;"> </font>may limit<font style="letter-spacing:0.1pt;"> </font>the number<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>underwritten<font style="letter-spacing:0.1pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>to the number<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>which we<font style="letter-spacing:-0.05pt;"> </font>and the underwriters<font style="letter-spacing:0.1pt;"> </font>determine<font style="letter-spacing:0.1pt;"> </font>in our sole discretion<font style="letter-spacing:0.05pt;"> </font>will not jeopardize<font style="letter-spacing:0.1pt;"> </font>the success<font style="letter-spacing:0.05pt;"> </font>of the offering.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expiration of registration<font style="letter-spacing:0.1pt;"> </font>rights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The demand registration<font style="letter-spacing:0.15pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>and short<font style="letter-spacing:0.05pt;"> </font>form<font style="letter-spacing:0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>granted<font style="letter-spacing:0.05pt;"> </font>under our second amended<font style="letter-spacing:0.05pt;"> </font>and restated<font style="letter-spacing:0.05pt;"> </font>investors&#8217;<font style="letter-spacing:0.05pt;"> </font>rights agreement<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:-0.05pt;"> </font>terminate<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:-0.05pt;"> </font>fifth anniversary<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>completion<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>our<font style="letter-spacing:-0.05pt;"> </font>initial<font style="letter-spacing:0.1pt;"> </font>public offering.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover effects<font style="letter-spacing:0.1pt;"> </font>of our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>bylaws and<font style="letter-spacing:-0.05pt;"> </font>Delaware law</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>and bylaws include<font style="letter-spacing:0.05pt;"> </font>a number<font style="letter-spacing:0.05pt;"> </font>of provisions<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>may have the effect<font style="letter-spacing:0.1pt;"> </font>of delaying,<font style="letter-spacing:0.05pt;"> </font>deferring<font style="letter-spacing:0.1pt;"> </font>or preventing<font style="letter-spacing:0.05pt;"> </font>another<font style="letter-spacing:0.05pt;"> </font>party<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>acquiring<font style="letter-spacing:0.05pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>of us and encouraging<font style="letter-spacing:0.05pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>considering<font style="letter-spacing:0.05pt;"> </font>unsolicited<font style="letter-spacing:0.05pt;"> </font>tender offers<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>unilateral<font style="letter-spacing:0.05pt;"> </font>takeover proposals<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>negotiate<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>our board<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>directors<font style="letter-spacing:0.1pt;"> </font>rather than pursue non-negotiated<font style="letter-spacing:0.1pt;"> </font>takeover<font style="letter-spacing:0.05pt;"> </font>attempts.<font style="letter-spacing:0.1pt;"> </font>These provisions<font style="letter-spacing:0.05pt;"> </font>include<font style="letter-spacing:0.05pt;"> </font>the items<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Board<font style="letter-spacing:-0.05pt;"> </font>composition<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>filling<font style="letter-spacing:0.05pt;"> </font>vacancies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>for the division<font style="letter-spacing:0.05pt;"> </font>of our board of directors<font style="letter-spacing:0.1pt;"> </font>into three<font style="letter-spacing:0.05pt;"> </font>classes<font style="letter-spacing:0.05pt;"> </font>serving<font style="letter-spacing:0.05pt;"> </font>staggered<font style="letter-spacing:0.05pt;"> </font>three-year<font style="letter-spacing:0.1pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>with one class<font style="letter-spacing:0.05pt;"> </font>being elected<font style="letter-spacing:0.05pt;"> </font>each year. Our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>also<font style="letter-spacing:0.05pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>directors<font style="letter-spacing:0.1pt;"> </font>may be removed<font style="letter-spacing:0.05pt;"> </font>only for cause and then only by the affirmative<font style="letter-spacing:0.15pt;"> </font>vote of the holders<font style="letter-spacing:0.05pt;"> </font>of two-thirds<font style="letter-spacing:0.05pt;"> </font>or <font style="letter-spacing:-2.35pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>of the shares<font style="letter-spacing:0.05pt;"> </font>then entitled<font style="letter-spacing:0.1pt;"> </font>to vote at an election<font style="letter-spacing:0.05pt;"> </font>of directors.<font style="letter-spacing:0.1pt;"> </font>Furthermore,<font style="letter-spacing:0.1pt;"> </font>any vacancy on our board of<font style="letter-spacing:0.05pt;"> </font>directors,<font style="letter-spacing:0.15pt;"> </font>however<font style="letter-spacing:0.05pt;"> </font>occurring,<font style="letter-spacing:0.15pt;"> </font>including<font style="letter-spacing:0.1pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>vacancy<font style="letter-spacing:0.1pt;"> </font>resulting<font style="letter-spacing:0.15pt;"> </font>from<font style="letter-spacing:0.15pt;"> </font>an<font style="letter-spacing:0.05pt;"> </font>increase<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>size<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.1pt;"> </font>our<font style="letter-spacing:0.05pt;"> </font>board,<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:0.05pt;"> </font>only<font style="letter-spacing:0.05pt;"> </font>be filled<font style="letter-spacing:0.05pt;"> </font>by the affirmative<font style="letter-spacing:0.15pt;"> </font>vote of a majority<font style="letter-spacing:0.1pt;"> </font>of our directors<font style="letter-spacing:0.1pt;"> </font>then in office<font style="letter-spacing:0.05pt;"> </font>even if less<font style="letter-spacing:0.05pt;"> </font>than a quorum. The<font style="letter-spacing:0.05pt;"> </font>classification<font style="letter-spacing:0.15pt;"> </font>of directors,<font style="letter-spacing:0.1pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>with the limitations<font style="letter-spacing:0.15pt;"> </font>on removal<font style="letter-spacing:0.05pt;"> </font>of directors<font style="letter-spacing:0.1pt;"> </font>and treatment<font style="letter-spacing:0.1pt;"> </font>of vacancies,<font style="letter-spacing:0.1pt;"> </font>has<font style="letter-spacing:0.05pt;"> </font>the effect<font style="letter-spacing:0.05pt;"> </font>of making<font style="letter-spacing:0.05pt;"> </font>it more<font style="letter-spacing:0.05pt;"> </font>difficult<font style="letter-spacing:0.1pt;"> </font>for stockholders<font style="letter-spacing:0.1pt;"> </font>to change the composition<font style="letter-spacing:0.1pt;"> </font>of our board of directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">No<font style="letter-spacing:-0.05pt;"> </font>written<font style="letter-spacing:0.05pt;"> </font>consent of stockholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>stockholder<font style="letter-spacing:0.05pt;"> </font>actions<font style="letter-spacing:0.05pt;"> </font>are required<font style="letter-spacing:0.05pt;"> </font>to be taken by a vote of the<font style="letter-spacing:0.05pt;"> </font>stockholders<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:-0.05pt;"> </font>an annual<font style="letter-spacing:-0.05pt;"> </font>or special meeting,<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>that stockholders<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:-0.05pt;"> </font>not take<font style="letter-spacing:-0.05pt;"> </font>any action by written consent in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lieu</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a meeting.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This limit</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may lengthen</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the amount</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of time</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to take stockholder</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actions</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and would</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prevent the amendment of </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our bylaws or removal of directors by our stockholders without holding a meeting o</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stockholders.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Meetings<font style="letter-spacing:0.05pt;"> </font>of stockholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>and bylaws provide<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>only a majority<font style="letter-spacing:0.1pt;"> </font>of the members<font style="letter-spacing:0.05pt;"> </font>of our board of directors<font style="letter-spacing:0.05pt;"> </font>then in office<font style="letter-spacing:0.05pt;"> </font>may call<font style="letter-spacing:0.05pt;"> </font>special<font style="letter-spacing:0.05pt;"> </font>meetings<font style="letter-spacing:0.05pt;"> </font>of stockholders<font style="letter-spacing:0.1pt;"> </font>and only those matters<font style="letter-spacing:0.1pt;"> </font>set forth<font style="letter-spacing:0.05pt;"> </font>in the notice<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>special<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.05pt;"> </font>may be considered<font style="letter-spacing:0.05pt;"> </font>or acted<font style="letter-spacing:0.05pt;"> </font>upon at a special<font style="letter-spacing:0.05pt;"> </font>meeting<font style="letter-spacing:0.05pt;"> </font>of stockholders.<font style="letter-spacing:0.1pt;"> </font>Our bylaws limit<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>business that may be<font style="letter-spacing:-0.05pt;"> </font>conducted<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:-0.05pt;"> </font>an annual<font style="letter-spacing:-0.05pt;"> </font>meeting of stockholders<font style="letter-spacing:0.05pt;"> </font>to those<font style="letter-spacing:-0.05pt;"> </font>matters<font style="letter-spacing:0.1pt;"> </font>properly brought<font style="letter-spacing:-0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>the meeting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advance notice<font style="letter-spacing:0.05pt;"> </font>requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws establish<font style="letter-spacing:0.1pt;"> </font>advance notice<font style="letter-spacing:0.05pt;"> </font>procedures<font style="letter-spacing:0.05pt;"> </font>with regard<font style="letter-spacing:0.05pt;"> </font>to stockholder<font style="letter-spacing:0.05pt;"> </font>proposals<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to the nomination <font style="letter-spacing:-2.35pt;"> </font>of candidates<font style="letter-spacing:0.05pt;"> </font>for election<font style="letter-spacing:0.05pt;"> </font>as directors<font style="letter-spacing:0.1pt;"> </font>or new<font style="letter-spacing:-0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>to be brought before<font style="letter-spacing:0.05pt;"> </font>meetings<font style="letter-spacing:0.05pt;"> </font>of our stockholders.<font style="letter-spacing:0.1pt;"> </font>These procedures<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>notice<font style="letter-spacing:0.05pt;"> </font>of stockholder<font style="letter-spacing:0.05pt;"> </font>proposals<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be timely<font style="letter-spacing:0.05pt;"> </font>given in writing<font style="letter-spacing:0.05pt;"> </font>to our corporate<font style="letter-spacing:0.05pt;"> </font>secretary<font style="letter-spacing:0.1pt;"> </font>prior<font style="letter-spacing:0.05pt;"> </font>to the meeting<font style="letter-spacing:0.05pt;"> </font>at which the action<font style="letter-spacing:0.05pt;"> </font>is to be taken. Generally,<font style="letter-spacing:0.1pt;"> </font>to be timely,<font style="letter-spacing:0.05pt;"> </font>notice<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be received <font style="letter-spacing:-2.35pt;"> </font>at our principal<font style="letter-spacing:0.1pt;"> </font>executive<font style="letter-spacing:0.05pt;"> </font>offices<font style="letter-spacing:0.05pt;"> </font>not less<font style="letter-spacing:0.05pt;"> </font>than 90 days nor more<font style="letter-spacing:0.05pt;"> </font>than 120 days prior<font style="letter-spacing:0.05pt;"> </font>to the first<font style="letter-spacing:0.05pt;"> </font>anniversary<font style="letter-spacing:0.1pt;"> </font>date <font style="letter-spacing:-2.35pt;"> </font>of the annual meeting<font style="letter-spacing:0.05pt;"> </font>for the preceding<font style="letter-spacing:0.05pt;"> </font>year. Our bylaws specify<font style="letter-spacing:0.05pt;"> </font>the requirements<font style="letter-spacing:0.1pt;"> </font>as to form<font style="letter-spacing:0.05pt;"> </font>and content<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>stockholders&#8217;<font style="letter-spacing:0.1pt;"> </font>notices.<font style="letter-spacing:0.05pt;"> </font>These requirements<font style="letter-spacing:0.1pt;"> </font>may preclude<font style="letter-spacing:0.05pt;"> </font>stockholders<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>bringing<font style="letter-spacing:0.05pt;"> </font>matters<font style="letter-spacing:0.1pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>stockholders<font style="letter-spacing:0.1pt;"> </font>at an annual or special<font style="letter-spacing:0.05pt;"> </font>meeting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amendment to certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>bylaws</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required<font style="letter-spacing:0.05pt;"> </font>by law or our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation,<font style="letter-spacing:0.1pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>thereafter<font style="letter-spacing:0.1pt;"> </font>be approved by a majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to vote on the amendment<font style="letter-spacing:0.05pt;"> </font>and a majority<font style="letter-spacing:0.1pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of each class<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to vote thereon<font style="letter-spacing:0.05pt;"> </font>as a class,<font style="letter-spacing:0.05pt;"> </font>except<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the amendment<font style="letter-spacing:0.05pt;"> </font>of the provisions<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to stockholder<font style="letter-spacing:0.05pt;"> </font>action,<font style="letter-spacing:0.05pt;"> </font>board composition,<font style="letter-spacing:0.1pt;"> </font>and limitation<font style="letter-spacing:0.15pt;"> </font>of liability<font style="letter-spacing:0.1pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be approved by not less<font style="letter-spacing:0.05pt;"> </font>than two-thirds<font style="letter-spacing:0.05pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to vote on the amendment,<font style="letter-spacing:0.05pt;"> </font>and not less<font style="letter-spacing:0.05pt;"> </font>than two-thirds<font style="letter-spacing:0.05pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of each class<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to vote thereon<font style="letter-spacing:0.05pt;"> </font>as a class.<font style="letter-spacing:0.05pt;"> </font>Our bylaws may be amended<font style="letter-spacing:0.05pt;"> </font>by the affirmative<font style="letter-spacing:0.15pt;"> </font>vote of a majority<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>directors<font style="letter-spacing:0.1pt;"> </font>then in office,<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to any limitations<font style="letter-spacing:0.15pt;"> </font>set forth<font style="letter-spacing:0.05pt;"> </font>in the bylaws; and may also be amended<font style="letter-spacing:0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>affirmative<font style="letter-spacing:0.15pt;"> </font>vote of a majority<font style="letter-spacing:0.1pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to vote on the amendment,<font style="letter-spacing:0.05pt;"> </font>voting<font style="letter-spacing:0.05pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>as a<font style="letter-spacing:0.05pt;"> </font>single<font style="letter-spacing:0.05pt;"> </font>class,<font style="letter-spacing:0.05pt;"> </font>except<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the amendment<font style="letter-spacing:0.05pt;"> </font>of the provisions<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to notice<font style="letter-spacing:0.05pt;"> </font>of stockholder<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>nominations<font style="letter-spacing:0.1pt;"> </font>and special<font style="letter-spacing:0.05pt;"> </font>meetings<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be approved by not less<font style="letter-spacing:0.05pt;"> </font>than two-thirds<font style="letter-spacing:0.05pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>entitled <font style="letter-spacing:-2.35pt;"> </font>to vote on the amendment,<font style="letter-spacing:0.05pt;"> </font>and not less<font style="letter-spacing:0.05pt;"> </font>than two-thirds<font style="letter-spacing:0.05pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of each class<font style="letter-spacing:0.05pt;"> </font>entitled<font style="letter-spacing:0.1pt;"> </font>to vote.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Undesignated preferred<font style="letter-spacing:0.05pt;"> </font>stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>for 10,000,000 authorized<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock. The existence<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>authorized<font style="letter-spacing:0.05pt;"> </font>but unissued<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock may enable<font style="letter-spacing:0.05pt;"> </font>our board of directors<font style="letter-spacing:0.1pt;"> </font>to discourage<font style="letter-spacing:0.05pt;"> </font>an attempt<font style="letter-spacing:0.1pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>obtain<font style="letter-spacing:0.05pt;"> </font>control<font style="letter-spacing:0.05pt;"> </font>of us by means<font style="letter-spacing:0.05pt;"> </font>of a merger,<font style="letter-spacing:0.05pt;"> </font>tender<font style="letter-spacing:0.05pt;"> </font>offer,<font style="letter-spacing:0.05pt;"> </font>proxy contest<font style="letter-spacing:0.05pt;"> </font>or otherwise.<font style="letter-spacing:0.05pt;"> </font>For example,<font style="letter-spacing:0.05pt;"> </font>if in the due<font style="letter-spacing:0.05pt;"> </font>exercise<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.1pt;"> </font>fiduciary<font style="letter-spacing:0.15pt;"> </font>obligations,<font style="letter-spacing:0.15pt;"> </font>our<font style="letter-spacing:0.05pt;"> </font>board<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>directors<font style="letter-spacing:0.15pt;"> </font>were<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>determine<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>takeover<font style="letter-spacing:0.1pt;"> </font>proposal<font style="letter-spacing:0.1pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>the best interests<font style="letter-spacing:0.1pt;"> </font>of our stockholders,<font style="letter-spacing:0.1pt;"> </font>our board of directors<font style="letter-spacing:0.1pt;"> </font>could cause shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock to be issued<font style="letter-spacing:0.05pt;"> </font>without<font style="letter-spacing:-0.05pt;"> </font>stockholder approval<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>one or<font style="letter-spacing:-0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>private offerings<font style="letter-spacing:0.05pt;"> </font>or other transactions<font style="letter-spacing:0.1pt;"> </font>that might dilute<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>voting or <font style="letter-spacing:-2.35pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>of the proposed acquirer<font style="letter-spacing:0.05pt;"> </font>or insurgent<font style="letter-spacing:0.05pt;"> </font>stockholder<font style="letter-spacing:0.05pt;"> </font>or stockholder<font style="letter-spacing:0.05pt;"> </font>group. In this<font style="letter-spacing:0.05pt;"> </font>regard,<font style="letter-spacing:0.05pt;"> </font>our certificate<font style="letter-spacing:0.05pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>grants<font style="letter-spacing:0.05pt;"> </font>our board of directors<font style="letter-spacing:0.1pt;"> </font>broad power to establish<font style="letter-spacing:0.1pt;"> </font>the rights<font style="letter-spacing:0.05pt;"> </font>and preferences<font style="letter-spacing:0.1pt;"> </font>of authorized<font style="letter-spacing:0.05pt;"> </font>and unissued<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock. The issuance<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock could decrease<font style="letter-spacing:0.05pt;"> </font>the amount<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>earnings<font style="letter-spacing:0.05pt;"> </font>and assets<font style="letter-spacing:0.05pt;"> </font>available<font style="letter-spacing:0.1pt;"> </font>for distribution<font style="letter-spacing:0.1pt;"> </font>to holders<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>of common<font style="letter-spacing:0.05pt;"> </font>stock. The issuance<font style="letter-spacing:0.05pt;"> </font>may also<font style="letter-spacing:0.05pt;"> </font>adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the rights<font style="letter-spacing:0.05pt;"> </font>and powers, including<font style="letter-spacing:0.05pt;"> </font>voting rights,<font style="letter-spacing:0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>and may have the effect<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>delaying,<font style="letter-spacing:0.05pt;"> </font>deterring<font style="letter-spacing:0.1pt;"> </font>or preventing<font style="letter-spacing:0.05pt;"> </font>a change in control<font style="letter-spacing:0.05pt;"> </font>of us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Choice of forum</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws provide<font style="letter-spacing:0.05pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>consent<font style="letter-spacing:0.05pt;"> </font>in writing<font style="letter-spacing:0.05pt;"> </font>to the selection<font style="letter-spacing:0.1pt;"> </font>of an alternative<font style="letter-spacing:0.1pt;"> </font>form,<font style="letter-spacing:0.05pt;"> </font>the Court of<font style="letter-spacing:0.05pt;"> </font>Chancery of the State<font style="letter-spacing:0.05pt;"> </font>of Delaware (or, if the Chancery Court does not have jurisdiction,<font style="letter-spacing:0.1pt;"> </font>the federal<font style="letter-spacing:0.1pt;"> </font>district<font style="letter-spacing:0.1pt;"> </font>court<font style="letter-spacing:0.05pt;"> </font>for the District<font style="letter-spacing:0.1pt;"> </font>of Delaware or other<font style="letter-spacing:0.05pt;"> </font>state<font style="letter-spacing:0.05pt;"> </font>courts<font style="letter-spacing:0.05pt;"> </font>of the State<font style="letter-spacing:0.05pt;"> </font>of Delaware)<font style="letter-spacing:0.05pt;"> </font>will be the sole and exclusive<font style="letter-spacing:0.05pt;"> </font>forum<font style="letter-spacing:0.05pt;"> </font>for:<font style="letter-spacing:0.05pt;"> </font>(1) any derivative<font style="letter-spacing:0.1pt;"> </font>action<font style="letter-spacing:0.05pt;"> </font>or proceeding<font style="letter-spacing:0.05pt;"> </font>brought on our behalf;<font style="letter-spacing:0.05pt;"> </font>(2) any action<font style="letter-spacing:0.05pt;"> </font>asserting<font style="letter-spacing:0.1pt;"> </font>a claim<font style="letter-spacing:0.05pt;"> </font>of breach<font style="letter-spacing:0.1pt;"> </font>of a fiduciary<font style="letter-spacing:0.1pt;"> </font>duty or other<font style="letter-spacing:0.05pt;"> </font>wrongdoing by any of our directors,<font style="letter-spacing:0.1pt;"> </font>officers,<font style="letter-spacing:0.1pt;"> </font>employees<font style="letter-spacing:0.05pt;"> </font>or agents<font style="letter-spacing:0.05pt;"> </font>to us or our<font style="letter-spacing:0.05pt;"> </font>stockholders;<font style="letter-spacing:0.1pt;"> </font>(3) any action<font style="letter-spacing:0.05pt;"> </font>asserting<font style="letter-spacing:0.1pt;"> </font>a claim<font style="letter-spacing:0.05pt;"> </font>against<font style="letter-spacing:0.05pt;"> </font>us arising<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to any provision<font style="letter-spacing:0.05pt;"> </font>of the General<font style="letter-spacing:0.05pt;"> </font>Corporation<font style="letter-spacing:0.05pt;"> </font>Law<font style="letter-spacing:-0.05pt;"> </font>of the State<font style="letter-spacing:0.05pt;"> </font>of Delaware or our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>or bylaws; (4) any action<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>interpret,<font style="letter-spacing:0.1pt;"> </font>apply, enforce<font style="letter-spacing:0.05pt;"> </font>or determine<font style="letter-spacing:0.1pt;"> </font>the validity<font style="letter-spacing:0.05pt;"> </font>of our certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>or bylaws; or<font style="letter-spacing:0.05pt;"> </font>(5) any action<font style="letter-spacing:0.05pt;"> </font>asserting<font style="letter-spacing:0.1pt;"> </font>a claim<font style="letter-spacing:0.05pt;"> </font>governed by the internal<font style="letter-spacing:0.1pt;"> </font>affairs<font style="letter-spacing:0.1pt;"> </font>doctrine.<font style="letter-spacing:0.05pt;"> </font>Our bylaws also provide<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>any person or entity<font style="letter-spacing:0.05pt;"> </font>purchasing or otherwise acquiring<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>our capital stock will<font style="letter-spacing:-0.05pt;"> </font>be deemed to have notice of and <font style="letter-spacing:-2.35pt;"> </font>to have consented<font style="letter-spacing:0.05pt;"> </font>to this<font style="letter-spacing:0.05pt;"> </font>choice<font style="letter-spacing:0.05pt;"> </font>of forum<font style="letter-spacing:0.05pt;"> </font>provision.<font style="letter-spacing:0.05pt;"> </font>It is possible<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>a court<font style="letter-spacing:0.05pt;"> </font>of law could rule<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the choice<font style="letter-spacing:0.1pt;"> </font>of <font style="letter-spacing:-2.35pt;"> </font>forum<font style="letter-spacing:0.05pt;"> </font>provision<font style="letter-spacing:0.05pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>in our restated<font style="letter-spacing:0.1pt;"> </font>certificate<font style="letter-spacing:0.15pt;"> </font>of incorporation<font style="letter-spacing:0.1pt;"> </font>is inapplicable<font style="letter-spacing:0.1pt;"> </font>or unenforceable<font style="letter-spacing:0.1pt;"> </font>if it is<font style="letter-spacing:0.05pt;"> </font>challenged<font style="letter-spacing:0.05pt;"> </font>in a proceeding<font style="letter-spacing:0.05pt;"> </font>or otherwise.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition,<font style="letter-spacing:0.05pt;"> </font>our bylaws provide<font style="letter-spacing:0.05pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>consent<font style="letter-spacing:0.05pt;"> </font>in writing<font style="letter-spacing:0.05pt;"> </font>to the selection<font style="letter-spacing:0.1pt;"> </font>of an alternative<font style="letter-spacing:0.1pt;"> </font>forum,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>United States<font style="letter-spacing:0.05pt;"> </font>District<font style="letter-spacing:0.1pt;"> </font>Court in the District<font style="letter-spacing:0.1pt;"> </font>of Massachusetts<font style="letter-spacing:0.1pt;"> </font>will be the exclusive<font style="letter-spacing:0.05pt;"> </font>forum<font style="letter-spacing:0.05pt;"> </font>for any private<font style="letter-spacing:0.05pt;"> </font>action<font style="letter-spacing:0.05pt;"> </font>asserting<font style="letter-spacing:0.1pt;"> </font>violations<font style="letter-spacing:0.1pt;"> </font>by us<font style="letter-spacing:0.05pt;"> </font>or any of<font style="letter-spacing:0.05pt;"> </font>our directors<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>officers<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>Securities<font style="letter-spacing:0.1pt;"> </font>Act or<font style="letter-spacing:0.05pt;"> </font>the Exchange Act,<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>and regulations<font style="letter-spacing:0.1pt;"> </font>promulgated<font style="letter-spacing:0.1pt;"> </font>thereunder,<font style="letter-spacing:0.05pt;"> </font>and of all<font style="letter-spacing:0.05pt;"> </font>suits<font style="letter-spacing:0.05pt;"> </font>in equity<font style="letter-spacing:0.05pt;"> </font>and actions<font style="letter-spacing:0.05pt;"> </font>at law brought to enforce<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:0.05pt;"> </font>liability<font style="letter-spacing:0.05pt;"> </font>or duty<font style="letter-spacing:-0.05pt;"> </font>created<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>those statutes<font style="letter-spacing:0.05pt;"> </font>or the<font style="letter-spacing:-0.05pt;"> </font>rules<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>regulations<font style="letter-spacing:0.1pt;"> </font>under<font style="letter-spacing:-0.05pt;"> </font>such statutes.<font style="letter-spacing:0.05pt;"> </font>If any action the subject <font style="letter-spacing:-2.35pt;"> </font>matter<font style="letter-spacing:0.1pt;"> </font>of which is within the scope of the preceding<font style="letter-spacing:0.05pt;"> </font>sentence<font style="letter-spacing:0.05pt;"> </font>is filed<font style="letter-spacing:0.05pt;"> </font>in a court<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>than the United States<font style="letter-spacing:0.05pt;"> </font>District<font style="letter-spacing:0.1pt;"> </font>of Massachusetts,<font style="letter-spacing:0.1pt;"> </font>the plaintiff<font style="letter-spacing:0.1pt;"> </font>or plaintiffs<font style="letter-spacing:0.1pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>be deemed<font style="letter-spacing:0.05pt;"> </font>by this<font style="letter-spacing:0.05pt;"> </font>provision<font style="letter-spacing:0.05pt;"> </font>of the bylaws (i)<font style="letter-spacing:0.05pt;"> </font>to have<font style="letter-spacing:0.05pt;"> </font>consented<font style="letter-spacing:0.05pt;"> </font>to removal<font style="letter-spacing:0.05pt;"> </font>of the action<font style="letter-spacing:0.05pt;"> </font>by us to the United States<font style="letter-spacing:0.05pt;"> </font>District<font style="letter-spacing:0.1pt;"> </font>Court in the District<font style="letter-spacing:0.1pt;"> </font>of Massachusetts,<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>the case of an action<font style="letter-spacing:0.05pt;"> </font>filed<font style="letter-spacing:0.05pt;"> </font>in a state<font style="letter-spacing:0.05pt;"> </font>court,<font style="letter-spacing:0.05pt;"> </font>and (ii)<font style="letter-spacing:0.05pt;"> </font>to have consented<font style="letter-spacing:0.05pt;"> </font>to transfer<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>action<font style="letter-spacing:0.05pt;"> </font>to the United States<font style="letter-spacing:0.05pt;"> </font>District<font style="letter-spacing:0.1pt;"> </font>Court in the District<font style="letter-spacing:0.1pt;"> </font>of Massachusetts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 203 of the Delaware general corporation<font style="letter-spacing:0.05pt;"> </font>law</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject<font style="letter-spacing:0.05pt;"> </font>to the provisions<font style="letter-spacing:0.05pt;"> </font>of Section<font style="letter-spacing:0.05pt;"> </font>203 of the Delaware General<font style="letter-spacing:0.05pt;"> </font>Corporation<font style="letter-spacing:0.05pt;"> </font>Law.<font style="letter-spacing:-0.05pt;"> </font>In general, Section<font style="letter-spacing:0.05pt;"> </font>203 prohibits<font style="letter-spacing:0.05pt;"> </font>a publicly<font style="letter-spacing:0.05pt;"> </font>held Delaware corporation<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>engaging in a &#8220;business<font style="letter-spacing:0.05pt;"> </font>combination&#8221;<font style="letter-spacing:0.1pt;"> </font>with an<font style="letter-spacing:0.05pt;"> </font>&#8220;interested<font style="letter-spacing:0.1pt;"> </font>stockholder&#8221;<font style="letter-spacing:0.1pt;"> </font>for a three-year<font style="letter-spacing:0.1pt;"> </font>period<font style="letter-spacing:0.05pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>the time<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>stockholder<font style="letter-spacing:0.05pt;"> </font>becomes<font style="letter-spacing:0.05pt;"> </font>an interested<font style="letter-spacing:0.05pt;"> </font>stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business <font style="letter-spacing:-2.35pt;"> </font>combination<font style="letter-spacing:0.1pt;"> </font>between a corporation<font style="letter-spacing:0.1pt;"> </font>and an interested<font style="letter-spacing:0.1pt;"> </font>stockholder<font style="letter-spacing:0.05pt;"> </font>is prohibited<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>it satisfies<font style="letter-spacing:0.1pt;"> </font>one of the<font style="letter-spacing:0.05pt;"> </font>following<font style="letter-spacing:0.05pt;"> </font>conditions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">before<font style="letter-spacing:0.05pt;"> </font>the stockholder<font style="letter-spacing:0.05pt;"> </font>became<font style="letter-spacing:0.05pt;"> </font>interested,<font style="letter-spacing:0.1pt;"> </font>our board of directors<font style="letter-spacing:0.1pt;"> </font>approved either<font style="letter-spacing:0.05pt;"> </font>the business<font style="letter-spacing:0.05pt;"> </font>combination<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>transaction<font style="letter-spacing:0.05pt;"> </font>which<font style="letter-spacing:-0.05pt;"> </font>resulted in<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>stockholder becoming an<font style="letter-spacing:-0.05pt;"> </font>interested<font style="letter-spacing:0.05pt;"> </font>stockholder;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">upon consummation<font style="letter-spacing:0.1pt;"> </font>of the transaction<font style="letter-spacing:0.1pt;"> </font>which resulted<font style="letter-spacing:0.05pt;"> </font>in the stockholder<font style="letter-spacing:0.05pt;"> </font>becoming<font style="letter-spacing:0.05pt;"> </font>an interested<font style="letter-spacing:0.05pt;"> </font>stockholder,<font style="letter-spacing:0.05pt;"> </font>the interested<font style="letter-spacing:0.1pt;"> </font>stockholder<font style="letter-spacing:0.05pt;"> </font>owned<font style="letter-spacing:-0.05pt;"> </font>at least<font style="letter-spacing:0.05pt;"> </font>85% of the voting stock of the corporation<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>at the time<font style="letter-spacing:0.05pt;"> </font>the transaction<font style="letter-spacing:0.1pt;"> </font>commenced,<font style="letter-spacing:0.05pt;"> </font>excluding<font style="letter-spacing:0.05pt;"> </font>for purposes<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>determining<font style="letter-spacing:0.1pt;"> </font>the voting stock outstanding,<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>owned<font style="letter-spacing:-0.05pt;"> </font>by persons<font style="letter-spacing:0.05pt;"> </font>who<font style="letter-spacing:-0.05pt;"> </font>are directors<font style="letter-spacing:0.1pt;"> </font>and also officers,<font style="letter-spacing:0.1pt;"> </font>and employee<font style="letter-spacing:0.05pt;"> </font>stock<font style="letter-spacing:0.05pt;"> </font>plans, in some instances,<font style="letter-spacing:0.05pt;"> </font>but not the outstanding<font style="letter-spacing:0.05pt;"> </font>voting stock owned<font style="letter-spacing:-0.05pt;"> </font>by the interested<font style="letter-spacing:0.1pt;"> </font>stockholder;<font style="letter-spacing:0.1pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">at or after<font style="letter-spacing:0.05pt;"> </font>the time<font style="letter-spacing:0.05pt;"> </font>the stockholder<font style="letter-spacing:0.05pt;"> </font>became<font style="letter-spacing:0.05pt;"> </font>interested,<font style="letter-spacing:0.1pt;"> </font>the business<font style="letter-spacing:0.05pt;"> </font>combination<font style="letter-spacing:0.1pt;"> </font>was approved by our<font style="letter-spacing:0.05pt;"> </font>board of directors and authorized at an annual or special meeting of the stockholders by the affirmative <font style="letter-spacing:-2.35pt;"> </font>vote of at least<font style="letter-spacing:0.05pt;"> </font>two-thirds<font style="letter-spacing:0.05pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>voting stock which is not owned<font style="letter-spacing:-0.05pt;"> </font>by the interested<font style="letter-spacing:0.05pt;"> </font>stockholder.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section<font style="letter-spacing:0.05pt;"> </font>203 defines<font style="letter-spacing:0.05pt;"> </font>a business<font style="letter-spacing:0.05pt;"> </font>combination<font style="letter-spacing:0.1pt;"> </font>to include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any merger<font style="letter-spacing:0.05pt;"> </font>or consolidation<font style="letter-spacing:0.1pt;"> </font>involving<font style="letter-spacing:0.05pt;"> </font>the corporation<font style="letter-spacing:0.1pt;"> </font>and the interested<font style="letter-spacing:0.1pt;"> </font>stockholder;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any sale,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transfer,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lease,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pledge or other</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disposition</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">involving</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the interested</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stockholder</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of 10% or</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more of</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the assets of the</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corporation;</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exceptions, any transaction</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results in</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the issuance</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="letter-spacing:-2.35pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or transfer</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the corporation</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of any stock of the corporation</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the interested</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">subject to<font style="letter-spacing:-0.05pt;"> </font>exceptions, any transaction<font style="letter-spacing:0.05pt;"> </font>involving the corporation<font style="letter-spacing:0.05pt;"> </font>that has<font style="letter-spacing:-0.05pt;"> </font>the effect of<font style="letter-spacing:-0.05pt;"> </font>increasing<font style="letter-spacing:0.1pt;"> </font>the proportionate<font style="letter-spacing:0.1pt;"> </font>share<font style="letter-spacing:0.05pt;"> </font>of the stock of any class<font style="letter-spacing:0.05pt;"> </font>or series<font style="letter-spacing:0.05pt;"> </font>of the corporation<font style="letter-spacing:0.1pt;"> </font>beneficially<font style="letter-spacing:0.1pt;"> </font>owned<font style="letter-spacing:-0.05pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>interested<font style="letter-spacing:0.1pt;"> </font>stockholder;<font style="letter-spacing:0.1pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the receipt<font style="letter-spacing:0.05pt;"> </font>by the interested<font style="letter-spacing:0.1pt;"> </font>stockholder<font style="letter-spacing:0.05pt;"> </font>of the benefit<font style="letter-spacing:0.05pt;"> </font>of any loans, advances,<font style="letter-spacing:0.05pt;"> </font>guarantees,<font style="letter-spacing:0.05pt;"> </font>pledges<font style="letter-spacing:0.1pt;"> </font>or <font style="letter-spacing:-2.35pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>benefits<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>by or through the corporation.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general,<font style="letter-spacing:0.05pt;"> </font>Section<font style="letter-spacing:0.05pt;"> </font>203 defines<font style="letter-spacing:0.05pt;"> </font>an interested<font style="letter-spacing:0.1pt;"> </font>stockholder<font style="letter-spacing:0.05pt;"> </font>as any entity<font style="letter-spacing:0.05pt;"> </font>or person beneficially<font style="letter-spacing:0.1pt;"> </font>owning 15% or<font style="letter-spacing:0.05pt;"> </font>more of the<font style="letter-spacing:-0.05pt;"> </font>outstanding voting stock<font style="letter-spacing:-0.05pt;"> </font>of the<font style="letter-spacing:-0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>any entity or person<font style="letter-spacing:-0.05pt;"> </font>affiliated<font style="letter-spacing:0.15pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>or controlling<font style="letter-spacing:0.05pt;"> </font>or <font style="letter-spacing:-2.35pt;"> </font>controlled<font style="letter-spacing:0.1pt;"> </font>by the entity<font style="letter-spacing:0.05pt;"> </font>or person.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer agent and<font style="letter-spacing:-0.05pt;"> </font>registrar</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s<font style="letter-spacing:0.15pt;"> </font>address<font style="letter-spacing:0.05pt;"> </font>is P.O.<font style="letter-spacing:-0.05pt;"> </font>Box<font style="letter-spacing:-0.05pt;"> </font>505000, Louisville,<font style="letter-spacing:0.05pt;"> </font>Kentucky 40233, and its<font style="letter-spacing:0.05pt;"> </font>telephone<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>within<font style="letter-spacing:0.05pt;"> </font>the U.S.<font style="letter-spacing:-0.05pt;"> </font>is (800) 736-3001 and outside<font style="letter-spacing:0.05pt;"> </font>the U.S.<font style="letter-spacing:-0.05pt;"> </font>is (781) 575-3100.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><a name="DESCRIPTION_DEBT_SECURITIES"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_DEBT_SECURITIES"></a>OF </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DEBT</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may offer<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>which may be senior<font style="letter-spacing:0.05pt;"> </font>or subordinated.<font style="letter-spacing:0.05pt;"> </font>We refer<font style="letter-spacing:0.05pt;"> </font>to senior<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>subordinated<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>collectively<font style="letter-spacing:0.1pt;"> </font>as debt securities.<font style="letter-spacing:0.1pt;"> </font>Each series<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>may have different<font style="letter-spacing:0.05pt;"> </font>terms.<font style="letter-spacing:0.05pt;"> </font>The following<font style="letter-spacing:0.05pt;"> </font>description<font style="letter-spacing:0.1pt;"> </font>summarizes<font style="letter-spacing:0.1pt;"> </font>the general<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>and provisions<font style="letter-spacing:0.05pt;"> </font>of the debt securities.<font style="letter-spacing:0.1pt;"> </font>We will<font style="letter-spacing:0.05pt;"> </font>describe<font style="letter-spacing:0.05pt;"> </font>the specific<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>and the extent,<font style="letter-spacing:0.05pt;"> </font>if any, to which the general<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>summarized<font style="letter-spacing:0.1pt;"> </font>below apply to any series<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>in the prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to the series<font style="letter-spacing:0.05pt;"> </font>and <font style="letter-spacing:-2.35pt;"> </font>any applicable<font style="letter-spacing:0.1pt;"> </font>free<font style="letter-spacing:0.05pt;"> </font>writing<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>authorize<font style="letter-spacing:0.05pt;"> </font>to be delivered.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue<font style="letter-spacing:0.05pt;"> </font>senior<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time,<font style="letter-spacing:0.05pt;"> </font>in one or more<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>under a senior<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>to be<font style="letter-spacing:0.05pt;"> </font>entered<font style="letter-spacing:0.05pt;"> </font>into between us and a senior<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>to be named in a prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>which we<font style="letter-spacing:-0.05pt;"> </font>refer<font style="letter-spacing:0.05pt;"> </font>to as the<font style="letter-spacing:0.05pt;"> </font>senior<font style="letter-spacing:0.05pt;"> </font>trustee.<font style="letter-spacing:0.05pt;"> </font>We may issue<font style="letter-spacing:0.05pt;"> </font>subordinated<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time,<font style="letter-spacing:0.05pt;"> </font>in one or more<font style="letter-spacing:0.05pt;"> </font>series,<font style="letter-spacing:0.05pt;"> </font>under a<font style="letter-spacing:0.05pt;"> </font>subordinated<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>to be entered<font style="letter-spacing:0.05pt;"> </font>into between us and a subordinated<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>to be named in a prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>which we<font style="letter-spacing:-0.05pt;"> </font>refer<font style="letter-spacing:0.05pt;"> </font>to as the subordinated<font style="letter-spacing:0.05pt;"> </font>trustee.<font style="letter-spacing:0.05pt;"> </font>The forms<font style="letter-spacing:0.05pt;"> </font>of senior<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>and subordinated<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>are filed<font style="letter-spacing:0.05pt;"> </font>as exhibits<font style="letter-spacing:0.05pt;"> </font>to the registration<font style="letter-spacing:0.15pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>of which this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>forms<font style="letter-spacing:0.05pt;"> </font>a part.<font style="letter-spacing:0.05pt;"> </font>Together,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>senior<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>and the subordinated<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>are referred<font style="letter-spacing:0.1pt;"> </font>to as the indentures<font style="letter-spacing:0.05pt;"> </font>and, together,<font style="letter-spacing:0.05pt;"> </font>the senior<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>and the subordinated<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>are referred<font style="letter-spacing:0.1pt;"> </font>to as the trustees.<font style="letter-spacing:0.1pt;"> </font>This prospectus<font style="letter-spacing:0.05pt;"> </font>briefly<font style="letter-spacing:0.05pt;"> </font>outlines<font style="letter-spacing:0.05pt;"> </font>some of the provisions of the indentures.<font style="letter-spacing:0.05pt;"> </font>The following<font style="letter-spacing:0.05pt;"> </font>summary<font style="letter-spacing:0.05pt;"> </font>of the material<font style="letter-spacing:0.1pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>of the indentures<font style="letter-spacing:0.05pt;"> </font>is qualified<font style="letter-spacing:0.1pt;"> </font>in its<font style="letter-spacing:0.05pt;"> </font>entirety<font style="letter-spacing:0.05pt;"> </font>by the provisions<font style="letter-spacing:0.05pt;"> </font>of the indentures,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>definitions<font style="letter-spacing:0.1pt;"> </font>of certain<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>used in the indentures.<font style="letter-spacing:0.05pt;"> </font>Wherever<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:0.05pt;"> </font>refer<font style="letter-spacing:0.05pt;"> </font>to particular<font style="letter-spacing:0.1pt;"> </font>sections<font style="letter-spacing:0.05pt;"> </font>or defined<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of the indentures,<font style="letter-spacing:0.05pt;"> </font>those sections<font style="letter-spacing:0.05pt;"> </font>or defined<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>are incorporated<font style="letter-spacing:0.1pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>reference<font style="letter-spacing:0.1pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>or the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>You<font style="letter-spacing:-0.05pt;"> </font>should review the indentures<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>filed<font style="letter-spacing:0.05pt;"> </font>as exhibits<font style="letter-spacing:0.05pt;"> </font>to the registration<font style="letter-spacing:0.15pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>of which this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>forms<font style="letter-spacing:0.05pt;"> </font>a part<font style="letter-spacing:0.05pt;"> </font>for additional<font style="letter-spacing:0.1pt;"> </font>information.<font style="letter-spacing:0.1pt;"> </font>As<font style="letter-spacing:0.05pt;"> </font>used<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.1pt;"> </font>this<font style="letter-spacing:0.2pt;"> </font>prospectus,<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.15pt;"> </font>term<font style="letter-spacing:0.15pt;"> </font>&#8220;debt<font style="letter-spacing:0.15pt;"> </font>securities&#8221;<font style="letter-spacing:0.2pt;"> </font>includes<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>debt<font style="letter-spacing:0.15pt;"> </font>securities<font style="letter-spacing:0.2pt;"> </font>being<font style="letter-spacing:0.1pt;"> </font>offered<font style="letter-spacing:0.2pt;"> </font>by<font style="letter-spacing:0.1pt;"> </font>this<font style="letter-spacing:0.2pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>and all<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>by us under the indentures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indentures:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">do not limit<font style="letter-spacing:0.1pt;"> </font>the amount<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may issue;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">allow us to issue<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>in one or more<font style="letter-spacing:0.05pt;"> </font>series;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">do not require<font style="letter-spacing:0.05pt;"> </font>us to issue<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>of a series<font style="letter-spacing:0.05pt;"> </font>at the same<font style="letter-spacing:0.05pt;"> </font>time;<font style="letter-spacing:0.05pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">allow us to reopen a series<font style="letter-spacing:0.05pt;"> </font>to issue<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>without the consent<font style="letter-spacing:0.05pt;"> </font>of the holders<font style="letter-spacing:0.05pt;"> </font>of the <font style="letter-spacing:-2.35pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>of such series.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>the senior<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>will be<font style="letter-spacing:0.05pt;"> </font>unsubordinated<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>and will rank equally<font style="letter-spacing:0.05pt;"> </font>with all<font style="letter-spacing:0.05pt;"> </font>of our other<font style="letter-spacing:0.05pt;"> </font>unsecured<font style="letter-spacing:0.05pt;"> </font>and unsubordinated<font style="letter-spacing:0.05pt;"> </font>indebtedness.<font style="letter-spacing:0.05pt;"> </font>Payments<font style="letter-spacing:0.05pt;"> </font>on the subordinated<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>will be subordinated<font style="letter-spacing:0.05pt;"> </font>to the prior<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>in full<font style="letter-spacing:0.05pt;"> </font>of all <font style="letter-spacing:-2.35pt;"> </font>of our senior<font style="letter-spacing:0.05pt;"> </font>indebtedness,<font style="letter-spacing:0.05pt;"> </font>as described<font style="letter-spacing:0.05pt;"> </font>under &#8220;&#8212;Subordination&#8221;<font style="letter-spacing:0.1pt;"> </font>and in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each indenture<font style="letter-spacing:0.05pt;"> </font>provides<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may, but need not, designate<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>than one trustee<font style="letter-spacing:0.05pt;"> </font>under an indenture.<font style="letter-spacing:0.05pt;"> </font>Any<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>under an indenture<font style="letter-spacing:0.05pt;"> </font>may resign<font style="letter-spacing:0.05pt;"> </font>or be removed<font style="letter-spacing:0.05pt;"> </font>and a successor<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>may be appointed<font style="letter-spacing:0.05pt;"> </font>to act with<font style="letter-spacing:0.05pt;"> </font>respect <font style="letter-spacing:-2.35pt;"> </font>to the series<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>administered<font style="letter-spacing:0.1pt;"> </font>by the resigning<font style="letter-spacing:0.05pt;"> </font>or removed<font style="letter-spacing:0.05pt;"> </font>trustee.<font style="letter-spacing:0.05pt;"> </font>If two or more<font style="letter-spacing:0.05pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>are acting <font style="letter-spacing:-2.35pt;"> </font>as trustee<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to different<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>of debt securities,<font style="letter-spacing:0.1pt;"> </font>each trustee<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>be a trustee<font style="letter-spacing:0.05pt;"> </font>of a trust<font style="letter-spacing:0.05pt;"> </font>under the<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>separate<font style="letter-spacing:0.05pt;"> </font>and apart<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the trust<font style="letter-spacing:0.05pt;"> </font>administered<font style="letter-spacing:0.1pt;"> </font>by any other<font style="letter-spacing:0.05pt;"> </font>trustee.<font style="letter-spacing:0.05pt;"> </font>Except as otherwise<font style="letter-spacing:0.05pt;"> </font>indicated<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus,<font style="letter-spacing:0.05pt;"> </font>any action<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>to be taken by each trustee<font style="letter-spacing:0.05pt;"> </font>may be taken by<font style="letter-spacing:0.05pt;"> </font>each trustee<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to, and only with respect<font style="letter-spacing:0.05pt;"> </font>to, the one or more<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>for which it is<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>under the applicable<font style="letter-spacing:0.1pt;"> </font>indenture.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>for each offering<font style="letter-spacing:0.05pt;"> </font>will provide<font style="letter-spacing:0.05pt;"> </font>the following<font style="letter-spacing:0.05pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>where applicable:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the title<font style="letter-spacing:0.05pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>and whether they are senior<font style="letter-spacing:0.05pt;"> </font>or subordinated;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any limit</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon the aggregate</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">principal</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the debt securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of that</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">series;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the date or dates<font style="letter-spacing:0.05pt;"> </font>on which the principal<font style="letter-spacing:0.1pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>is payable;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the price<font style="letter-spacing:0.05pt;"> </font>at which the debt securities<font style="letter-spacing:0.1pt;"> </font>will be issued,<font style="letter-spacing:0.05pt;"> </font>expressed<font style="letter-spacing:0.05pt;"> </font>as a percentage<font style="letter-spacing:0.05pt;"> </font>of the principal<font style="letter-spacing:0.1pt;"> </font>and, if<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>than the principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>thereof,<font style="letter-spacing:0.05pt;"> </font>the portion<font style="letter-spacing:0.05pt;"> </font>of the principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>thereof<font style="letter-spacing:0.05pt;"> </font>payable<font style="letter-spacing:0.05pt;"> </font>upon<font style="letter-spacing:0.05pt;"> </font>declaration<font style="letter-spacing:0.1pt;"> </font>of acceleration<font style="letter-spacing:0.1pt;"> </font>of the maturity<font style="letter-spacing:0.1pt;"> </font>thereof<font style="letter-spacing:0.05pt;"> </font>or, if applicable,<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>portion<font style="letter-spacing:0.05pt;"> </font>of the principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of such debt securities that is convertible into another security of ours or the method by which any such portion<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>be determined;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the rate<font style="letter-spacing:0.05pt;"> </font>or rates<font style="letter-spacing:0.05pt;"> </font>at which the debt securities<font style="letter-spacing:0.1pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>bear interest<font style="letter-spacing:0.15pt;"> </font>or the manner<font style="letter-spacing:0.05pt;"> </font>of calculation <font style="letter-spacing:-2.35pt;"> </font>of such rate<font style="letter-spacing:0.05pt;"> </font>or rates,<font style="letter-spacing:0.05pt;"> </font>if any;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the<font style="letter-spacing:-0.05pt;"> </font>date<font style="letter-spacing:-0.05pt;"> </font>or dates from<font style="letter-spacing:0.05pt;"> </font>which<font style="letter-spacing:-0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:-0.05pt;"> </font>accrue, the interest<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>dates on which<font style="letter-spacing:-0.05pt;"> </font>such interest<font style="letter-spacing:0.05pt;"> </font>will <font style="letter-spacing:-2.35pt;"> </font>be<font style="letter-spacing:-0.05pt;"> </font>payable or<font style="letter-spacing:-0.05pt;"> </font>the manner of<font style="letter-spacing:-0.05pt;"> </font>determination<font style="letter-spacing:0.15pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>such<font style="letter-spacing:-0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>payment dates, the<font style="letter-spacing:-0.05pt;"> </font>place(s)<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>payment, and the record<font style="letter-spacing:0.05pt;"> </font>date for the determination<font style="letter-spacing:0.15pt;"> </font>of holders<font style="letter-spacing:0.05pt;"> </font>to whom interest<font style="letter-spacing:0.1pt;"> </font>is payable<font style="letter-spacing:0.05pt;"> </font>on any such interest<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>dates<font style="letter-spacing:0.05pt;"> </font>or the manner<font style="letter-spacing:0.05pt;"> </font>of determination<font style="letter-spacing:0.15pt;"> </font>of such record<font style="letter-spacing:0.05pt;"> </font>dates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the right,<font style="letter-spacing:0.05pt;"> </font>if any, to extend the interest<font style="letter-spacing:0.1pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>periods<font style="letter-spacing:0.05pt;"> </font>and the duration<font style="letter-spacing:0.05pt;"> </font>of such extension;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the period<font style="letter-spacing:0.05pt;"> </font>or periods<font style="letter-spacing:0.05pt;"> </font>within which, the price<font style="letter-spacing:0.05pt;"> </font>or prices<font style="letter-spacing:0.05pt;"> </font>at which and the terms<font style="letter-spacing:0.05pt;"> </font>and conditions<font style="letter-spacing:0.05pt;"> </font>upon <font style="letter-spacing:-2.35pt;"> </font>which debt securities<font style="letter-spacing:0.1pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>may be redeemed,<font style="letter-spacing:0.05pt;"> </font>converted<font style="letter-spacing:0.05pt;"> </font>or exchanged, in whole or in part;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our obligation,<font style="letter-spacing:0.05pt;"> </font>if any, to redeem<font style="letter-spacing:0.05pt;"> </font>or purchase<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to any sinking<font style="letter-spacing:0.05pt;"> </font>fund, mandatory<font style="letter-spacing:0.05pt;"> </font>redemption,<font style="letter-spacing:0.1pt;"> </font>or analogous<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>(including<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>made in cash in satisfaction<font style="letter-spacing:0.15pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>future<font style="letter-spacing:0.05pt;"> </font>sinking<font style="letter-spacing:0.05pt;"> </font>fund obligations)<font style="letter-spacing:0.1pt;"> </font>or at the option of a holder<font style="letter-spacing:0.05pt;"> </font>thereof<font style="letter-spacing:0.05pt;"> </font>and the period<font style="letter-spacing:0.05pt;"> </font>or periods<font style="letter-spacing:0.05pt;"> </font>within<font style="letter-spacing:0.05pt;"> </font>which, the price<font style="letter-spacing:0.05pt;"> </font>or prices<font style="letter-spacing:0.05pt;"> </font>at which, and the terms<font style="letter-spacing:0.05pt;"> </font>and conditions<font style="letter-spacing:0.05pt;"> </font>upon which, debt securities<font style="letter-spacing:0.1pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>be redeemed<font style="letter-spacing:0.05pt;"> </font>or purchased,<font style="letter-spacing:0.05pt;"> </font>in whole or in part,<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to such obligation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the form<font style="letter-spacing:0.05pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the form<font style="letter-spacing:0.05pt;"> </font>of the Certificate<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>Authentication<font style="letter-spacing:0.1pt;"> </font>for <font style="letter-spacing:-2.35pt;"> </font>such series;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if other<font style="letter-spacing:0.05pt;"> </font>than minimum<font style="letter-spacing:0.1pt;"> </font>denominations<font style="letter-spacing:0.1pt;"> </font>of one thousand U.S.<font style="letter-spacing:-0.05pt;"> </font>dollars<font style="letter-spacing:0.05pt;"> </font>($1,000) or any integral<font style="letter-spacing:0.1pt;"> </font>multiple<font style="letter-spacing:0.1pt;"> </font>of $1,000 thereof,<font style="letter-spacing:0.05pt;"> </font>the denominations<font style="letter-spacing:0.1pt;"> </font>in which the debt securities<font style="letter-spacing:0.1pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>be issuable;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">whether the debt securities<font style="letter-spacing:0.1pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>be issued<font style="letter-spacing:0.05pt;"> </font>in whole or in part<font style="letter-spacing:0.05pt;"> </font>in the form<font style="letter-spacing:0.05pt;"> </font>of a global<font style="letter-spacing:0.05pt;"> </font>debt security<font style="letter-spacing:0.05pt;"> </font>or global<font style="letter-spacing:0.05pt;"> </font>debt securities;<font style="letter-spacing:0.15pt;"> </font>the terms<font style="letter-spacing:0.05pt;"> </font>and conditions,<font style="letter-spacing:0.05pt;"> </font>if any, upon which such global<font style="letter-spacing:0.05pt;"> </font>debt<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>or global<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>may be exchanged in whole or in part<font style="letter-spacing:0.05pt;"> </font>for other<font style="letter-spacing:0.05pt;"> </font>individual<font style="letter-spacing:0.05pt;"> </font>debt<font style="letter-spacing:0.05pt;"> </font>securities;<font style="letter-spacing:0.15pt;"> </font>and the depositary<font style="letter-spacing:0.05pt;"> </font>for such global<font style="letter-spacing:0.05pt;"> </font>debt security<font style="letter-spacing:0.05pt;"> </font>or global<font style="letter-spacing:0.05pt;"> </font>debt securities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">whether the debt securities<font style="letter-spacing:0.1pt;"> </font>will be convertible<font style="letter-spacing:0.1pt;"> </font>into or exchangeable<font style="letter-spacing:0.05pt;"> </font>for common<font style="letter-spacing:0.05pt;"> </font>stock or other<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>of ours or any other<font style="letter-spacing:0.05pt;"> </font>Person and, if so, the terms<font style="letter-spacing:0.05pt;"> </font>and conditions<font style="letter-spacing:0.05pt;"> </font>upon which such debt<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>will be so convertible<font style="letter-spacing:0.1pt;"> </font>or exchangeable,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the conversion<font style="letter-spacing:0.05pt;"> </font>or exchange price,<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option<font style="letter-spacing:-2.35pt;"> </font>or the holders&#8217;<font style="letter-spacing:0.05pt;"> </font>option)<font style="letter-spacing:0.05pt;"> </font>conversion<font style="letter-spacing:0.05pt;"> </font>or exchange features,<font style="letter-spacing:0.1pt;"> </font>and the applicable<font style="letter-spacing:0.1pt;"> </font>conversion<font style="letter-spacing:0.05pt;"> </font>or exchange<font style="letter-spacing:0.05pt;"> </font>period;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any additional<font style="letter-spacing:0.1pt;"> </font>or alternative<font style="letter-spacing:0.1pt;"> </font>events<font style="letter-spacing:0.05pt;"> </font>of default<font style="letter-spacing:0.05pt;"> </font>to those set forth<font style="letter-spacing:0.05pt;"> </font>in the indenture;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any additional<font style="letter-spacing:0.1pt;"> </font>or alternative<font style="letter-spacing:0.1pt;"> </font>covenants<font style="letter-spacing:0.05pt;"> </font>to those set forth<font style="letter-spacing:0.05pt;"> </font>in the indenture;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the currency<font style="letter-spacing:0.05pt;"> </font>or currencies<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>composite<font style="letter-spacing:0.05pt;"> </font>currencies,<font style="letter-spacing:0.1pt;"> </font>in which payment<font style="letter-spacing:0.05pt;"> </font>of the principal<font style="letter-spacing:0.1pt;"> </font>of (and<font style="letter-spacing:0.05pt;"> </font>premium, if any) and interest, if any, on such debt securities shall be payable (if other than the currency <font style="letter-spacing:-2.35pt;"> </font>of the United States<font style="letter-spacing:0.05pt;"> </font>of America),<font style="letter-spacing:0.05pt;"> </font>which unless<font style="letter-spacing:0.05pt;"> </font>otherwise<font style="letter-spacing:0.05pt;"> </font>specified<font style="letter-spacing:0.1pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>be the currency<font style="letter-spacing:0.05pt;"> </font>of the United<font style="letter-spacing:0.05pt;"> </font>States<font style="letter-spacing:0.05pt;"> </font>of America<font style="letter-spacing:0.05pt;"> </font>as at the time<font style="letter-spacing:0.05pt;"> </font>of payment<font style="letter-spacing:0.05pt;"> </font>is legal<font style="letter-spacing:0.05pt;"> </font>tender<font style="letter-spacing:0.05pt;"> </font>for payment<font style="letter-spacing:0.05pt;"> </font>of public<font style="letter-spacing:0.05pt;"> </font>or private<font style="letter-spacing:0.05pt;"> </font>debts;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if the principal<font style="letter-spacing:0.1pt;"> </font>of (and premium,<font style="letter-spacing:0.05pt;"> </font>if any), or interest,<font style="letter-spacing:0.1pt;"> </font>if any, on such debt securities<font style="letter-spacing:0.1pt;"> </font>is to be payable,<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font>our election<font style="letter-spacing:0.05pt;"> </font>or at the election<font style="letter-spacing:0.05pt;"> </font>of any holder<font style="letter-spacing:0.05pt;"> </font>thereof,<font style="letter-spacing:0.05pt;"> </font>in a coin or currency<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>than that<font style="letter-spacing:0.1pt;"> </font>in which such <font style="letter-spacing:-2.35pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>are stated<font style="letter-spacing:0.05pt;"> </font>to be payable,<font style="letter-spacing:0.05pt;"> </font>then the period<font style="letter-spacing:0.05pt;"> </font>or periods<font style="letter-spacing:0.05pt;"> </font>within which, and the terms<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>conditions<font style="letter-spacing:0.05pt;"> </font>upon which, such election<font style="letter-spacing:0.05pt;"> </font>may be made;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="letter-spacing:-2.35pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the terms</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and conditions</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon which the election</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be made;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest,<font style="letter-spacing:0.05pt;"> </font>premium, if any and principal amounts of the debt securities of the series to any holder that is not a<font style="letter-spacing:-2.35pt;"> </font>&#8220;United States<font style="letter-spacing:0.05pt;"> </font>person&#8221;<font style="letter-spacing:0.05pt;"> </font>for federal<font style="letter-spacing:0.05pt;"> </font>tax purposes;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">additional or alternative provisions, if any, related to defeasance and discharge of the offered debt securities<font style="letter-spacing:0.1pt;"> </font>than those set forth<font style="letter-spacing:0.05pt;"> </font>in the indenture;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the applicability<font style="letter-spacing:0.15pt;"> </font>of any guarantees;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any restrictions<font style="letter-spacing:0.15pt;"> </font>on transfer,<font style="letter-spacing:0.1pt;"> </font>sale<font style="letter-spacing:0.05pt;"> </font>or assignment<font style="letter-spacing:0.1pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>of the series;<font style="letter-spacing:0.1pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any other terms of the debt securities (which may supplement, modify or delete any provision of the indenture<font style="letter-spacing:0.05pt;"> </font>insofar<font style="letter-spacing:0.05pt;"> </font>as it applies<font style="letter-spacing:0.05pt;"> </font>to such series).</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>for less<font style="letter-spacing:0.05pt;"> </font>than the entire<font style="letter-spacing:0.05pt;"> </font>principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>thereof<font style="letter-spacing:0.05pt;"> </font>to be payable<font style="letter-spacing:0.1pt;"> </font>upon<font style="letter-spacing:0.05pt;"> </font>declaration<font style="letter-spacing:0.1pt;"> </font>of acceleration<font style="letter-spacing:0.1pt;"> </font>of the maturity<font style="letter-spacing:0.1pt;"> </font>of the debt securities.<font style="letter-spacing:0.1pt;"> </font>We refer<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>any such debt securities<font style="letter-spacing:0.1pt;"> </font>throughout <font style="letter-spacing:-2.35pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>as &#8220;original<font style="letter-spacing:0.1pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>discount<font style="letter-spacing:0.05pt;"> </font>securities.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will provide<font style="letter-spacing:0.05pt;"> </font>you with more<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>regarding<font style="letter-spacing:0.05pt;"> </font>any deletions,<font style="letter-spacing:0.05pt;"> </font>modifications, or additions to the events of default or covenants that are described below, including any addition <font style="letter-spacing:-2.35pt;"> </font>of a covenant<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>provision<font style="letter-spacing:0.05pt;"> </font>providing<font style="letter-spacing:0.05pt;"> </font>event risk<font style="letter-spacing:0.05pt;"> </font>or similar<font style="letter-spacing:0.1pt;"> </font>protection.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>the principal<font style="letter-spacing:0.1pt;"> </font>of, and any premium<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>make-<font style="letter-spacing:-2.35pt;"> </font>whole amount, and interest on, any series of the debt securities will be payable by mailing a check to the address of the person entitled<font style="letter-spacing:0.1pt;"> </font>to it as it appears<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>register<font style="letter-spacing:0.1pt;"> </font>for the debt securities<font style="letter-spacing:0.1pt;"> </font>or by wire transfer<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>funds to that<font style="letter-spacing:0.05pt;"> </font>person at an account<font style="letter-spacing:0.05pt;"> </font>maintained<font style="letter-spacing:0.1pt;"> </font>within the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All monies<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>pay to a paying agent or a trustee<font style="letter-spacing:0.05pt;"> </font>for the payment<font style="letter-spacing:0.05pt;"> </font>of the principal<font style="letter-spacing:0.1pt;"> </font>of,<font style="letter-spacing:0.05pt;"> </font>and any premium,<font style="letter-spacing:0.05pt;"> </font>or interest<font style="letter-spacing:0.1pt;"> </font>on, any debt security<font style="letter-spacing:0.05pt;"> </font>will be repaid<font style="letter-spacing:0.05pt;"> </font>to us if unclaimed<font style="letter-spacing:0.05pt;"> </font>at the end of two years<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.05pt;"> </font>the obligation<font style="letter-spacing:0.05pt;"> </font>underlying<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>becomes<font style="letter-spacing:0.05pt;"> </font>due and payable.<font style="letter-spacing:0.05pt;"> </font>After<font style="letter-spacing:0.05pt;"> </font>funds have been returned<font style="letter-spacing:0.05pt;"> </font>to us, the holder<font style="letter-spacing:0.05pt;"> </font>of the debt<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>may look only to us for payment,<font style="letter-spacing:0.05pt;"> </font>without payment<font style="letter-spacing:0.05pt;"> </font>of interest<font style="letter-spacing:0.1pt;"> </font>for the period<font style="letter-spacing:0.05pt;"> </font>which we<font style="letter-spacing:-0.05pt;"> </font>hold the funds.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Merger,<font style="letter-spacing:0.05pt;"> </font>Consolidation or Sale of Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indentures<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may, without the consent<font style="letter-spacing:0.05pt;"> </font>of the holders<font style="letter-spacing:0.05pt;"> </font>of any outstanding<font style="letter-spacing:0.05pt;"> </font>debt securities, (i) consolidate<font style="letter-spacing:0.05pt;"> </font>with, (ii) sell,<font style="letter-spacing:0.05pt;"> </font>lease or convey<font style="letter-spacing:-0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>substantially<font style="letter-spacing:0.1pt;"> </font>all of our assets to, or<font style="letter-spacing:-0.05pt;"> </font>(iii)<font style="letter-spacing:0.1pt;"> </font>merge with or<font style="letter-spacing:-0.05pt;"> </font>into, any other<font style="letter-spacing:0.05pt;"> </font>entity<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">either<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>are the continuing<font style="letter-spacing:0.05pt;"> </font>entity,<font style="letter-spacing:0.05pt;"> </font>or the successor<font style="letter-spacing:0.05pt;"> </font>entity,<font style="letter-spacing:0.05pt;"> </font>if other<font style="letter-spacing:0.05pt;"> </font>than us, assumes<font style="letter-spacing:0.05pt;"> </font>the obligations (a)<font style="letter-spacing:0.05pt;"> </font>to pay the principal<font style="letter-spacing:0.1pt;"> </font>of, and any premium,<font style="letter-spacing:0.05pt;"> </font>and interest<font style="letter-spacing:0.1pt;"> </font>on, all<font style="letter-spacing:0.05pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>and (b) to duly<font style="letter-spacing:0.05pt;"> </font>perform<font style="letter-spacing:0.05pt;"> </font>and observe<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>of the covenants<font style="letter-spacing:0.05pt;"> </font>and conditions<font style="letter-spacing:0.05pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>indenture;<font style="letter-spacing:0.1pt;"> </font>and in<font style="letter-spacing:0.05pt;"> </font>the event the debt securities<font style="letter-spacing:0.1pt;"> </font>are convertible<font style="letter-spacing:0.1pt;"> </font>into or exchangeable<font style="letter-spacing:0.05pt;"> </font>for common<font style="letter-spacing:0.05pt;"> </font>stock or other<font style="letter-spacing:0.1pt;"> </font>securities<font style="letter-spacing:0.05pt;"> </font>of ours, such successor<font style="letter-spacing:0.05pt;"> </font>entity<font style="letter-spacing:0.05pt;"> </font>will, by such supplemental<font style="letter-spacing:0.1pt;"> </font>indenture,<font style="letter-spacing:0.05pt;"> </font>make provision<font style="letter-spacing:0.05pt;"> </font>so that<font style="letter-spacing:0.05pt;"> </font>the holders<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>thereafter<font style="letter-spacing:0.1pt;"> </font>be entitled<font style="letter-spacing:0.1pt;"> </font>to receive<font style="letter-spacing:0.05pt;"> </font>upon conversion<font style="letter-spacing:0.05pt;"> </font>or exchange of<font style="letter-spacing:0.05pt;"> </font>such debt securities<font style="letter-spacing:0.1pt;"> </font>the number<font style="letter-spacing:0.05pt;"> </font>of securities<font style="letter-spacing:0.1pt;"> </font>or property<font style="letter-spacing:0.05pt;"> </font>to which a holder<font style="letter-spacing:0.05pt;"> </font>of the number<font style="letter-spacing:0.05pt;"> </font>of common<font style="letter-spacing:0.05pt;"> </font>stock or other<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>of ours deliverable<font style="letter-spacing:0.1pt;"> </font>upon conversion<font style="letter-spacing:0.05pt;"> </font>or exchange of those debt securities<font style="letter-spacing:0.1pt;"> </font>would <font style="letter-spacing:-2.35pt;"> </font>have been entitled<font style="letter-spacing:0.1pt;"> </font>had such conversion<font style="letter-spacing:0.05pt;"> </font>or exchange occurred<font style="letter-spacing:0.05pt;"> </font>immediately<font style="letter-spacing:0.15pt;"> </font>prior<font style="letter-spacing:0.05pt;"> </font>to such consolidation,<font style="letter-spacing:0.05pt;"> </font>merger,<font style="letter-spacing:0.05pt;"> </font>sale,<font style="letter-spacing:0.05pt;"> </font>conveyance,<font style="letter-spacing:0.05pt;"> </font>transfer<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>disposition;<font style="letter-spacing:0.1pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">an officers&#8217;<font style="letter-spacing:0.1pt;"> </font>certificate<font style="letter-spacing:0.15pt;"> </font>and legal<font style="letter-spacing:0.05pt;"> </font>opinion covering<font style="letter-spacing:0.05pt;"> </font>such conditions<font style="letter-spacing:0.05pt;"> </font>are delivered<font style="letter-spacing:0.1pt;"> </font>to each applicable trustee.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Events of Default, Notice and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Waiver</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>states<font style="letter-spacing:0.05pt;"> </font>otherwise,<font style="letter-spacing:0.05pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>refer<font style="letter-spacing:0.05pt;"> </font>to &#8220;events<font style="letter-spacing:0.05pt;"> </font>of default&#8221;<font style="letter-spacing:0.05pt;"> </font>as defined<font style="letter-spacing:0.05pt;"> </font>in <font style="letter-spacing:-2.35pt;"> </font>the indentures<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to any series<font style="letter-spacing:0.05pt;"> </font>of debt securities,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>mean:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">default<font style="letter-spacing:0.05pt;"> </font>in the payment<font style="letter-spacing:0.05pt;"> </font>of any installment<font style="letter-spacing:0.15pt;"> </font>of interest<font style="letter-spacing:0.1pt;"> </font>on any debt security<font style="letter-spacing:0.05pt;"> </font>of such series<font style="letter-spacing:0.1pt;"> </font>continuing for <font style="letter-spacing:-2.35pt;"> </font>90 days unless<font style="letter-spacing:0.05pt;"> </font>such date has been extended<font style="letter-spacing:0.05pt;"> </font>or deferred;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">default<font style="letter-spacing:0.05pt;"> </font>in the payment<font style="letter-spacing:0.05pt;"> </font>of principal<font style="letter-spacing:0.1pt;"> </font>of, or any premium<font style="letter-spacing:0.05pt;"> </font>on, any debt security<font style="letter-spacing:0.05pt;"> </font>of such series<font style="letter-spacing:0.05pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>due and payable<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>such date has been extended<font style="letter-spacing:0.05pt;"> </font>or deferred;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">default<font style="letter-spacing:0.05pt;"> </font>in the performance<font style="letter-spacing:0.1pt;"> </font>or breach<font style="letter-spacing:0.05pt;"> </font>of any covenant<font style="letter-spacing:0.05pt;"> </font>or warranty<font style="letter-spacing:0.05pt;"> </font>in the debt securities<font style="letter-spacing:0.1pt;"> </font>or in<font style="letter-spacing:0.05pt;"> </font>the <font style="letter-spacing:-2.35pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>by us continuing<font style="letter-spacing:0.05pt;"> </font>for 90 days after<font style="letter-spacing:0.05pt;"> </font>written<font style="letter-spacing:0.05pt;"> </font>notice<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>below;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">bankruptcy, insolvency or<font style="letter-spacing:-0.05pt;"> </font>reorganization,<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>court appointment<font style="letter-spacing:0.05pt;"> </font>of a<font style="letter-spacing:-0.05pt;"> </font>receiver,<font style="letter-spacing:0.05pt;"> </font>liquidator<font style="letter-spacing:0.05pt;"> </font>or trustee of<font style="letter-spacing:-0.05pt;"> </font>us; <font style="letter-spacing:-2.35pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any other<font style="letter-spacing:0.05pt;"> </font>event of default<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to a particular<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>of debt securities.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an event of default<font style="letter-spacing:0.05pt;"> </font>(other<font style="letter-spacing:0.05pt;"> </font>than an event of default<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in the fourth<font style="letter-spacing:0.05pt;"> </font>bullet<font style="letter-spacing:0.05pt;"> </font>point above) occurs<font style="letter-spacing:0.05pt;"> </font>and is<font style="letter-spacing:0.05pt;"> </font>continuing<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to debt securities<font style="letter-spacing:0.1pt;"> </font>of any series<font style="letter-spacing:0.05pt;"> </font>outstanding,<font style="letter-spacing:0.05pt;"> </font>then the applicable<font style="letter-spacing:0.1pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>or the holders<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>25% or more<font style="letter-spacing:0.05pt;"> </font>in principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>will have the right<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>declare<font style="letter-spacing:0.05pt;"> </font>the principal<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of, and accrued<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>on, all<font style="letter-spacing:0.05pt;"> </font>the debt securities<font style="letter-spacing:0.1pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>to be due and payable.<font style="letter-spacing:0.05pt;"> </font>If an event of<font style="letter-spacing:0.05pt;"> </font>default<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in the fourth<font style="letter-spacing:0.05pt;"> </font>bullet<font style="letter-spacing:0.05pt;"> </font>point above occurs,<font style="letter-spacing:0.05pt;"> </font>the principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of, and accrued<font style="letter-spacing:0.1pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>on, all<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>will automatically<font style="letter-spacing:0.15pt;"> </font>become<font style="letter-spacing:0.05pt;"> </font>and will be immediately<font style="letter-spacing:0.15pt;"> </font>due and payable<font style="letter-spacing:0.1pt;"> </font>without any<font style="letter-spacing:0.05pt;"> </font>declaration<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>act on the part<font style="letter-spacing:0.05pt;"> </font>of the trustee<font style="letter-spacing:0.05pt;"> </font>or the holders<font style="letter-spacing:0.05pt;"> </font>of the debt securities.<font style="letter-spacing:0.1pt;"> </font>However,<font style="letter-spacing:0.05pt;"> </font>at any time<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.05pt;"> </font>such a declaration<font style="letter-spacing:0.1pt;"> </font>of acceleration<font style="letter-spacing:0.1pt;"> </font>has been made, but before<font style="letter-spacing:0.05pt;"> </font>a judgment<font style="letter-spacing:0.05pt;"> </font>or decree<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>of the money due <font style="letter-spacing:-2.35pt;"> </font>has been obtained<font style="letter-spacing:0.05pt;"> </font>by the applicable<font style="letter-spacing:0.1pt;"> </font>trustee,<font style="letter-spacing:0.05pt;"> </font>the holders<font style="letter-spacing:0.05pt;"> </font>of at least<font style="letter-spacing:0.05pt;"> </font>a majority<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of outstanding<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>of such series<font style="letter-spacing:0.05pt;"> </font>or of all<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>then outstanding<font style="letter-spacing:0.05pt;"> </font>under the applicable<font style="letter-spacing:0.15pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>may rescind and annul such declaration<font style="letter-spacing:0.1pt;"> </font>and its<font style="letter-spacing:0.05pt;"> </font>consequences<font style="letter-spacing:0.05pt;"> </font>if:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we<font style="letter-spacing:-0.05pt;"> </font>have deposited<font style="letter-spacing:0.05pt;"> </font>with the applicable<font style="letter-spacing:0.1pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>required<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>of the principal,<font style="letter-spacing:0.1pt;"> </font>any premium,<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.05pt;"> </font>and,<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>the extent permitted<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>law, interest<font style="letter-spacing:0.05pt;"> </font>on<font style="letter-spacing:-0.05pt;"> </font>overdue installment<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>interest,<font style="letter-spacing:0.05pt;"> </font>plus applicable <font style="letter-spacing:-2.35pt;"> </font>fees,<font style="letter-spacing:0.05pt;"> </font>expenses,<font style="letter-spacing:0.05pt;"> </font>disbursements<font style="letter-spacing:0.1pt;"> </font>and advances<font style="letter-spacing:0.05pt;"> </font>of the applicable<font style="letter-spacing:0.1pt;"> </font>trustee;<font style="letter-spacing:0.1pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">all events of<font style="letter-spacing:-0.05pt;"> </font>default,<font style="letter-spacing:0.05pt;"> </font>other than<font style="letter-spacing:-0.05pt;"> </font>the non-payment of<font style="letter-spacing:-0.05pt;"> </font>accelerated<font style="letter-spacing:0.1pt;"> </font>principal,<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>a specified<font style="letter-spacing:0.05pt;"> </font>portion thereof, and any premium,<font style="letter-spacing:0.05pt;"> </font>have been cured or waived.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indentures<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>of any series<font style="letter-spacing:0.05pt;"> </font>may not institute<font style="letter-spacing:0.1pt;"> </font>any proceedings,<font style="letter-spacing:0.05pt;"> </font>judicial<font style="letter-spacing:0.15pt;"> or o</font>therwise,<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to such indenture<font style="letter-spacing:0.05pt;"> </font>or for any remedy<font style="letter-spacing:0.05pt;"> </font>under the indenture,<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>the trustee<font style="letter-spacing:0.05pt;"> </font>fails<font style="letter-spacing:0.05pt;"> </font>to act for <font style="letter-spacing:-2.35pt;"> </font>a period<font style="letter-spacing:0.05pt;"> </font>of 90 days after<font style="letter-spacing:0.05pt;"> </font>the trustee<font style="letter-spacing:0.05pt;"> </font>has received<font style="letter-spacing:0.05pt;"> </font>a written<font style="letter-spacing:0.05pt;"> </font>request<font style="letter-spacing:0.05pt;"> </font>to institute<font style="letter-spacing:0.1pt;"> </font>proceedings<font style="letter-spacing:0.05pt;"> </font>in respect<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>an event<font style="letter-spacing:0.05pt;"> </font>of default<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the holders<font style="letter-spacing:0.05pt;"> </font>of 25% or more<font style="letter-spacing:0.05pt;"> </font>in principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>of such series,<font style="letter-spacing:0.05pt;"> </font>as well as an offer<font style="letter-spacing:0.05pt;"> </font>of indemnity<font style="letter-spacing:0.05pt;"> </font>reasonably<font style="letter-spacing:0.05pt;"> </font>satisfactory<font style="letter-spacing:0.15pt;"> </font>to the trustee.<font style="letter-spacing:0.05pt;"> </font>However, this<font style="letter-spacing:0.05pt;"> </font>provision<font style="letter-spacing:0.05pt;"> </font>will not prevent<font style="letter-spacing:0.05pt;"> </font>any holder<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>instituting<font style="letter-spacing:0.1pt;"> </font>suit<font style="letter-spacing:0.05pt;"> </font>for the enforcement<font style="letter-spacing:0.1pt;"> </font>of payment<font style="letter-spacing:0.05pt;"> </font>of the principal<font style="letter-spacing:0.1pt;"> </font>of, and any<font style="letter-spacing:0.05pt;"> </font>premium,<font style="letter-spacing:0.05pt;"> </font>and interest<font style="letter-spacing:0.1pt;"> </font>on, such debt securities<font style="letter-spacing:0.1pt;"> </font>at the respective<font style="letter-spacing:0.1pt;"> </font>due dates<font style="letter-spacing:0.05pt;"> </font>thereof.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indentures<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to provisions<font style="letter-spacing:0.05pt;"> </font>in each indenture<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to its<font style="letter-spacing:0.05pt;"> </font>duties<font style="letter-spacing:0.05pt;"> </font>in the<font style="letter-spacing:0.05pt;"> </font>case of a default,<font style="letter-spacing:0.05pt;"> a t</font>rustee<font style="letter-spacing:0.05pt;"> </font>has no obligation<font style="letter-spacing:0.05pt;"> </font>to exercise<font style="letter-spacing:0.05pt;"> </font>any of its<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or powers at the request<font style="letter-spacing:0.05pt;"> </font>or direction<font style="letter-spacing:0.1pt;"> </font>of any holders<font style="letter-spacing:0.05pt;"> </font>of any<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>then outstanding<font style="letter-spacing:0.05pt;"> </font>under the indenture,<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>the holders<font style="letter-spacing:0.05pt;"> </font>have offered<font style="letter-spacing:0.05pt;"> </font>to the trustee<font style="letter-spacing:0.05pt;"> </font>reasonable<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>or indemnity.<font style="letter-spacing:0.05pt;"> </font>The holders<font style="letter-spacing:0.05pt;"> </font>of at least<font style="letter-spacing:0.05pt;"> </font>a majority<font style="letter-spacing:0.1pt;"> </font>in principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>debt<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>of any series<font style="letter-spacing:0.05pt;"> </font>or of all<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>then outstanding<font style="letter-spacing:0.05pt;"> </font>under an indenture<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>have the right<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>direct<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>time, method<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>place<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>conducting<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>proceeding for any<font style="letter-spacing:-0.05pt;"> </font>remedy<font style="letter-spacing:0.05pt;"> </font>available<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:-0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>trustee, or<font style="letter-spacing:-0.05pt;"> </font>of exercising<font style="letter-spacing:0.1pt;"> </font>any trust<font style="letter-spacing:0.05pt;"> </font>or power conferred<font style="letter-spacing:0.05pt;"> </font>upon such trustee.<font style="letter-spacing:0.05pt;"> </font>However, a trustee<font style="letter-spacing:0.05pt;"> </font>may refuse<font style="letter-spacing:0.05pt;"> </font>to follow any direction<font style="letter-spacing:0.05pt;"> </font>which:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">is in conflict<font style="letter-spacing:0.1pt;"> </font>with any law or the applicable<font style="letter-spacing:0.1pt;"> </font>indenture;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may involve</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the trustee</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in personal</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability;</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">may be unduly prejudicial<font style="letter-spacing:0.1pt;"> </font>to the holders<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>not joining<font style="letter-spacing:0.05pt;"> </font>the proceeding.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within<font style="letter-spacing:0.05pt;"> </font>120 days after<font style="letter-spacing:0.05pt;"> </font>the close<font style="letter-spacing:0.05pt;"> </font>of each fiscal<font style="letter-spacing:0.05pt;"> </font>year, we<font style="letter-spacing:-0.05pt;"> </font>will be required<font style="letter-spacing:0.05pt;"> </font>to deliver<font style="letter-spacing:0.05pt;"> </font>to each trustee<font style="letter-spacing:0.1pt;"> </font>a certificate,<font style="letter-spacing:0.05pt;"> </font>signed by one of our several<font style="letter-spacing:0.05pt;"> </font>specified<font style="letter-spacing:0.1pt;"> </font>officers,<font style="letter-spacing:0.1pt;"> </font>stating<font style="letter-spacing:0.05pt;"> </font>whether or not that<font style="letter-spacing:0.05pt;"> </font>officer<font style="letter-spacing:0.1pt;"> </font>has knowledge of any default<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:-0.05pt;"> </font>the applicable<font style="letter-spacing:0.05pt;"> </font>indenture. If the<font style="letter-spacing:-0.05pt;"> </font>officer<font style="letter-spacing:0.1pt;"> </font>has<font style="letter-spacing:-0.05pt;"> </font>knowledge of<font style="letter-spacing:-0.05pt;"> </font>any default, the notice must<font style="letter-spacing:0.05pt;"> </font>specify the nature and status<font style="letter-spacing:0.05pt;"> </font>of the default.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Modification<font style="letter-spacing:0.1pt;"> </font>of the Indentures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject<font style="letter-spacing:0.05pt;"> </font>to certain<font style="letter-spacing:0.05pt;"> </font>exceptions,<font style="letter-spacing:0.05pt;"> </font>the indentures<font style="letter-spacing:0.05pt;"> </font>may be amended<font style="letter-spacing:0.05pt;"> </font>with the consent<font style="letter-spacing:0.05pt;"> </font>of the holders<font style="letter-spacing:0.05pt;"> </font>of a majority<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>aggregate principal<font style="letter-spacing:0.05pt;"> </font>amount of the<font style="letter-spacing:-0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>debt<font style="letter-spacing:-0.05pt;"> </font>securities<font style="letter-spacing:0.05pt;"> </font>of all series affected<font style="letter-spacing:0.1pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>such<font style="letter-spacing:-0.05pt;"> </font>amendment<font style="letter-spacing:0.05pt;"> </font>(including consents<font style="letter-spacing:0.05pt;"> </font>obtained<font style="letter-spacing:0.05pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with a tender<font style="letter-spacing:0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>or exchange for the debt securities<font style="letter-spacing:0.1pt;"> </font>of such series).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>the applicable<font style="letter-spacing:0.05pt;"> </font>trustee may make<font style="letter-spacing:-0.05pt;"> </font>modifications<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>amendments<font style="letter-spacing:0.05pt;"> </font>of an<font style="letter-spacing:-0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>without<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>consent<font style="letter-spacing:0.05pt;"> </font>of <font style="letter-spacing:-2.35pt;"> </font>any holder<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>for any of the following<font style="letter-spacing:0.05pt;"> </font>purposes:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to<font style="letter-spacing:-0.05pt;"> </font>cure<font style="letter-spacing:-0.05pt;"> </font>any ambiguity, defect,<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>inconsistency<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>the applicable<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>in the<font style="letter-spacing:-0.05pt;"> </font>Securities<font style="letter-spacing:0.05pt;"> </font>of any series;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to comply<font style="letter-spacing:0.05pt;"> </font>with the covenant<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>above under &#8220;&#8212;Merger,<font style="letter-spacing:0.05pt;"> </font>Consolidation<font style="letter-spacing:0.05pt;"> </font>or Sale of Assets;&#8221;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to provide<font style="letter-spacing:0.05pt;"> </font>for uncertificated<font style="letter-spacing:0.15pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>in addition<font style="letter-spacing:0.05pt;"> </font>to or in place<font style="letter-spacing:0.1pt;"> </font>of certificated<font style="letter-spacing:0.15pt;"> </font>debt securities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to add events<font style="letter-spacing:0.05pt;"> </font>of default<font style="letter-spacing:0.05pt;"> </font>for the benefit<font style="letter-spacing:0.05pt;"> </font>of the holders<font style="letter-spacing:0.05pt;"> </font>of all<font style="letter-spacing:0.05pt;"> </font>or any series<font style="letter-spacing:0.05pt;"> </font>of debt securities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to<font style="letter-spacing:0.05pt;"> </font>add<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>covenants,<font style="letter-spacing:0.1pt;"> </font>restrictions,<font style="letter-spacing:0.2pt;"> </font>conditions<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.1pt;"> </font>relating<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>us<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>benefit<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of all<font style="letter-spacing:0.05pt;"> </font>or any series<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>(and if such covenants,<font style="letter-spacing:0.05pt;"> </font>restrictions,<font style="letter-spacing:0.15pt;"> </font>conditions<font style="letter-spacing:0.05pt;"> </font>or provisions<font style="letter-spacing:0.05pt;"> </font>are to <font style="letter-spacing:-2.35pt;"> </font>be for the benefit<font style="letter-spacing:0.05pt;"> </font>of less<font style="letter-spacing:0.05pt;"> </font>than all<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>of debt securities,<font style="letter-spacing:0.1pt;"> </font>stating<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>such covenants,<font style="letter-spacing:0.05pt;"> </font>restrictions,<font style="letter-spacing:0.05pt;"> </font>conditions<font style="letter-spacing:0.05pt;"> </font>or provisions<font style="letter-spacing:0.05pt;"> </font>are expressly<font style="letter-spacing:0.05pt;"> </font>being included<font style="letter-spacing:0.05pt;"> </font>solely<font style="letter-spacing:0.05pt;"> </font>for the benefit<font style="letter-spacing:0.05pt;"> </font>of such series),<font style="letter-spacing:0.1pt;"> </font>to make the<font style="letter-spacing:0.05pt;"> </font>occurrence,<font style="letter-spacing:0.05pt;"> </font>or the occurrence<font style="letter-spacing:0.05pt;"> </font>and the continuance,<font style="letter-spacing:0.05pt;"> </font>of a default<font style="letter-spacing:0.05pt;"> </font>in any such additional<font style="letter-spacing:0.1pt;"> </font>covenants,<font style="letter-spacing:0.05pt;"> </font>restrictions,<font style="letter-spacing:0.15pt;"> </font>conditions<font style="letter-spacing:0.05pt;"> </font>or provisions<font style="letter-spacing:0.05pt;"> </font>an event of default,<font style="letter-spacing:0.05pt;"> </font>or to surrender<font style="letter-spacing:0.05pt;"> </font>any right<font style="letter-spacing:0.05pt;"> </font>or power in the<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>conferred<font style="letter-spacing:0.05pt;"> </font>upon us;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to add to, delete<font style="letter-spacing:0.05pt;"> </font>from,<font style="letter-spacing:0.05pt;"> </font>or revise<font style="letter-spacing:0.05pt;"> </font>the conditions,<font style="letter-spacing:0.05pt;"> </font>limitations,<font style="letter-spacing:0.15pt;"> </font>and restrictions<font style="letter-spacing:0.15pt;"> </font>on the authorized<font style="letter-spacing:0.1pt;"> </font>amount,<font style="letter-spacing:0.05pt;"> </font>terms, or<font style="letter-spacing:-0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>issue,<font style="letter-spacing:0.05pt;"> </font>authentication,<font style="letter-spacing:0.05pt;"> </font>and delivery of debt<font style="letter-spacing:-0.05pt;"> </font>securities,<font style="letter-spacing:0.05pt;"> </font>as set<font style="letter-spacing:-0.05pt;"> </font>forth<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>the applicable indenture;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to make any change that<font style="letter-spacing:0.05pt;"> </font>does not adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the rights<font style="letter-spacing:0.05pt;"> </font>of any holder<font style="letter-spacing:0.05pt;"> </font>of notes under the<font style="letter-spacing:0.05pt;"> </font>applicable indenture<font style="letter-spacing:0.05pt;"> </font>in any material<font style="letter-spacing:0.1pt;"> </font>respect;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to provide<font style="letter-spacing:0.05pt;"> </font>for the issuance<font style="letter-spacing:0.05pt;"> </font>of and establish<font style="letter-spacing:0.1pt;"> </font>the form<font style="letter-spacing:0.05pt;"> </font>and terms<font style="letter-spacing:0.05pt;"> </font>and conditions<font style="letter-spacing:0.05pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>series as provided in<font style="letter-spacing:-0.05pt;"> </font>the applicable<font style="letter-spacing:0.05pt;"> </font>indenture, to establish<font style="letter-spacing:0.05pt;"> </font>the form of<font style="letter-spacing:-0.05pt;"> </font>any certifications<font style="letter-spacing:0.1pt;"> </font>required to<font style="letter-spacing:-2.35pt;"> </font>be furnished<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to the terms<font style="letter-spacing:0.05pt;"> </font>of the applicable<font style="letter-spacing:0.1pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>or any series<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>under the<font style="letter-spacing:0.05pt;"> </font>applicable<font style="letter-spacing:0.1pt;"> </font>indenture,<font style="letter-spacing:0.05pt;"> </font>or to add to the rights<font style="letter-spacing:0.05pt;"> </font>of the holders<font style="letter-spacing:0.05pt;"> </font>of any series<font style="letter-spacing:0.05pt;"> </font>of debt securities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to evidence and provide for the acceptance of appointment under the applicable indenture by a successor<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>or to appoint<font style="letter-spacing:0.05pt;"> </font>a separate<font style="letter-spacing:0.05pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to any series;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to comply with any requirements of the SEC or any successor in connection with the qualification of the indenture<font style="letter-spacing:0.05pt;"> </font>under the Trust Indenture<font style="letter-spacing:0.05pt;"> </font>Act of 1939, as amended,<font style="letter-spacing:0.05pt;"> </font>or the Trust Indenture<font style="letter-spacing:0.05pt;"> </font>Act; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to conform the applicable indenture to this &#8220;&#8212;Description of Debt Securities&#8221; or any other similarly titled<font style="letter-spacing:0.05pt;"> </font>section<font style="letter-spacing:0.05pt;"> </font>in any prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>document<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to a series<font style="letter-spacing:0.05pt;"> </font>of debt<font style="letter-spacing:0.05pt;"> </font>securities.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subordination</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment<font style="letter-spacing:0.05pt;"> </font>by us of the principal<font style="letter-spacing:0.1pt;"> </font>of, premium,<font style="letter-spacing:0.05pt;"> </font>if any, and interest<font style="letter-spacing:0.1pt;"> </font>on any series<font style="letter-spacing:0.05pt;"> </font>of subordinated<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>under the subordinated<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>will be subordinated<font style="letter-spacing:0.05pt;"> </font>to the extent<font style="letter-spacing:0.05pt;"> </font>set forth<font style="letter-spacing:0.05pt;"> </font>in an indenture<font style="letter-spacing:0.05pt;"> </font>supplemental <font style="letter-spacing:-2.35pt;"> </font>to the subordinated<font style="letter-spacing:0.05pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to such series.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discharge, Defeasance and<font style="letter-spacing:-0.05pt;"> </font>Covenant<font style="letter-spacing:-0.05pt;"> </font>Defeasance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise provided in the applicable prospectus supplement, the indentures allow us to discharge our obligations<font style="letter-spacing:0.1pt;"> </font>to holders<font style="letter-spacing:0.05pt;"> </font>of any series<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.1pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>under any indenture<font style="letter-spacing:0.05pt;"> </font>when:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">either<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>of such series<font style="letter-spacing:0.05pt;"> </font>have already<font style="letter-spacing:0.05pt;"> </font>been delivered<font style="letter-spacing:0.05pt;"> </font>to the applicable<font style="letter-spacing:0.1pt;"> </font>trustee<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>cancellation;<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>(ii)<font style="letter-spacing:0.05pt;"> </font>all securities<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>such series have<font style="letter-spacing:-0.05pt;"> </font>not already been delivered to the<font style="letter-spacing:-0.05pt;"> </font>applicable<font style="letter-spacing:0.05pt;"> </font>trustee for cancellation<font style="letter-spacing:0.1pt;"> </font>but (a)<font style="letter-spacing:0.1pt;"> </font>have become<font style="letter-spacing:0.05pt;"> </font>due<font style="letter-spacing:0.05pt;"> </font>and payable,<font style="letter-spacing:0.05pt;"> </font>(b) will<font style="letter-spacing:0.05pt;"> </font>become<font style="letter-spacing:0.05pt;"> </font>due and<font style="letter-spacing:0.05pt;"> </font>payable<font style="letter-spacing:0.05pt;"> </font>within one<font style="letter-spacing:0.05pt;"> </font>year, or (c)<font style="letter-spacing:0.05pt;"> </font>if redeemable<font style="letter-spacing:0.1pt;"> </font>at our option, are to be redeemed<font style="letter-spacing:0.05pt;"> </font>within one year, and we<font style="letter-spacing:-0.05pt;"> </font>have irrevocably<font style="letter-spacing:0.05pt;"> </font>deposited<font style="letter-spacing:0.05pt;"> </font>with the applicable<font style="letter-spacing:0.1pt;"> </font>trustee,<font style="letter-spacing:0.05pt;"> </font>in trust,<font style="letter-spacing:0.05pt;"> </font>funds in such currency<font style="letter-spacing:0.05pt;"> </font>or currencies,<font style="letter-spacing:0.1pt;"> </font>or governmental<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.1pt;"> </font>in an amount<font style="letter-spacing:0.05pt;"> </font>sufficient<font style="letter-spacing:0.1pt;"> </font>to pay the entire<font style="letter-spacing:0.05pt;"> </font>indebtedness<font style="letter-spacing:0.05pt;"> </font>on such debt securities<font style="letter-spacing:0.1pt;"> </font>in respect<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>principal<font style="letter-spacing:0.1pt;"> </font>and any premium,<font style="letter-spacing:0.05pt;"> </font>and interest<font style="letter-spacing:0.1pt;"> </font>to the date of such deposit<font style="letter-spacing:0.05pt;"> </font>if such debt securities<font style="letter-spacing:0.15pt;"> </font>have become<font style="letter-spacing:0.05pt;"> </font>due and payable<font style="letter-spacing:0.05pt;"> </font>or, if they have not, to the stated<font style="letter-spacing:0.05pt;"> </font>maturity<font style="letter-spacing:0.1pt;"> </font>or redemption<font style="letter-spacing:0.1pt;"> </font>date;<font style="letter-spacing:0.05pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we<font style="letter-spacing:-0.05pt;"> </font>have paid or caused to be paid all<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>sums payable.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise<font style="letter-spacing:0.05pt;"> </font>provided<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>the indentures<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>that,<font style="letter-spacing:0.05pt;"> </font>upon our<font style="letter-spacing:0.05pt;"> </font>irrevocable<font style="letter-spacing:0.1pt;"> </font>deposit<font style="letter-spacing:0.05pt;"> </font>with the applicable<font style="letter-spacing:0.1pt;"> </font>trustee,<font style="letter-spacing:0.05pt;"> </font>in trust,<font style="letter-spacing:0.05pt;"> </font>of an amount,<font style="letter-spacing:0.05pt;"> </font>in such currency<font style="letter-spacing:0.05pt;"> </font>or currencies<font style="letter-spacing:0.1pt;"> </font>in which<font style="letter-spacing:0.05pt;"> </font>such debt securities<font style="letter-spacing:0.1pt;"> </font>are payable<font style="letter-spacing:0.05pt;"> </font>at stated<font style="letter-spacing:0.05pt;"> </font>maturity,<font style="letter-spacing:0.1pt;"> </font>or government<font style="letter-spacing:0.05pt;"> </font>obligations,<font style="letter-spacing:0.1pt;"> </font>or both, applicable<font style="letter-spacing:0.1pt;"> </font>to such debt<font style="letter-spacing:0.05pt;"> </font>securities,<font style="letter-spacing:0.1pt;"> </font>which through the scheduled<font style="letter-spacing:0.05pt;"> </font>payment<font style="letter-spacing:0.05pt;"> </font>of principal<font style="letter-spacing:0.1pt;"> </font>and interest<font style="letter-spacing:0.1pt;"> </font>in accordance<font style="letter-spacing:0.05pt;"> </font>with their<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>provide<font style="letter-spacing:0.05pt;"> </font>money in an amount<font style="letter-spacing:0.05pt;"> </font>sufficient<font style="letter-spacing:0.1pt;"> </font>to pay the principal<font style="letter-spacing:0.1pt;"> </font>of, and any premium<font style="letter-spacing:0.05pt;"> </font>or make-whole<font style="letter-spacing:0.05pt;"> </font>amount,<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>interest<font style="letter-spacing:0.1pt;"> </font>on, such debt securities,<font style="letter-spacing:0.1pt;"> </font>and any mandatory<font style="letter-spacing:0.05pt;"> </font>sinking<font style="letter-spacing:0.05pt;"> </font>fund or analogous<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>thereon,<font style="letter-spacing:0.05pt;"> </font>on the<font style="letter-spacing:0.05pt;"> </font>scheduled due<font style="letter-spacing:-0.05pt;"> </font>dates<font style="letter-spacing:0.05pt;"> </font>therefor,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>issuing<font style="letter-spacing:0.05pt;"> </font>company<font style="letter-spacing:-0.05pt;"> </font>shall be released from its<font style="letter-spacing:0.05pt;"> </font>obligations<font style="letter-spacing:0.05pt;"> </font>with respect to<font style="letter-spacing:-0.05pt;"> </font>such debt <font style="letter-spacing:-2.35pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>under the applicable<font style="letter-spacing:0.1pt;"> </font>indenture<font style="letter-spacing:0.05pt;"> </font>or, if provided<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>its<font style="letter-spacing:0.1pt;"> </font>obligations<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to any other<font style="letter-spacing:0.05pt;"> </font>covenant,<font style="letter-spacing:0.05pt;"> </font>and any omission<font style="letter-spacing:0.05pt;"> </font>to comply<font style="letter-spacing:0.05pt;"> </font>with such obligations<font style="letter-spacing:0.1pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>not constitute<font style="letter-spacing:0.1pt;"> </font>an<font style="letter-spacing:0.05pt;"> </font>event of default<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to such debt securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:-0.05pt;"> </font>applicable<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement may<font style="letter-spacing:-0.05pt;"> </font>further<font style="letter-spacing:0.05pt;"> </font>describe the<font style="letter-spacing:-0.05pt;"> </font>provisions,<font style="letter-spacing:0.05pt;"> </font>if<font style="letter-spacing:-0.05pt;"> </font>any, permitting<font style="letter-spacing:0.05pt;"> </font>such<font style="letter-spacing:-0.05pt;"> </font>defeasance<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-2.35pt;"> </font>covenant<font style="letter-spacing:0.05pt;"> </font>defeasance,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>any modifications<font style="letter-spacing:0.15pt;"> </font>to the provisions<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>above, with respect<font style="letter-spacing:0.05pt;"> </font>to the debt<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>of or within a particular<font style="letter-spacing:0.1pt;"> </font>series.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion<font style="letter-spacing:-0.05pt;"> </font>Rights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms<font style="letter-spacing:0.05pt;"> </font>and conditions,<font style="letter-spacing:0.05pt;"> </font>if any, upon which the debt securities<font style="letter-spacing:0.1pt;"> </font>are convertible<font style="letter-spacing:0.1pt;"> </font>into common<font style="letter-spacing:0.05pt;"> </font>stock or other<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>of ours will be set forth<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>The terms<font style="letter-spacing:0.05pt;"> </font>will include<font style="letter-spacing:0.05pt;"> </font>whether<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>are convertible<font style="letter-spacing:0.1pt;"> </font>into shares<font style="letter-spacing:0.05pt;"> </font>of common<font style="letter-spacing:0.05pt;"> </font>stock or other<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>of ours, the conversion<font style="letter-spacing:0.05pt;"> </font>price,<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>manner of calculation thereof, the conversion period, provisions as to whether conversion will be at the issuing <font style="letter-spacing:-2.35pt;"> </font>company&#8217;s<font style="letter-spacing:0.05pt;"> </font>option or the option of the holders,<font style="letter-spacing:0.05pt;"> </font>the events<font style="letter-spacing:0.05pt;"> </font>requiring<font style="letter-spacing:0.05pt;"> </font>an adjustment<font style="letter-spacing:0.1pt;"> </font>of the conversion<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>affecting<font style="letter-spacing:0.1pt;"> </font>conversion<font style="letter-spacing:0.05pt;"> </font>in the event of the redemption<font style="letter-spacing:0.1pt;"> </font>of the debt securities<font style="letter-spacing:0.1pt;"> </font>and any restrictions<font style="letter-spacing:0.15pt;"> </font>on<font style="letter-spacing:0.05pt;"> </font>conversion.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Governing Law</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indentures<font style="letter-spacing:0.05pt;"> </font>and the debt securities<font style="letter-spacing:0.1pt;"> </font>will be governed by and construed<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.05pt;"> </font>with the laws of the<font style="letter-spacing:0.05pt;"> </font>State <font style="letter-spacing:-2.35pt;"> </font>of New<font style="letter-spacing:-0.05pt;"> </font>York, except<font style="letter-spacing:0.05pt;"> </font>to the extent<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the Trust Indenture<font style="letter-spacing:0.05pt;"> </font>Act is applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><a name="DESCRIPTION_WARRANTS"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION</font><font style="letter-spacing:-0.15pt;"><a name="DESCRIPTION_WARRANTS"></a> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF WARRANTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<font style="letter-spacing:0.05pt;"> </font>description,<font style="letter-spacing:0.1pt;"> </font>together<font style="letter-spacing:0.05pt;"> </font>with the additional<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may include<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>any applicable<font style="letter-spacing:0.1pt;"> </font>prospectus supplements,<font style="letter-spacing:0.1pt;"> </font>summarizes<font style="letter-spacing:0.1pt;"> </font>the material<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>and provisions<font style="letter-spacing:0.05pt;"> </font>of the warrants<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may offer<font style="letter-spacing:0.05pt;"> </font>under this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>and the related<font style="letter-spacing:0.05pt;"> </font>warrant<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>and warrant<font style="letter-spacing:0.05pt;"> </font>certificates.<font style="letter-spacing:0.15pt;"> </font>While<font style="letter-spacing:0.05pt;"> </font>the terms<font style="letter-spacing:0.05pt;"> </font>summarized<font style="letter-spacing:0.15pt;"> </font>below will<font style="letter-spacing:0.05pt;"> </font>apply generally<font style="letter-spacing:0.05pt;"> </font>to any warrants<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may offer,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will describe<font style="letter-spacing:0.05pt;"> </font>the particular<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of any series<font style="letter-spacing:0.05pt;"> </font>of warrants <font style="letter-spacing:-2.35pt;"> </font>in more<font style="letter-spacing:0.05pt;"> </font>detail<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>indicate<font style="letter-spacing:0.05pt;"> </font>in the prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.1pt;"> </font>the terms<font style="letter-spacing:0.05pt;"> </font>of any warrants<font style="letter-spacing:0.05pt;"> </font>offered<font style="letter-spacing:0.05pt;"> </font>under that<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>may differ<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the terms<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>below. Specific<font style="letter-spacing:0.05pt;"> </font>warrant<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>will contain<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.1pt;"> </font>important<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>and provisions<font style="letter-spacing:0.05pt;"> </font>and will<font style="letter-spacing:0.05pt;"> </font>be incorporated<font style="letter-spacing:0.1pt;"> </font>by reference as an exhibit<font style="letter-spacing:0.05pt;"> </font>to the registration<font style="letter-spacing:0.15pt;"> </font>statement,<font style="letter-spacing:0.1pt;"> </font>which includes<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>prospectus.</p>
<p style="margin-top:16pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue<font style="letter-spacing:0.05pt;"> </font>warrants<font style="letter-spacing:0.05pt;"> </font>for the purchase<font style="letter-spacing:0.05pt;"> </font>of common<font style="letter-spacing:0.05pt;"> </font>stock, preferred<font style="letter-spacing:0.1pt;"> </font>stock and/or<font style="letter-spacing:0.05pt;"> </font>debt securities<font style="letter-spacing:0.1pt;"> </font>in one or more series.<font style="letter-spacing:0.05pt;"> </font>We may issue<font style="letter-spacing:0.05pt;"> </font>warrants<font style="letter-spacing:0.05pt;"> </font>independently<font style="letter-spacing:0.05pt;"> </font>or together<font style="letter-spacing:0.05pt;"> </font>with common<font style="letter-spacing:0.05pt;"> </font>stock, preferred<font style="letter-spacing:0.1pt;"> </font>stock and/or<font style="letter-spacing:0.05pt;"> </font>debt<font style="letter-spacing:0.05pt;"> </font>securities,<font style="letter-spacing:0.1pt;"> </font>and the warrants<font style="letter-spacing:0.05pt;"> </font>may be attached<font style="letter-spacing:0.05pt;"> </font>to or separate<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will evidence<font style="letter-spacing:0.05pt;"> </font>each series<font style="letter-spacing:0.05pt;"> </font>of warrants<font style="letter-spacing:0.05pt;"> </font>by warrant<font style="letter-spacing:0.05pt;"> </font>certificates<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will issue<font style="letter-spacing:0.05pt;"> </font>under a separate<font style="letter-spacing:0.05pt;"> </font>warrant<font style="letter-spacing:0.05pt;"> </font>agreement.<font style="letter-spacing:0.1pt;"> </font>We will enter<font style="letter-spacing:0.05pt;"> </font>into the warrant<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>with a warrant<font style="letter-spacing:0.05pt;"> </font>agent. We will<font style="letter-spacing:0.05pt;"> </font>indicate<font style="letter-spacing:0.05pt;"> </font>the name and address <font style="letter-spacing:-2.35pt;"> </font>of the warrant<font style="letter-spacing:0.05pt;"> </font>agent in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to a particular<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>of warrants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will describe<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>the terms<font style="letter-spacing:0.05pt;"> </font>of the series<font style="letter-spacing:0.05pt;"> </font>of warrants,<font style="letter-spacing:0.05pt;"> </font>including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the offering<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>and aggregate<font style="letter-spacing:0.05pt;"> </font>number<font style="letter-spacing:0.05pt;"> </font>of warrants<font style="letter-spacing:0.05pt;"> </font>offered;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the currency<font style="letter-spacing:0.05pt;"> </font>for which the warrants<font style="letter-spacing:0.05pt;"> </font>may be purchased;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if applicable,<font style="letter-spacing:0.1pt;"> </font>the designation<font style="letter-spacing:0.05pt;"> </font>and terms<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>with which the warrants<font style="letter-spacing:0.05pt;"> </font>are issued<font style="letter-spacing:0.05pt;"> </font>and the number<font style="letter-spacing:0.05pt;"> </font>of warrants<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>with each such security<font style="letter-spacing:0.05pt;"> </font>or each principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of such security;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if applicable,<font style="letter-spacing:0.1pt;"> </font>the date on and after<font style="letter-spacing:0.05pt;"> </font>which the warrants<font style="letter-spacing:0.05pt;"> </font>and the related<font style="letter-spacing:0.1pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>will be separately transferable;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">in the case of warrants<font style="letter-spacing:0.05pt;"> </font>to purchase<font style="letter-spacing:0.05pt;"> </font>debt securities,<font style="letter-spacing:0.1pt;"> </font>the principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of debt securities<font style="letter-spacing:0.15pt;"> </font>purchasable <font style="letter-spacing:-2.35pt;"> </font>upon exercise<font style="letter-spacing:0.05pt;"> </font>of one warrant<font style="letter-spacing:0.05pt;"> </font>and the price<font style="letter-spacing:0.05pt;"> </font>at, and currency<font style="letter-spacing:0.05pt;"> </font>in which, this<font style="letter-spacing:0.05pt;"> </font>principal<font style="letter-spacing:0.1pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>of debt<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>may be purchased<font style="letter-spacing:0.05pt;"> </font>upon such exercise;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">in the case of warrants<font style="letter-spacing:0.05pt;"> </font>to purchase<font style="letter-spacing:0.05pt;"> </font>common<font style="letter-spacing:0.05pt;"> </font>stock or preferred<font style="letter-spacing:0.1pt;"> </font>stock, the number<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>of common<font style="letter-spacing:0.05pt;"> </font>stock or preferred<font style="letter-spacing:0.1pt;"> </font>stock, as the case may be, purchasable<font style="letter-spacing:0.05pt;"> </font>upon the exercise<font style="letter-spacing:0.05pt;"> </font>of one warrant<font style="letter-spacing:0.05pt;"> </font>and the price <font style="letter-spacing:-2.35pt;"> </font>at which these<font style="letter-spacing:0.05pt;"> </font>shares<font style="letter-spacing:0.05pt;"> </font>may be purchased<font style="letter-spacing:0.05pt;"> </font>upon such exercise;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant <font style="letter-spacing:-2.35pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>and the warrants;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms<font style="letter-spacing:0.05pt;"> </font>of any rights<font style="letter-spacing:0.05pt;"> </font>to redeem<font style="letter-spacing:0.05pt;"> </font>or call<font style="letter-spacing:0.05pt;"> </font>the warrants;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any provisions<font style="letter-spacing:0.05pt;"> </font>for changes to or adjustments<font style="letter-spacing:0.1pt;"> </font>in the exercise<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>or number<font style="letter-spacing:0.05pt;"> </font>of securities<font style="letter-spacing:0.1pt;"> </font>issuable<font style="letter-spacing:0.05pt;"> </font>upon exercise<font style="letter-spacing:0.05pt;"> </font>of the warrants;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the periods<font style="letter-spacing:0.05pt;"> </font>during which, and places<font style="letter-spacing:0.05pt;"> </font>at which, the warrants<font style="letter-spacing:0.05pt;"> </font>are exercisable;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the manner<font style="letter-spacing:0.05pt;"> </font>of exercise;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the dates<font style="letter-spacing:0.05pt;"> </font>on which the right<font style="letter-spacing:0.05pt;"> </font>to exercise<font style="letter-spacing:0.05pt;"> </font>the warrants<font style="letter-spacing:0.05pt;"> </font>will commence<font style="letter-spacing:0.05pt;"> </font>and expire;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the manner<font style="letter-spacing:0.05pt;"> </font>in which the warrant<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>and warrants<font style="letter-spacing:0.05pt;"> </font>may be modified;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">federal<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax consequences<font style="letter-spacing:0.05pt;"> </font>of holding or exercising<font style="letter-spacing:0.1pt;"> </font>the warrants;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>issuable<font style="letter-spacing:0.05pt;"> </font>upon exercise<font style="letter-spacing:0.05pt;"> </font>of the warrants;<font style="letter-spacing:0.05pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any other<font style="letter-spacing:0.05pt;"> </font>specific<font style="letter-spacing:0.1pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>preferences,<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>or limitations<font style="letter-spacing:0.15pt;"> </font>of or restrictions<font style="letter-spacing:0.15pt;"> </font>on the warrants.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><a name="DESCRIPTION_UNITS"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="DESCRIPTION_UNITS"></a>DESCRIPTION</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF UNITS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>comprised<font style="letter-spacing:0.05pt;"> </font>of shares<font style="letter-spacing:0.05pt;"> </font>of common<font style="letter-spacing:0.05pt;"> </font>stock, shares<font style="letter-spacing:0.05pt;"> </font>of preferred<font style="letter-spacing:0.1pt;"> </font>stock, debt securities<font style="letter-spacing:0.1pt;"> </font>and warrants <font style="letter-spacing:-2.35pt;"> </font>in any combination.<font style="letter-spacing:0.1pt;"> </font>We may issue<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>in such amounts<font style="letter-spacing:0.05pt;"> </font>and in as many distinct<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>wish. This section<font style="letter-spacing:0.05pt;"> </font>outlines<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>of the units<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may issue.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>units,<font style="letter-spacing:0.05pt;"> </font>they will be issued<font style="letter-spacing:0.05pt;"> </font>under one or more unit agreements<font style="letter-spacing:0.1pt;"> </font>to be entered<font style="letter-spacing:0.05pt;"> </font>into between us and a bank or other<font style="letter-spacing:0.05pt;"> </font>financial<font style="letter-spacing:0.1pt;"> </font>institution,<font style="letter-spacing:0.1pt;"> </font>as unit agent. The<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>section<font style="letter-spacing:0.05pt;"> </font>may not be complete<font style="letter-spacing:0.05pt;"> </font>in all<font style="letter-spacing:0.05pt;"> </font>respects<font style="letter-spacing:0.05pt;"> </font>and is<font style="letter-spacing:0.05pt;"> </font>qualified<font style="letter-spacing:0.1pt;"> </font>entirely<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>the unit agreement<font style="letter-spacing:0.1pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to the units<font style="letter-spacing:0.05pt;"> </font>of any particular<font style="letter-spacing:0.1pt;"> </font>series.<font style="letter-spacing:0.05pt;"> </font>The specific<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of any series<font style="letter-spacing:0.05pt;"> </font>of units<font style="letter-spacing:0.05pt;"> </font>offered<font style="letter-spacing:0.05pt;"> </font>will be described<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>If so described<font style="letter-spacing:0.05pt;"> </font>in a particular<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>the specific<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of any series<font style="letter-spacing:0.05pt;"> </font>of units<font style="letter-spacing:0.05pt;"> </font>may differ<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the general<font style="letter-spacing:0.05pt;"> </font>description<font style="letter-spacing:0.1pt;"> </font>of terms<font style="letter-spacing:0.05pt;"> </font>presented<font style="letter-spacing:0.05pt;"> </font>below. We urge you to read any prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to any series<font style="letter-spacing:0.05pt;"> </font>of units<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may offer,<font style="letter-spacing:0.05pt;"> </font>as well as the <font style="letter-spacing:-2.35pt;"> </font>complete<font style="letter-spacing:0.05pt;"> </font>unit agreement<font style="letter-spacing:0.1pt;"> </font>and unit certificate<font style="letter-spacing:0.15pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>contain<font style="letter-spacing:0.05pt;"> </font>the terms<font style="letter-spacing:0.05pt;"> </font>of the units.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>units,<font style="letter-spacing:0.05pt;"> </font>forms<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>unit<font style="letter-spacing:0.05pt;"> </font>agreements<font style="letter-spacing:0.1pt;"> </font>and unit certificates<font style="letter-spacing:0.15pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to such units<font style="letter-spacing:0.05pt;"> </font>will be incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>as exhibits<font style="letter-spacing:0.05pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>statement,<font style="letter-spacing:0.1pt;"> </font>which includes<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>prospectus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each unit that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may issue<font style="letter-spacing:0.05pt;"> </font>will be issued<font style="letter-spacing:0.05pt;"> </font>so that<font style="letter-spacing:0.05pt;"> </font>the holder<font style="letter-spacing:0.05pt;"> </font>of the unit is also the holder<font style="letter-spacing:0.05pt;"> </font>of each security<font style="letter-spacing:0.05pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>in the unit. Thus, the holder<font style="letter-spacing:0.05pt;"> </font>of a unit will have the rights<font style="letter-spacing:0.05pt;"> </font>and obligations<font style="letter-spacing:0.1pt;"> </font>of a holder<font style="letter-spacing:0.05pt;"> </font>of each included<font style="letter-spacing:0.05pt;"> </font>security.<font style="letter-spacing:0.05pt;"> </font>The unit agreement<font style="letter-spacing:0.1pt;"> </font>under which a unit is issued<font style="letter-spacing:0.05pt;"> </font>may provide<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the securities<font style="letter-spacing:0.15pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>in the unit may <font style="letter-spacing:-2.35pt;"> </font>not<font style="letter-spacing:-0.05pt;"> </font>be held<font style="letter-spacing:-0.05pt;"> </font>or transferred<font style="letter-spacing:0.05pt;"> </font>separately,<font style="letter-spacing:0.1pt;"> </font>at<font style="letter-spacing:-0.05pt;"> </font>any time or at<font style="letter-spacing:-0.05pt;"> </font>any time before<font style="letter-spacing:0.05pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font>specified<font style="letter-spacing:0.1pt;"> </font>date.<font style="letter-spacing:-0.05pt;"> </font>The applicable<font style="letter-spacing:0.05pt;"> </font>prospectus supplement<font style="letter-spacing:0.05pt;"> </font>may describe:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the designation<font style="letter-spacing:0.05pt;"> </font>and terms<font style="letter-spacing:0.05pt;"> </font>of the units<font style="letter-spacing:0.05pt;"> </font>and of the securities<font style="letter-spacing:0.1pt;"> </font>comprising<font style="letter-spacing:0.1pt;"> </font>the units,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>whether and under what circumstances<font style="letter-spacing:0.15pt;"> </font>those securities<font style="letter-spacing:0.1pt;"> </font>may be held or transferred<font style="letter-spacing:0.1pt;"> </font>separately;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any provisions<font style="letter-spacing:0.05pt;"> </font>of the governing<font style="letter-spacing:0.05pt;"> </font>unit agreement;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the price<font style="letter-spacing:0.05pt;"> </font>or prices<font style="letter-spacing:0.05pt;"> </font>at which such units<font style="letter-spacing:0.05pt;"> </font>will be issued;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the applicable<font style="letter-spacing:0.1pt;"> </font>United States<font style="letter-spacing:0.05pt;"> </font>federal<font style="letter-spacing:0.05pt;"> </font>income<font style="letter-spacing:0.05pt;"> </font>tax considerations<font style="letter-spacing:0.1pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to the<font style="letter-spacing:0.05pt;"> </font>units;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any provisions<font style="letter-spacing:0.05pt;"> </font>for the issuance,<font style="letter-spacing:0.05pt;"> </font>payment,<font style="letter-spacing:0.05pt;"> </font>settlement,<font style="letter-spacing:0.1pt;"> </font>transfer<font style="letter-spacing:0.1pt;"> </font>or exchange of the units<font style="letter-spacing:0.05pt;"> </font>or of the <font style="letter-spacing:-2.35pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>comprising<font style="letter-spacing:0.1pt;"> </font>the units;<font style="letter-spacing:0.05pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any other<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of the units<font style="letter-spacing:0.05pt;"> </font>and of the securities<font style="letter-spacing:0.1pt;"> </font>comprising<font style="letter-spacing:0.1pt;"> </font>the units.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>section,<font style="letter-spacing:0.05pt;"> </font>as well as those described<font style="letter-spacing:0.05pt;"> </font>under &#8220;Description<font style="letter-spacing:0.1pt;"> </font>of Capital<font style="letter-spacing:0.05pt;"> </font>Stock,&#8221;<font style="letter-spacing:0.05pt;"> </font>&#8220;Description<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>Debt Securities&#8221;<font style="letter-spacing:0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>&#8220;Description<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>Warrants&#8221;<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:-0.05pt;"> </font>apply<font style="letter-spacing:-0.05pt;"> </font>to the<font style="letter-spacing:-0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>included in<font style="letter-spacing:-0.05pt;"> </font>each unit, <font style="letter-spacing:-2.35pt;"> </font>to the extent<font style="letter-spacing:0.05pt;"> </font>relevant<font style="letter-spacing:0.05pt;"> </font>and as may be updated in any prospectus<font style="letter-spacing:0.05pt;"> </font>supplements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance<font style="letter-spacing:-0.05pt;"> </font>in Series</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may issue<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>in such amounts<font style="letter-spacing:0.05pt;"> </font>and in as many distinct<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>as we<font style="letter-spacing:-0.05pt;"> </font>wish. This section<font style="letter-spacing:0.05pt;"> </font>summarizes<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of the units<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>apply generally<font style="letter-spacing:0.05pt;"> </font>to all<font style="letter-spacing:0.05pt;"> </font>series.<font style="letter-spacing:0.05pt;"> </font>Most of the financial<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>specific<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of a<font style="letter-spacing:0.05pt;"> </font>particular<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>will be described<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unit Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will issue<font style="letter-spacing:0.05pt;"> </font>the units<font style="letter-spacing:0.05pt;"> </font>under one or more<font style="letter-spacing:0.05pt;"> </font>unit agreements<font style="letter-spacing:0.1pt;"> </font>to be entered<font style="letter-spacing:0.05pt;"> </font>into between us and a bank or other financial<font style="letter-spacing:0.1pt;"> </font>institution,<font style="letter-spacing:0.1pt;"> </font>as unit agent. We may add, replace<font style="letter-spacing:0.05pt;"> </font>or terminate<font style="letter-spacing:0.1pt;"> </font>unit<font style="letter-spacing:0.05pt;"> </font>agents<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time.<font style="letter-spacing:0.05pt;"> </font>We will<font style="letter-spacing:0.05pt;"> </font>identify<font style="letter-spacing:0.05pt;"> </font>the unit agreement<font style="letter-spacing:0.1pt;"> </font>under which each series<font style="letter-spacing:0.05pt;"> </font>of units<font style="letter-spacing:0.05pt;"> </font>will be issued<font style="letter-spacing:0.05pt;"> </font>and the unit agent under that<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following provis</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ions will generally apply to all unit agreements unless otherwise stated in the applicabl</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplement:</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Modification<font style="letter-spacing:0.1pt;"> </font>without Consent</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and the applicable<font style="letter-spacing:0.1pt;"> </font>unit agent may amend any unit or unit agreement<font style="letter-spacing:0.1pt;"> </font>without<font style="letter-spacing:0.05pt;"> </font>the consent<font style="letter-spacing:0.05pt;"> </font>of any holder:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to cure any ambiguity, including modifying any provisions of the governing unit agreement that differ <font style="letter-spacing:-2.35pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>those described<font style="letter-spacing:0.05pt;"> </font>below;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to correct<font style="letter-spacing:0.05pt;"> </font>or supplement<font style="letter-spacing:0.05pt;"> </font>any defective<font style="letter-spacing:0.1pt;"> </font>or inconsistent<font style="letter-spacing:0.1pt;"> </font>provision;<font style="letter-spacing:0.05pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">to make any other<font style="letter-spacing:0.05pt;"> </font>change that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>believe<font style="letter-spacing:0.05pt;"> </font>is necessary<font style="letter-spacing:0.05pt;"> </font>or desirable<font style="letter-spacing:0.1pt;"> </font>and will not adversely<font style="letter-spacing:0.1pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the interests<font style="letter-spacing:0.1pt;"> </font>of the affected<font style="letter-spacing:0.1pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>in any material<font style="letter-spacing:0.1pt;"> </font>respect.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not need any approval<font style="letter-spacing:0.05pt;"> </font>to make changes that<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>only units<font style="letter-spacing:0.05pt;"> </font>to be issued<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.05pt;"> </font>the changes<font style="letter-spacing:0.05pt;"> </font>take effect.<font style="letter-spacing:0.05pt;"> </font>We may also make changes that<font style="letter-spacing:0.05pt;"> </font>do not adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>a particular<font style="letter-spacing:0.1pt;"> </font>unit in any material<font style="letter-spacing:0.1pt;"> </font>respect,<font style="letter-spacing:0.05pt;"> </font>even if they<font style="letter-spacing:0.05pt;"> </font>adversely<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>in a material<font style="letter-spacing:0.1pt;"> </font>respect.<font style="letter-spacing:0.05pt;"> </font>In those cases,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>do not need to obtain<font style="letter-spacing:0.05pt;"> </font>the approval<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>holder<font style="letter-spacing:0.05pt;"> </font>of the unaffected<font style="letter-spacing:0.1pt;"> </font>unit;<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>need only obtain<font style="letter-spacing:0.05pt;"> </font>any required<font style="letter-spacing:0.05pt;"> </font>approvals<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>the holders<font style="letter-spacing:0.05pt;"> </font>of the affected<font style="letter-spacing:0.1pt;"> </font>units.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Modification<font style="letter-spacing:0.1pt;"> </font>with Consent</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not amend any particular<font style="letter-spacing:0.1pt;"> </font>unit or a unit agreement<font style="letter-spacing:0.1pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to any<font style="letter-spacing:0.05pt;"> </font>particular<font style="letter-spacing:0.1pt;"> </font>unit unless<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>obtain<font style="letter-spacing:0.05pt;"> </font>the consent<font style="letter-spacing:0.05pt;"> </font>of the holder<font style="letter-spacing:0.05pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>unit, if the amendment<font style="letter-spacing:0.05pt;"> </font>would:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">impair any right of the holder to exercise or enforce any right under a security included in the unit if the terms of that security require the consent of the holder to any changes that would impair the exercise or<font style="letter-spacing:0.05pt;"> </font>enforcement<font style="letter-spacing:0.1pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>right;<font style="letter-spacing:0.05pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reduce<font style="letter-spacing:0.05pt;"> </font>the percentage<font style="letter-spacing:0.05pt;"> </font>of outstanding<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>or any series<font style="letter-spacing:0.05pt;"> </font>or class<font style="letter-spacing:0.05pt;"> </font>the consent<font style="letter-spacing:0.05pt;"> </font>of whose holders<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>required to<font style="letter-spacing:-0.05pt;"> </font>amend that series<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>class,<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>the applicable<font style="letter-spacing:0.05pt;"> </font>unit<font style="letter-spacing:-0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>respect<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>series or <font style="letter-spacing:-2.35pt;"> </font>class,<font style="letter-spacing:0.05pt;"> </font>as described<font style="letter-spacing:0.05pt;"> </font>below.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any other change to a particular unit agreement and the units issued under that agreement would require the following<font style="letter-spacing:0.05pt;"> </font>approval:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If the change affects<font style="letter-spacing:0.1pt;"> </font>only the units<font style="letter-spacing:0.05pt;"> </font>of a particular<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>under that<font style="letter-spacing:0.05pt;"> </font>agreement,<font style="letter-spacing:0.1pt;"> </font>the change must <font style="letter-spacing:-2.35pt;"> </font>be approved by the holders<font style="letter-spacing:0.05pt;"> </font>of a majority<font style="letter-spacing:0.1pt;"> </font>of the outstanding<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>of that<font style="letter-spacing:0.05pt;"> </font>series;<font style="letter-spacing:0.1pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If<font style="letter-spacing:-0.05pt;"> </font>the change<font style="letter-spacing:-0.05pt;"> </font>affects<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>units of more than one series issued under that agreement,<font style="letter-spacing:0.1pt;"> </font>it<font style="letter-spacing:-0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be<font style="letter-spacing:-0.05pt;"> </font>approved by the holders<font style="letter-spacing:0.05pt;"> </font>of a majority<font style="letter-spacing:0.1pt;"> </font>of all<font style="letter-spacing:0.05pt;"> </font>outstanding<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>of all<font style="letter-spacing:0.05pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>affected<font style="letter-spacing:0.1pt;"> </font>by the change, with the units<font style="letter-spacing:0.05pt;"> </font>of all<font style="letter-spacing:0.05pt;"> </font>the affected<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>voting together<font style="letter-spacing:0.05pt;"> </font>as one class<font style="letter-spacing:0.05pt;"> </font>for this<font style="letter-spacing:0.05pt;"> </font>purpose.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These<font style="letter-spacing:-0.05pt;"> </font>provisions regarding<font style="letter-spacing:0.05pt;"> </font>changes<font style="letter-spacing:-0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>majority<font style="letter-spacing:0.1pt;"> </font>approval also<font style="letter-spacing:-0.05pt;"> </font>apply to<font style="letter-spacing:-0.05pt;"> </font>changes affecting<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>issued under a unit agreement,<font style="letter-spacing:0.1pt;"> </font>as the governing<font style="letter-spacing:0.05pt;"> </font>document.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In each case, the required<font style="letter-spacing:0.05pt;"> </font>approval<font style="letter-spacing:0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>be given by written<font style="letter-spacing:0.05pt;"> </font>consent.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unit Agreements<font style="letter-spacing:0.05pt;"> </font>Will<font style="letter-spacing:0.05pt;"> </font>Not Be<font style="letter-spacing:-0.05pt;"> </font>Qualified<font style="letter-spacing:0.05pt;"> </font>under Trust Indenture Act</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No<font style="letter-spacing:-0.05pt;"> </font>unit agreement<font style="letter-spacing:0.1pt;"> </font>will be qualified<font style="letter-spacing:0.1pt;"> </font>as an indenture,<font style="letter-spacing:0.05pt;"> </font>and no unit agent will be required<font style="letter-spacing:0.1pt;"> </font>to qualify<font style="letter-spacing:0.05pt;"> </font>as a trustee, <font style="letter-spacing:-2.35pt;"> </font>under the Trust Indenture<font style="letter-spacing:0.05pt;"> </font>Act. Therefore,<font style="letter-spacing:0.05pt;"> </font>holders<font style="letter-spacing:0.05pt;"> </font>of units<font style="letter-spacing:0.05pt;"> </font>issued<font style="letter-spacing:0.05pt;"> </font>under unit agreements<font style="letter-spacing:0.1pt;"> </font>will not have the<font style="letter-spacing:0.05pt;"> </font>protections<font style="letter-spacing:0.1pt;"> </font>of the Trust Indenture<font style="letter-spacing:0.05pt;"> </font>Act with respect<font style="letter-spacing:0.05pt;"> </font>to their<font style="letter-spacing:0.05pt;"> </font>units.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Mergers</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Similar</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Transactions</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Permitted;</font><font style="letter-spacing:0.1pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">No</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restrictive</font><font style="letter-spacing:0.1pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Covenants or Events of Default</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unit agreements<font style="letter-spacing:0.1pt;"> </font>will not restrict<font style="letter-spacing:0.1pt;"> </font>our ability<font style="letter-spacing:0.05pt;"> </font>to merge<font style="letter-spacing:0.05pt;"> </font>or consolidate<font style="letter-spacing:0.1pt;"> </font>with, or sell<font style="letter-spacing:0.05pt;"> </font>our assets<font style="letter-spacing:0.05pt;"> </font>to, another<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>entity<font style="letter-spacing:0.05pt;"> </font>or to engage in any other<font style="letter-spacing:0.05pt;"> </font>transactions.<font style="letter-spacing:0.1pt;"> </font>If at any time<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>merge<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>consolidate<font style="letter-spacing:0.1pt;"> </font>with, or<font style="letter-spacing:0.05pt;"> </font>sell<font style="letter-spacing:0.05pt;"> </font>our assets<font style="letter-spacing:0.05pt;"> </font>substantially<font style="letter-spacing:0.1pt;"> </font>as an entirety<font style="letter-spacing:0.1pt;"> </font>to, another<font style="letter-spacing:0.05pt;"> </font>corporation<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>entity,<font style="letter-spacing:0.05pt;"> </font>the successor<font style="letter-spacing:0.1pt;"> </font>entity<font style="letter-spacing:0.05pt;"> </font>will succeed <font style="letter-spacing:-2.35pt;"> </font>to and assume<font style="letter-spacing:0.05pt;"> </font>our obligations<font style="letter-spacing:0.1pt;"> </font>under the unit agreements.<font style="letter-spacing:0.1pt;"> </font>We will then be relieved<font style="letter-spacing:0.05pt;"> </font>of any further<font style="letter-spacing:0.1pt;"> </font>obligation<font style="letter-spacing:0.05pt;"> </font>under these<font style="letter-spacing:0.05pt;"> </font>agreements.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unit agreements will not include any restrictions on our ability to put liens on our assets, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence<font style="letter-spacing:0.05pt;"> </font>of any events<font style="letter-spacing:0.05pt;"> </font>of default.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Governing Law</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unit agreements<font style="letter-spacing:0.1pt;"> </font>and the units<font style="letter-spacing:0.05pt;"> </font>will be governed by Delaware law.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Form, Exchange<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>Transfer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will issue each unit in global&#8212;i.e., book-entry&#8212;form only. Units in book-entry form will be represented by a global<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>in the name of a depositary,<font style="letter-spacing:0.05pt;"> </font>which will be the holder<font style="letter-spacing:0.05pt;"> </font>of all<font style="letter-spacing:0.05pt;"> </font>the units<font style="letter-spacing:0.05pt;"> </font>represented<font style="letter-spacing:0.15pt;"> </font>by the<font style="letter-spacing:0.05pt;"> </font>global<font style="letter-spacing:0.05pt;"> </font>security.<font style="letter-spacing:0.05pt;"> </font>Those who<font style="letter-spacing:-0.05pt;"> </font>own<font style="letter-spacing:-0.05pt;"> </font>beneficial<font style="letter-spacing:0.1pt;"> </font>interests<font style="letter-spacing:0.1pt;"> </font>in a unit will do so through participants<font style="letter-spacing:0.1pt;"> </font>in the depositary&#8217;s<font style="letter-spacing:0.05pt;"> </font>system,<font style="letter-spacing:0.05pt;"> </font>and the rights<font style="letter-spacing:0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>indirect<font style="letter-spacing:0.1pt;"> </font>owners will be governed solely<font style="letter-spacing:0.05pt;"> </font>by the applicable<font style="letter-spacing:0.1pt;"> </font>procedures<font style="letter-spacing:0.05pt;"> </font>of the<font style="letter-spacing:0.05pt;"> </font>depositary<font style="letter-spacing:0.25pt;"> </font>and<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.25pt;"> </font>participants.<font style="letter-spacing:0.3pt;"> </font>We<font style="letter-spacing:0.2pt;"> </font>will<font style="letter-spacing:0.25pt;"> </font>describe<font style="letter-spacing:0.25pt;"> </font>book-entry<font style="letter-spacing:0.25pt;"> </font>securities,<font style="letter-spacing:0.3pt;"> </font>and<font style="letter-spacing:0.2pt;"> </font>other<font style="letter-spacing:0.25pt;"> </font>terms<font style="letter-spacing:0.3pt;"> </font>regarding<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.2pt;"> </font>issuance<font style="letter-spacing:0.05pt;"> </font>and registration<font style="letter-spacing:0.15pt;"> </font>of the units<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each unit and all<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>comprising<font style="letter-spacing:0.1pt;"> </font>the unit will be issued<font style="letter-spacing:0.05pt;"> </font>in the same<font style="letter-spacing:0.05pt;"> </font>form.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we issue any units in registered, non-global form, the following will apply to them. The units will be issued in the denominations<font style="letter-spacing:0.1pt;"> </font>stated<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>Holders may exchange their<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>for units<font style="letter-spacing:0.1pt;"> </font>of <font style="letter-spacing:-2.35pt;"> </font>smaller<font style="letter-spacing:0.1pt;"> </font>denominations<font style="letter-spacing:0.1pt;"> </font>or combined<font style="letter-spacing:0.05pt;"> </font>into fewer units<font style="letter-spacing:0.05pt;"> </font>of larger<font style="letter-spacing:0.05pt;"> </font>denominations,<font style="letter-spacing:0.1pt;"> </font>as long as the total<font style="letter-spacing:0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>is not<font style="letter-spacing:0.05pt;"> </font>changed.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Holders may exchange or transfer<font style="letter-spacing:0.1pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>at the office<font style="letter-spacing:0.05pt;"> </font>of the unit agent. Holders may also replace<font style="letter-spacing:0.05pt;"> </font>lost, stolen, destroyed<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>mutilated<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:-0.05pt;"> </font>that office.<font style="letter-spacing:0.05pt;"> </font>We<font style="letter-spacing:-0.05pt;"> </font>may appoint another entity<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>perform these functions<font style="letter-spacing:0.05pt;"> </font>or perform<font style="letter-spacing:0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>ourselves.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Holders will not be required<font style="letter-spacing:0.05pt;"> </font>to pay a service<font style="letter-spacing:0.05pt;"> </font>charge<font style="letter-spacing:0.05pt;"> </font>to transfer<font style="letter-spacing:0.1pt;"> </font>or exchange their<font style="letter-spacing:0.05pt;"> </font>units,<font style="letter-spacing:0.05pt;"> </font>but they may be required<font style="letter-spacing:0.05pt;"> </font>to pay for any tax or other<font style="letter-spacing:0.05pt;"> </font>governmental<font style="letter-spacing:0.1pt;"> </font>charge<font style="letter-spacing:0.05pt;"> </font>associated<font style="letter-spacing:0.1pt;"> </font>with the transfer<font style="letter-spacing:0.1pt;"> </font>or exchange. The<font style="letter-spacing:0.05pt;"> </font>transfer<font style="letter-spacing:0.1pt;"> </font>or exchange, and any replacement,<font style="letter-spacing:0.1pt;"> </font>will be made only if our transfer<font style="letter-spacing:0.1pt;"> </font>agent is satisfied<font style="letter-spacing:0.1pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>holder&#8217;s<font style="letter-spacing:0.05pt;"> </font>proof of legal<font style="letter-spacing:0.05pt;"> </font>ownership. The transfer<font style="letter-spacing:0.1pt;"> </font>agent may also require<font style="letter-spacing:0.05pt;"> </font>an indemnity<font style="letter-spacing:0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>replacing<font style="letter-spacing:0.05pt;"> </font>any units.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we<font style="letter-spacing:-0.05pt;"> </font>have the right<font style="letter-spacing:0.05pt;"> </font>to redeem,<font style="letter-spacing:0.05pt;"> </font>accelerate<font style="letter-spacing:0.1pt;"> </font>or settle<font style="letter-spacing:0.05pt;"> </font>any units<font style="letter-spacing:0.05pt;"> </font>before<font style="letter-spacing:0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>maturity,<font style="letter-spacing:0.1pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>exercise<font style="letter-spacing:0.05pt;"> </font>our<font style="letter-spacing:0.05pt;"> </font>right<font style="letter-spacing:0.05pt;"> </font>as to less<font style="letter-spacing:0.05pt;"> </font>than all<font style="letter-spacing:0.05pt;"> </font>those units<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>securities,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may block the exchange or transfer<font style="letter-spacing:0.1pt;"> </font>of those<font style="letter-spacing:0.05pt;"> </font>units<font style="letter-spacing:0.05pt;"> </font>during the period<font style="letter-spacing:0.05pt;"> </font>beginning<font style="letter-spacing:0.05pt;"> </font>15 days before<font style="letter-spacing:0.05pt;"> </font>the day we<font style="letter-spacing:-0.05pt;"> </font>mail<font style="letter-spacing:0.05pt;"> </font>the notice<font style="letter-spacing:0.05pt;"> </font>of exercise<font style="letter-spacing:0.05pt;"> </font>and ending on<font style="letter-spacing:0.05pt;"> </font>the day of that<font style="letter-spacing:0.05pt;"> </font>mailing,<font style="letter-spacing:0.05pt;"> </font>in order<font style="letter-spacing:0.05pt;"> </font>to freeze<font style="letter-spacing:0.05pt;"> </font>the list<font style="letter-spacing:0.05pt;"> </font>of holders<font style="letter-spacing:0.05pt;"> </font>to prepare<font style="letter-spacing:0.05pt;"> </font>the mailing.<font style="letter-spacing:0.05pt;"> </font>We<font style="letter-spacing:0.05pt;"> </font>may also refuse to register<font style="letter-spacing:0.1pt;"> </font>transfers<font style="letter-spacing:0.1pt;"> </font>of or exchange any unit selected<font style="letter-spacing:0.05pt;"> </font>for early<font style="letter-spacing:0.05pt;"> </font>settlement,<font style="letter-spacing:0.1pt;"> </font>except<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we will continue<font style="letter-spacing:0.05pt;"> </font>to permit<font style="letter-spacing:0.05pt;"> </font>transfers<font style="letter-spacing:0.1pt;"> </font>and exchanges<font style="letter-spacing:0.05pt;"> </font>of the unsettled<font style="letter-spacing:0.05pt;"> </font>portion<font style="letter-spacing:0.05pt;"> </font>of any unit being partially<font style="letter-spacing:0.1pt;"> </font>settled.<font style="letter-spacing:0.05pt;"> </font>We may<font style="letter-spacing:0.05pt;"> </font>also block the transfer<font style="letter-spacing:0.1pt;"> </font>or exchange of any unit in this<font style="letter-spacing:0.05pt;"> </font>manner<font style="letter-spacing:0.05pt;"> </font>if the unit includes<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>may be selected<font style="letter-spacing:0.05pt;"> </font>for early<font style="letter-spacing:0.05pt;"> </font>settlement.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only the depositary<font style="letter-spacing:0.05pt;"> </font>will be entitled<font style="letter-spacing:0.1pt;"> </font>to transfer<font style="letter-spacing:0.1pt;"> </font>or exchange a unit in global<font style="letter-spacing:0.05pt;"> </font>form,<font style="letter-spacing:0.05pt;"> </font>since<font style="letter-spacing:0.05pt;"> </font>it will<font style="letter-spacing:0.05pt;"> </font>be the sole holder <font style="letter-spacing:-2.35pt;"> </font>of the unit.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Payments</font><font style="letter-spacing:0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Notices</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In making<font style="letter-spacing:0.05pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>and giving notices<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to our units,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will follow the procedures<font style="letter-spacing:0.05pt;"> </font>as described<font style="letter-spacing:0.05pt;"> </font>in <font style="letter-spacing:-2.35pt;"> </font>the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><a name="PLAN_DISTRIBUTION"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PLAN</font><font style="letter-spacing:-0.15pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PLAN_DISTRIBUTION"></a>OF DIS</font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRIBUTION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may sell<font style="letter-spacing:0.05pt;"> </font>securities:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">through underwriters;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">through dealers;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">through agents;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">directly<font style="letter-spacing:0.1pt;"> </font>to purchasers;<font style="letter-spacing:0.1pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">through a combination<font style="letter-spacing:0.1pt;"> </font>of any of these<font style="letter-spacing:0.05pt;"> </font>methods<font style="letter-spacing:0.05pt;"> </font>or any other<font style="letter-spacing:0.05pt;"> </font>method<font style="letter-spacing:0.05pt;"> </font>permitted<font style="letter-spacing:0.1pt;"> </font>by law.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may issue<font style="letter-spacing:0.05pt;"> </font>the securities<font style="letter-spacing:0.1pt;"> </font>as a dividend<font style="letter-spacing:0.05pt;"> </font>or distribution<font style="letter-spacing:0.1pt;"> </font>or in a subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>to our existing<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>holders.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may directly<font style="letter-spacing:0.1pt;"> </font>solicit<font style="letter-spacing:0.1pt;"> </font>offers<font style="letter-spacing:0.05pt;"> </font>to purchase<font style="letter-spacing:0.05pt;"> </font>securities,<font style="letter-spacing:0.1pt;"> </font>or agents<font style="letter-spacing:0.05pt;"> </font>may be designated<font style="letter-spacing:0.05pt;"> </font>to solicit<font style="letter-spacing:0.1pt;"> </font>such offers.<font style="letter-spacing:0.05pt;"> </font>In the<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to such offering,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will name any agent that<font style="letter-spacing:0.05pt;"> </font>could be viewed as an underwriter under the Securities<font style="letter-spacing:0.1pt;"> </font>Act and describe<font style="letter-spacing:0.05pt;"> </font>any commissions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>must<font style="letter-spacing:0.05pt;"> </font>pay to any such agent. Any<font style="letter-spacing:-0.05pt;"> </font>such agent will be acting<font style="letter-spacing:0.05pt;"> </font>on a best efforts<font style="letter-spacing:0.1pt;"> </font>basis<font style="letter-spacing:0.05pt;"> </font>for the period<font style="letter-spacing:0.05pt;"> </font>of its<font style="letter-spacing:0.05pt;"> </font>appointment<font style="letter-spacing:0.1pt;"> </font>or, if indicated<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>on a firm<font style="letter-spacing:0.05pt;"> </font>commitment<font style="letter-spacing:0.1pt;"> </font>basis.<font style="letter-spacing:0.05pt;"> </font>This prospectus<font style="letter-spacing:0.05pt;"> </font>may be used in connection<font style="letter-spacing:0.05pt;"> </font>with any offering<font style="letter-spacing:0.05pt;"> </font>of our<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>through any of these<font style="letter-spacing:0.05pt;"> </font>methods<font style="letter-spacing:0.05pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>methods<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution<font style="letter-spacing:0.1pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>may be effected<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time<font style="letter-spacing:0.05pt;"> </font>in one<font style="letter-spacing:0.05pt;"> </font>or more<font style="letter-spacing:0.05pt;"> </font>transactions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">at a fixed<font style="letter-spacing:0.05pt;"> </font>price,<font style="letter-spacing:0.05pt;"> </font>or prices,<font style="letter-spacing:0.05pt;"> </font>which may be changed from<font style="letter-spacing:0.05pt;"> </font>time<font style="letter-spacing:0.05pt;"> </font>to time;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">at market<font style="letter-spacing:0.05pt;"> </font>prices<font style="letter-spacing:0.05pt;"> </font>prevailing<font style="letter-spacing:0.1pt;"> </font>at the time<font style="letter-spacing:0.05pt;"> </font>of sale;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">at prices<font style="letter-spacing:0.05pt;"> </font>related<font style="letter-spacing:0.05pt;"> </font>to such prevailing<font style="letter-spacing:0.1pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>prices;<font style="letter-spacing:0.05pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">at negotiated<font style="letter-spacing:0.05pt;"> </font>prices.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each prospectus supplement will describe the method of distribution of the securities and any applicable <font style="letter-spacing:-2.35pt;"> </font>restrictions.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>with respect<font style="letter-spacing:0.05pt;"> </font>to the securities<font style="letter-spacing:0.1pt;"> </font>of a particular<font style="letter-spacing:0.1pt;"> </font>series<font style="letter-spacing:0.05pt;"> </font>will describe<font style="letter-spacing:0.05pt;"> </font>the terms<font style="letter-spacing:0.1pt;"> </font>of the <font style="letter-spacing:-2.35pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>of the securities,<font style="letter-spacing:0.1pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the name of the agent or any underwriters;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the public<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>or purchase<font style="letter-spacing:0.05pt;"> </font>price;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any discounts<font style="letter-spacing:0.05pt;"> </font>and commissions<font style="letter-spacing:0.1pt;"> </font>to be allowed or paid to the agent or underwriters;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">all<font style="letter-spacing:0.05pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>items<font style="letter-spacing:0.05pt;"> </font>constituting<font style="letter-spacing:0.1pt;"> </font>underwriting<font style="letter-spacing:0.05pt;"> </font>compensation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any discounts<font style="letter-spacing:0.05pt;"> </font>and commissions<font style="letter-spacing:0.1pt;"> </font>to be allowed or paid to dealers;<font style="letter-spacing:0.1pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any exchanges<font style="letter-spacing:0.05pt;"> </font>on which the securities<font style="letter-spacing:0.1pt;"> </font>will be listed.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any underwriters<font style="letter-spacing:0.1pt;"> </font>or agents<font style="letter-spacing:0.05pt;"> </font>are used in the sale<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>in respect<font style="letter-spacing:0.05pt;"> </font>of which this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>is delivered,<font style="letter-spacing:-2.35pt;"> </font>we<font style="letter-spacing:-0.1pt;"> </font>will enter into an<font style="letter-spacing:-0.05pt;"> </font>underwriting<font style="letter-spacing:0.05pt;"> </font>agreement,<font style="letter-spacing:0.05pt;"> </font>sales<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.05pt;"> </font>or other agreement<font style="letter-spacing:0.1pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>them<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:-0.05pt;"> </font>the time of sale to <font style="letter-spacing:-2.35pt;"> </font>them,<font style="letter-spacing:0.05pt;"> </font>and we<font style="letter-spacing:-0.05pt;"> </font>will set forth<font style="letter-spacing:0.05pt;"> </font>in the prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>relating<font style="letter-spacing:0.1pt;"> </font>to such offering<font style="letter-spacing:0.05pt;"> </font>the names<font style="letter-spacing:0.05pt;"> </font>of the underwriters<font style="letter-spacing:0.05pt;"> </font>or agents<font style="letter-spacing:0.05pt;"> </font>and the terms<font style="letter-spacing:0.05pt;"> </font>of the related<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>with them.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection<font style="letter-spacing:0.05pt;"> </font>with the offering<font style="letter-spacing:0.05pt;"> </font>of securities,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may grant<font style="letter-spacing:0.05pt;"> </font>to the underwriters<font style="letter-spacing:0.1pt;"> </font>an option to purchase<font style="letter-spacing:0.05pt;"> </font>additional<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>with an additional<font style="letter-spacing:0.1pt;"> </font>underwriting<font style="letter-spacing:0.05pt;"> </font>commission,<font style="letter-spacing:0.1pt;"> </font>as may be set forth<font style="letter-spacing:0.05pt;"> </font>in the accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>grant<font style="letter-spacing:0.05pt;"> </font>any such option, the terms<font style="letter-spacing:0.05pt;"> </font>of such option will be set forth<font style="letter-spacing:0.05pt;"> </font>in the prospectus<font style="letter-spacing:0.05pt;"> </font>supplement <font style="letter-spacing:-2.35pt;"> </font>for such securities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a dealer</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is used in the sale</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in respect</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of which the prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is delivered,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will sell</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the dealer,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as principal.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dealer,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">who</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be deemed</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be an &#8220;underwriter&#8221;</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defined</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the Securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act, may then resell</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the public</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at varying</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prices</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be determined</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y </font><font style="letter-spacing:-2.35pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such dealer</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the time</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of resale.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we<font style="letter-spacing:-0.05pt;"> </font>offer<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>in a subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>to our existing<font style="letter-spacing:0.05pt;"> </font>security<font style="letter-spacing:0.05pt;"> </font>holders,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may enter<font style="letter-spacing:0.05pt;"> </font>into a<font style="letter-spacing:0.05pt;"> </font>standby underwriting<font style="letter-spacing:0.05pt;"> </font>agreement<font style="letter-spacing:0.1pt;"> </font>with dealers,<font style="letter-spacing:0.05pt;"> </font>acting<font style="letter-spacing:0.05pt;"> </font>as standby underwriters.<font style="letter-spacing:0.1pt;"> </font>We may pay the standby<font style="letter-spacing:0.05pt;"> </font>underwriters<font style="letter-spacing:0.1pt;"> </font>a commitment<font style="letter-spacing:0.1pt;"> </font>fee for the securities<font style="letter-spacing:0.1pt;"> </font>they commit<font style="letter-spacing:0.05pt;"> </font>to purchase<font style="letter-spacing:0.05pt;"> </font>on a standby basis.<font style="letter-spacing:0.05pt;"> </font>If we<font style="letter-spacing:-0.05pt;"> </font>do not enter into a standby underwriting<font style="letter-spacing:0.05pt;"> </font>arrangement,<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>may retain<font style="letter-spacing:0.05pt;"> </font>a dealer-manager<font style="letter-spacing:0.15pt;"> </font>to manage<font style="letter-spacing:0.05pt;"> </font>a subscription<font style="letter-spacing:0.1pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>for us. Agents, underwriters,<font style="letter-spacing:0.1pt;"> </font>dealers<font style="letter-spacing:0.05pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>may be entitled<font style="letter-spacing:0.1pt;"> </font>under agreements<font style="letter-spacing:0.1pt;"> </font>which they<font style="letter-spacing:0.05pt;"> </font>may enter<font style="letter-spacing:0.05pt;"> </font>into with us to indemnification<font style="letter-spacing:0.15pt;"> </font>by us against<font style="letter-spacing:0.05pt;"> </font>certain<font style="letter-spacing:0.05pt;"> </font>civil<font style="letter-spacing:0.05pt;"> </font>liabilities,<font style="letter-spacing:0.15pt;"> </font>including<font style="letter-spacing:0.1pt;"> </font>liabilities<font style="letter-spacing:0.15pt;"> </font>under the<font style="letter-spacing:0.05pt;"> </font>Securities<font style="letter-spacing:0.1pt;"> </font>Act, and may be customers<font style="letter-spacing:0.1pt;"> </font>of, engage in transactions<font style="letter-spacing:0.1pt;"> </font>with or perform<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.05pt;"> </font>for us in the ordinary<font style="letter-spacing:0.05pt;"> </font>course<font style="letter-spacing:0.05pt;"> </font>of business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so indicated<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will authorize<font style="letter-spacing:0.05pt;"> </font>underwriters<font style="letter-spacing:0.1pt;"> </font>or other<font style="letter-spacing:0.05pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>acting<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>our agents<font style="letter-spacing:0.05pt;"> </font>to solicit<font style="letter-spacing:0.1pt;"> </font>offers<font style="letter-spacing:0.05pt;"> </font>by certain<font style="letter-spacing:0.05pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>to purchase<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>us pursuant<font style="letter-spacing:0.05pt;"> </font>to delayed<font style="letter-spacing:0.05pt;"> </font>delivery<font style="letter-spacing:0.05pt;"> </font>contracts<font style="letter-spacing:0.1pt;"> </font>providing<font style="letter-spacing:0.05pt;"> </font>for payment<font style="letter-spacing:0.05pt;"> </font>and delivery<font style="letter-spacing:0.05pt;"> </font>on the date stated<font style="letter-spacing:0.05pt;"> </font>in the prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>Each<font style="letter-spacing:0.05pt;"> </font>contract<font style="letter-spacing:0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be<font style="letter-spacing:-0.05pt;"> </font>for an<font style="letter-spacing:-0.05pt;"> </font>amount<font style="letter-spacing:0.05pt;"> </font>not<font style="letter-spacing:-0.05pt;"> </font>less<font style="letter-spacing:0.05pt;"> </font>than,<font style="letter-spacing:-0.05pt;"> </font>and the<font style="letter-spacing:-0.05pt;"> </font>aggregate<font style="letter-spacing:0.05pt;"> </font>amount of securities<font style="letter-spacing:0.05pt;"> </font>sold pursuant to such<font style="letter-spacing:-0.05pt;"> </font>contracts<font style="letter-spacing:0.1pt;"> </font>shall not be<font style="letter-spacing:-2.35pt;"> </font>less<font style="letter-spacing:0.05pt;"> </font>nor more<font style="letter-spacing:0.05pt;"> </font>than, the respective<font style="letter-spacing:0.1pt;"> </font>amounts<font style="letter-spacing:0.05pt;"> </font>stated<font style="letter-spacing:0.05pt;"> </font>in the prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>Institutions<font style="letter-spacing:0.1pt;"> </font>with whom the<font style="letter-spacing:0.05pt;"> </font>contracts,<font style="letter-spacing:0.1pt;"> </font>when<font style="letter-spacing:-0.05pt;"> </font>authorized,<font style="letter-spacing:0.05pt;"> </font>may be made include<font style="letter-spacing:0.05pt;"> </font>commercial<font style="letter-spacing:0.1pt;"> </font>and savings<font style="letter-spacing:0.05pt;"> </font>banks, insurance<font style="letter-spacing:0.05pt;"> </font>companies,<font style="letter-spacing:0.05pt;"> </font>pension<font style="letter-spacing:0.05pt;"> </font>funds, investment<font style="letter-spacing:0.1pt;"> </font>companies,<font style="letter-spacing:0.05pt;"> </font>educational<font style="letter-spacing:0.1pt;"> </font>and charitable<font style="letter-spacing:0.1pt;"> </font>institutions<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>institutions,<font style="letter-spacing:0.1pt;"> </font>but shall<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>cases<font style="letter-spacing:0.05pt;"> </font>be subject<font style="letter-spacing:0.05pt;"> </font>to our approval.<font style="letter-spacing:0.05pt;"> </font>Delayed delivery<font style="letter-spacing:0.05pt;"> </font>contracts<font style="letter-spacing:0.1pt;"> </font>will not be subject<font style="letter-spacing:0.05pt;"> </font>to any conditions<font style="letter-spacing:0.05pt;"> </font>except<font style="letter-spacing:0.05pt;"> </font>that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the purchase<font style="letter-spacing:0.05pt;"> </font>by an institution<font style="letter-spacing:0.1pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>covered<font style="letter-spacing:0.05pt;"> </font>under that<font style="letter-spacing:0.05pt;"> </font>contract<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.05pt;"> </font>not at<font style="letter-spacing:0.05pt;"> </font>the time<font style="letter-spacing:0.05pt;"> </font>of delivery<font style="letter-spacing:0.05pt;"> </font>be prohibited<font style="letter-spacing:0.05pt;"> </font>under the laws of the jurisdiction<font style="letter-spacing:0.1pt;"> </font>to which that<font style="letter-spacing:0.05pt;"> </font>institution<font style="letter-spacing:0.1pt;"> </font>is subject;<font style="letter-spacing:0.05pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if the securities<font style="letter-spacing:0.1pt;"> </font>are also being sold to underwriters<font style="letter-spacing:0.1pt;"> </font>acting<font style="letter-spacing:0.05pt;"> </font>as principals<font style="letter-spacing:0.1pt;"> </font>for their<font style="letter-spacing:0.05pt;"> </font>own<font style="letter-spacing:-0.05pt;"> </font>account,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and <font style="letter-spacing:-2.35pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>persons<font style="letter-spacing:0.05pt;"> </font>acting<font style="letter-spacing:0.05pt;"> </font>as our agents<font style="letter-spacing:0.05pt;"> </font>will not have any responsibility<font style="letter-spacing:0.15pt;"> </font>in respect<font style="letter-spacing:0.05pt;"> </font>of the validity<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>performance<font style="letter-spacing:0.1pt;"> </font>of delayed<font style="letter-spacing:0.05pt;"> </font>delivery<font style="letter-spacing:0.05pt;"> </font>contracts.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offered<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>may also be offered<font style="letter-spacing:0.05pt;"> </font>and sold, if so indicated<font style="letter-spacing:0.05pt;"> </font>in the prospectus<font style="letter-spacing:0.05pt;"> </font>supplement,<font style="letter-spacing:0.05pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>a remarketing<font style="letter-spacing:0.1pt;"> </font>upon their<font style="letter-spacing:0.05pt;"> </font>purchase,<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.05pt;"> </font>with a redemption<font style="letter-spacing:0.1pt;"> </font>or repayment<font style="letter-spacing:0.05pt;"> </font>pursuant<font style="letter-spacing:0.05pt;"> </font>to their<font style="letter-spacing:0.05pt;"> </font>terms,<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:0.05pt;"> </font>otherwise, by one<font style="letter-spacing:-0.05pt;"> </font>or more remarketing<font style="letter-spacing:0.1pt;"> </font>firms, acting<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>principals<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:-0.05pt;"> </font>their<font style="letter-spacing:0.05pt;"> </font>own<font style="letter-spacing:-0.1pt;"> </font>accounts<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>as agents for us.<font style="letter-spacing:-0.05pt;"> </font>Any remarketing<font style="letter-spacing:0.1pt;"> </font>firm<font style="letter-spacing:0.05pt;"> </font>will be identified<font style="letter-spacing:0.1pt;"> </font>and the terms<font style="letter-spacing:0.05pt;"> </font>of its<font style="letter-spacing:0.05pt;"> </font>agreement,<font style="letter-spacing:0.1pt;"> </font>if any, with us and its<font style="letter-spacing:0.05pt;"> </font>compensation<font style="letter-spacing:0.1pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>be<font style="letter-spacing:0.05pt;"> </font>described<font style="letter-spacing:0.05pt;"> </font>in the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>Remarketing<font style="letter-spacing:0.05pt;"> </font>firms<font style="letter-spacing:0.05pt;"> </font>may be deemed<font style="letter-spacing:0.05pt;"> </font>to be underwriters<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>connection<font style="letter-spacing:0.05pt;"> </font>with their<font style="letter-spacing:0.05pt;"> </font>remarketing<font style="letter-spacing:0.1pt;"> </font>of offered<font style="letter-spacing:0.05pt;"> </font>securities.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain agents, underwriters and dealers, and their associates and affiliates, may be customers of, have borrowing relationships with, engage in other transactions with, or perform services, including investment banking services,<font style="letter-spacing:0.05pt;"> </font>for us or one or more<font style="letter-spacing:0.05pt;"> </font>of our respective<font style="letter-spacing:0.1pt;"> </font>affiliates<font style="letter-spacing:0.15pt;"> </font>in the ordinary<font style="letter-spacing:0.05pt;"> </font>course<font style="letter-spacing:0.05pt;"> </font>of business.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order<font style="letter-spacing:0.05pt;"> </font>to facilitate<font style="letter-spacing:0.15pt;"> </font>the offering<font style="letter-spacing:0.05pt;"> </font>of the securities,<font style="letter-spacing:0.1pt;"> </font>any underwriters<font style="letter-spacing:0.1pt;"> </font>may engage in transactions<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>stabilize,<font style="letter-spacing:0.05pt;"> </font>maintain<font style="letter-spacing:0.1pt;"> </font>or otherwise<font style="letter-spacing:0.05pt;"> </font>affect<font style="letter-spacing:0.05pt;"> </font>the price<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>or any other<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>the prices<font style="letter-spacing:0.05pt;"> </font>of which may be used<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>determine<font style="letter-spacing:0.1pt;"> </font>payments<font style="letter-spacing:0.05pt;"> </font>on such securities.<font style="letter-spacing:0.1pt;"> </font>Specifically,<font style="letter-spacing:0.1pt;"> </font>any underwriters<font style="letter-spacing:0.1pt;"> </font>may overallot<font style="letter-spacing:0.1pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with the<font style="letter-spacing:0.05pt;"> </font>offering,<font style="letter-spacing:0.05pt;"> </font>creating<font style="letter-spacing:0.05pt;"> </font>a short<font style="letter-spacing:0.05pt;"> </font>position<font style="letter-spacing:0.05pt;"> </font>for their<font style="letter-spacing:0.05pt;"> </font>own<font style="letter-spacing:-0.05pt;"> </font>accounts.<font style="letter-spacing:0.05pt;"> </font>In addition,<font style="letter-spacing:0.05pt;"> </font>to cover overallotments<font style="letter-spacing:0.15pt;"> </font>or to stabilize<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>or of any such other<font style="letter-spacing:0.05pt;"> </font>securities,<font style="letter-spacing:0.1pt;"> </font>the underwriters<font style="letter-spacing:0.1pt;"> </font>may bid for, and purchase,<font style="letter-spacing:0.05pt;"> </font>the securities<font style="letter-spacing:0.1pt;"> </font>or<font style="letter-spacing:-2.35pt;"> </font>any such other<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>in the open market.<font style="letter-spacing:0.05pt;"> </font>Finally,<font style="letter-spacing:0.05pt;"> </font>in any offering<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>through a syndicate<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>underwriters,<font style="letter-spacing:0.1pt;"> </font>the underwriting<font style="letter-spacing:0.05pt;"> </font>syndicate<font style="letter-spacing:0.05pt;"> </font>may reclaim<font style="letter-spacing:0.1pt;"> </font>selling<font style="letter-spacing:0.05pt;"> </font>concessions<font style="letter-spacing:0.05pt;"> </font>allowed to an underwriter<font style="letter-spacing:0.1pt;"> </font>or a dealer<font style="letter-spacing:0.05pt;"> </font>for distributing<font style="letter-spacing:0.1pt;"> </font>the securities<font style="letter-spacing:0.1pt;"> </font>in the offering<font style="letter-spacing:0.05pt;"> </font>if the syndicate<font style="letter-spacing:0.05pt;"> </font>repurchases<font style="letter-spacing:0.1pt;"> </font>previously<font style="letter-spacing:0.05pt;"> </font>distributed<font style="letter-spacing:0.1pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>transactions<font style="letter-spacing:0.1pt;"> </font>to cover syndicate<font style="letter-spacing:0.05pt;"> </font>short<font style="letter-spacing:0.05pt;"> </font>positions,<font style="letter-spacing:0.05pt;"> </font>in stabilization<font style="letter-spacing:0.15pt;"> </font>transactions<font style="letter-spacing:0.1pt;"> </font>or otherwise.<font style="letter-spacing:0.05pt;"> </font>Any<font style="letter-spacing:-0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.05pt;"> </font>may stabilize<font style="letter-spacing:0.1pt;"> </font>or maintain<font style="letter-spacing:0.1pt;"> </font>the market<font style="letter-spacing:0.05pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of the securities<font style="letter-spacing:0.1pt;"> </font>above independent<font style="letter-spacing:0.05pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>levels.<font style="letter-spacing:0.05pt;"> </font>Any<font style="letter-spacing:-0.05pt;"> </font>such<font style="letter-spacing:0.05pt;"> </font>underwriters<font style="letter-spacing:0.1pt;"> </font>are not required<font style="letter-spacing:0.05pt;"> </font>to engage in these<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>and may end any of these<font style="letter-spacing:0.05pt;"> </font>activities<font style="letter-spacing:0.1pt;"> </font>at any time.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may engage in at the </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">offerings</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into an existing</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trading</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in accordance</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with Rule 415(a)(4)</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the Securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act.</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enter</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into derivative</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transactions</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with third</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or sell</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not covered</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to third</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">privately</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negotiated</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transactions.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the applicable</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplement</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so indicates,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in connection</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with those derivatives,</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the third</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may sell</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covered</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the applicable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplement,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in short</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sale</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transactions.</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the third</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may use securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pledged by us or borrowed from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us or others</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to settle</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those sales</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or to close</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ut a</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny related</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">open borrowings</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of stock, and may use securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us in settlement</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of those derivatives</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to close</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out any related</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">open borrowings</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of stock. The third</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in such sale</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transactions</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be an underwrit</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er a</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd, if not identified</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be named in the applicable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplement</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(or a post-</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amendment).</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may otherwise</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loan or pledge securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to a financial</font><font style="letter-spacing:0.15pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">institution</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in turn may sell</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">short</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using this</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and an applicable</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplement. Such</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">institution</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other third</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party m</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ay</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transfer</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its economic short position</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="letter-spacing:-0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investors i</font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n </font><font style="letter-spacing:-2.35pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our securities</font><font style="letter-spacing:0.1pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or in connection</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a concurrent</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">offering</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of other</font><font style="letter-spacing:0.05pt;"> </font><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Rule 15c6-1 of the Exchange Act, trades<font style="letter-spacing:0.05pt;"> </font>in the secondary<font style="letter-spacing:0.05pt;"> </font>market<font style="letter-spacing:0.05pt;"> </font>generally<font style="letter-spacing:0.05pt;"> </font>are required<font style="letter-spacing:0.05pt;"> </font>to settle<font style="letter-spacing:0.05pt;"> </font>in two<font style="letter-spacing:0.05pt;"> </font>business<font style="letter-spacing:0.05pt;"> </font>days, unless<font style="letter-spacing:0.05pt;"> </font>the parties<font style="letter-spacing:0.05pt;"> </font>to any such trade<font style="letter-spacing:0.05pt;"> </font>expressly<font style="letter-spacing:0.05pt;"> </font>agree<font style="letter-spacing:0.05pt;"> </font>otherwise.<font style="letter-spacing:0.05pt;"> </font>The applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement<font style="letter-spacing:0.05pt;"> </font>may provide<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the original<font style="letter-spacing:0.05pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>date for your securities<font style="letter-spacing:0.1pt;"> </font>may be more<font style="letter-spacing:0.05pt;"> </font>than two scheduled<font style="letter-spacing:0.1pt;"> </font>business <font style="letter-spacing:-2.35pt;"> </font>days after<font style="letter-spacing:0.05pt;"> </font>the trade<font style="letter-spacing:0.05pt;"> </font>date for your securities.<font style="letter-spacing:0.1pt;"> </font>Accordingly,<font style="letter-spacing:0.05pt;"> </font>in such a case, if you wish to trade<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>on any<font style="letter-spacing:0.05pt;"> </font>date prior<font style="letter-spacing:0.05pt;"> </font>to the second business<font style="letter-spacing:0.05pt;"> </font>day before<font style="letter-spacing:0.05pt;"> </font>the original<font style="letter-spacing:0.05pt;"> </font>issue<font style="letter-spacing:0.05pt;"> </font>date for your securities,<font style="letter-spacing:0.1pt;"> </font>you will be required,<font style="letter-spacing:0.05pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>virtue<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>fact<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>your<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.15pt;"> </font>initially<font style="letter-spacing:0.15pt;"> </font>are<font style="letter-spacing:0.05pt;"> </font>expected<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.05pt;"> </font>settle<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.1pt;"> </font>than two<font style="letter-spacing:0.05pt;"> </font>scheduled<font style="letter-spacing:0.1pt;"> </font>business<font style="letter-spacing:0.1pt;"> </font>days<font style="letter-spacing:0.05pt;"> </font>after<font style="letter-spacing:0.05pt;"> </font>the trade<font style="letter-spacing:0.05pt;"> </font>date for your securities,<font style="letter-spacing:0.1pt;"> </font>to make alternative<font style="letter-spacing:0.15pt;"> </font>settlement<font style="letter-spacing:0.1pt;"> </font>arrangements<font style="letter-spacing:0.1pt;"> </font>to prevent<font style="letter-spacing:0.05pt;"> </font>a failed<font style="letter-spacing:0.05pt;"> </font>settlement.<font style="letter-spacing:-2.35pt;"> </font>The<font style="letter-spacing:-0.05pt;"> </font>securities<font style="letter-spacing:0.05pt;"> </font>may be<font style="letter-spacing:-0.05pt;"> </font>new<font style="letter-spacing:-0.05pt;"> </font>issues of securities<font style="letter-spacing:0.05pt;"> </font>and may<font style="letter-spacing:-0.05pt;"> </font>have no<font style="letter-spacing:-0.05pt;"> </font>established<font style="letter-spacing:0.1pt;"> </font>trading market.<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:-0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>may<font style="letter-spacing:-0.05pt;"> </font>or may not be listed<font style="letter-spacing:0.05pt;"> </font>on a national<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>exchange. We can make no assurance<font style="letter-spacing:0.05pt;"> </font>as to the liquidity<font style="letter-spacing:0.1pt;"> </font>of or the<font style="letter-spacing:0.05pt;"> </font>existence<font style="letter-spacing:0.05pt;"> </font>of trading<font style="letter-spacing:0.05pt;"> </font>markets<font style="letter-spacing:0.05pt;"> </font>for any of the securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The specific<font style="letter-spacing:0.1pt;"> </font>terms<font style="letter-spacing:0.05pt;"> </font>of any lock-up<font style="letter-spacing:0.05pt;"> </font>provisions<font style="letter-spacing:0.05pt;"> </font>in respect<font style="letter-spacing:0.05pt;"> </font>of any given offering<font style="letter-spacing:0.05pt;"> </font>will be described<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>the applicable prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The underwriters,<font style="letter-spacing:0.1pt;"> </font>dealers<font style="letter-spacing:0.05pt;"> </font>and agents<font style="letter-spacing:0.05pt;"> </font>may engage in transactions<font style="letter-spacing:0.1pt;"> </font>with us, or perform<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.05pt;"> </font>for us, in the <font style="letter-spacing:-2.35pt;"> </font>ordinary<font style="letter-spacing:0.05pt;"> </font>course<font style="letter-spacing:0.05pt;"> </font>of business<font style="letter-spacing:0.05pt;"> </font>for which they receive<font style="letter-spacing:0.05pt;"> </font>compensation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The anticipated<font style="letter-spacing:0.1pt;"> </font>date of delivery<font style="letter-spacing:0.05pt;"> </font>of offered<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>will be set forth<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>the applicable<font style="letter-spacing:0.1pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement relating<font style="letter-spacing:0.1pt;"> </font>to each offer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a><a name="LEGAL_MATTERS_1"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LEGAL</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="LEGAL_MATTERS_1"></a>M</font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATTERS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain<font style="letter-spacing:0.05pt;"> </font>legal<font style="letter-spacing:0.05pt;"> </font>matters<font style="letter-spacing:0.1pt;"> </font>in connection<font style="letter-spacing:0.05pt;"> </font>with this<font style="letter-spacing:0.05pt;"> </font>offering<font style="letter-spacing:0.05pt;"> </font>will be passed upon for us by Goodwin<font style="letter-spacing:-0.05pt;"> </font>Procter<font style="letter-spacing:0.05pt;"> </font>LLP,<font style="letter-spacing:0.05pt;"> </font>Boston, Massachusetts. Any underwriters will also be advised about the validity of the securities and other legal matters<font style="letter-spacing:0.1pt;"> </font>by their<font style="letter-spacing:0.05pt;"> </font>own<font style="letter-spacing:-0.05pt;"> </font>counsel,<font style="letter-spacing:0.05pt;"> </font>which will be named in the prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXPERTS_1"></a><a name="EXPERTS_1"></a>EXPERTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ernst &amp; Young<font style="letter-spacing:-0.05pt;"> </font>LLP,<font style="letter-spacing:-0.05pt;"> </font>independent<font style="letter-spacing:0.05pt;"> </font>registered<font style="letter-spacing:0.1pt;"> </font>public<font style="letter-spacing:0.05pt;"> </font>accounting<font style="letter-spacing:0.05pt;"> </font>firm,<font style="letter-spacing:0.05pt;"> </font>has audited<font style="letter-spacing:0.05pt;"> </font>our consolidated<font style="letter-spacing:0.1pt;"> </font>financial<font style="letter-spacing:0.05pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>included<font style="letter-spacing:0.05pt;"> </font>in our Annual Report on Form 10-K for the year ended December<font style="letter-spacing:0.05pt;"> </font>31, 2020, as set forth<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>their report, which is<font style="letter-spacing:-0.05pt;"> </font>incorporated<font style="letter-spacing:0.05pt;"> </font>by reference<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>prospectus and<font style="letter-spacing:-0.05pt;"> </font>elsewhere<font style="letter-spacing:0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>statement.<font style="letter-spacing:0.05pt;"> </font>Our financial<font style="letter-spacing:0.1pt;"> </font>statements<font style="letter-spacing:0.1pt;"> </font>are incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>in reliance<font style="letter-spacing:0.1pt;"> </font>on Ernst &amp; Young<font style="letter-spacing:-0.05pt;"> </font>LLP&#8217;s report,<font style="letter-spacing:0.05pt;"> </font>given on their<font style="letter-spacing:0.05pt;"> </font>authority<font style="letter-spacing:0.05pt;"> </font>as experts<font style="letter-spacing:0.05pt;"> </font>in accounting<font style="letter-spacing:0.05pt;"> </font>and auditing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION_1"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHERE</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">YOU</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CAN</font><font style="letter-spacing:-0.1pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="WHERE_YOU_CAN_FIND_MORE_INFORMATION_1"></a>FIND</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MORE</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus<font style="letter-spacing:0.05pt;"> </font>is part<font style="letter-spacing:0.05pt;"> </font>of a registration<font style="letter-spacing:0.15pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have filed<font style="letter-spacing:0.05pt;"> </font>with the SEC.<font style="letter-spacing:-0.05pt;"> </font>Certain<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>in<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>has been omitted<font style="letter-spacing:0.05pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>in accordance<font style="letter-spacing:0.05pt;"> </font>with the rules<font style="letter-spacing:0.05pt;"> </font>of the SEC.<font style="letter-spacing:-0.05pt;"> </font>We are<font style="letter-spacing:0.05pt;"> </font>subject<font style="letter-spacing:0.05pt;"> </font>to the information<font style="letter-spacing:0.1pt;"> </font>requirements<font style="letter-spacing:0.1pt;"> </font>of the Exchange Act and, in<font style="letter-spacing:0.05pt;"> </font>accordance<font style="letter-spacing:0.05pt;"> </font>therewith,<font style="letter-spacing:0.05pt;"> </font>file<font style="letter-spacing:0.05pt;"> </font>annual, quarterly and current<font style="letter-spacing:0.05pt;"> </font>reports,<font style="letter-spacing:0.05pt;"> </font>proxy statements<font style="letter-spacing:0.1pt;"> </font>and other<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>with the SEC.<font style="letter-spacing:-0.05pt;"> </font>These documents<font style="letter-spacing:0.05pt;"> </font>also may be<font style="letter-spacing:0.05pt;"> </font>accessed<font style="letter-spacing:0.05pt;"> </font>through the SEC&#8217;s<font style="letter-spacing:-0.05pt;"> </font>electronic<font style="letter-spacing:0.1pt;"> </font>data gathering,<font style="letter-spacing:0.05pt;"> </font>analysis<font style="letter-spacing:0.05pt;"> </font>and retrieval<font style="letter-spacing:0.1pt;"> </font>system,<font style="letter-spacing:0.05pt;"> </font>or EDGAR,<font style="letter-spacing:-0.1pt;"> </font>via electronic<font style="letter-spacing:0.05pt;"> </font>means,<font style="letter-spacing:0.05pt;"> </font>including<font style="letter-spacing:0.05pt;"> </font>the SEC&#8217;s<font style="letter-spacing:-0.05pt;"> </font>home page on the Internet<font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;">(www.sec.gov</font>). We also maintain<font style="letter-spacing:0.1pt;"> </font>a website<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;">www.relaytx.com</font>. The information<font style="letter-spacing:0.1pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>in or accessible<font style="letter-spacing:0.1pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>our website<font style="letter-spacing:0.05pt;"> </font>is not incorporated<font style="letter-spacing:0.1pt;"> </font>into this<font style="letter-spacing:0.05pt;"> </font>prospectus,<font style="letter-spacing:0.05pt;"> </font>and you should not consider<font style="letter-spacing:0.05pt;"> </font>it part<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>prospectus.<font style="letter-spacing:0.05pt;"> </font>We have included<font style="letter-spacing:0.05pt;"> </font>our website<font style="letter-spacing:0.05pt;"> </font>address<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>solely<font style="letter-spacing:0.05pt;"> </font>as an inactive<font style="letter-spacing:0.05pt;"> </font>textual<font style="letter-spacing:0.05pt;"> </font>reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have the authority<font style="letter-spacing:0.05pt;"> </font>to designate<font style="letter-spacing:0.05pt;"> </font>and issue<font style="letter-spacing:0.05pt;"> </font>more<font style="letter-spacing:0.05pt;"> </font>than one class<font style="letter-spacing:0.05pt;"> </font>or series<font style="letter-spacing:0.05pt;"> </font>of stock having various<font style="letter-spacing:0.05pt;"> </font>preferences,<font style="letter-spacing:0.05pt;"> </font>conversion and<font style="letter-spacing:-0.05pt;"> </font>other rights, voting<font style="letter-spacing:-0.05pt;"> </font>powers,<font style="letter-spacing:-0.05pt;"> </font>restrictions,<font style="letter-spacing:0.15pt;"> </font>limitations<font style="letter-spacing:0.1pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>dividends, qualifications,<font style="letter-spacing:0.1pt;"> </font>and terms and conditions<font style="letter-spacing:0.05pt;"> </font>of redemption.<font style="letter-spacing:0.1pt;"> </font>See &#8220;Description<font style="letter-spacing:0.1pt;"> </font>of Capital<font style="letter-spacing:0.05pt;"> </font>Stock.&#8221; We will furnish<font style="letter-spacing:0.05pt;"> </font>a full<font style="letter-spacing:0.05pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>of the relative<font style="letter-spacing:0.05pt;"> </font>rights<font style="letter-spacing:0.05pt;"> </font>and preferences<font style="letter-spacing:0.1pt;"> </font>of each class<font style="letter-spacing:0.05pt;"> </font>or series<font style="letter-spacing:0.05pt;"> </font>of our stock which has been so designated<font style="letter-spacing:0.05pt;"> </font>and any restrictions<font style="letter-spacing:0.15pt;"> </font>on<font style="letter-spacing:0.05pt;"> </font>the ownership or transfer<font style="letter-spacing:0.1pt;"> </font>of our stock to any stockholder<font style="letter-spacing:0.05pt;"> </font>upon request<font style="letter-spacing:0.05pt;"> </font>and without charge.<font style="letter-spacing:0.05pt;"> </font>Written<font style="letter-spacing:0.1pt;"> </font>requests<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>such copies should be directed to Relay Therapeutics, Inc., 399 Binney Street, 2nd<font style="letter-spacing:0.05pt;"> </font>Floor, Cambridge,<font style="letter-spacing:0.05pt;"> </font>Massachusetts<font style="letter-spacing:0.1pt;"> </font>02139, telephone:<font style="letter-spacing:0.05pt;"> </font>(617) 370-8837. Information<font style="letter-spacing:0.1pt;"> </font>contained<font style="letter-spacing:0.05pt;"> </font>on our website<font style="letter-spacing:0.05pt;"> </font>is not incorporated<font style="letter-spacing:0.1pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>reference<font style="letter-spacing:0.1pt;"> </font>into this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>and you should not consider<font style="letter-spacing:0.05pt;"> </font>any information<font style="letter-spacing:0.1pt;"> </font>on, or that<font style="letter-spacing:0.05pt;"> </font>can be accessed<font style="letter-spacing:0.05pt;"> </font>from,<font style="letter-spacing:0.05pt;"> </font>our<font style="letter-spacing:0.05pt;"> </font>website<font style="letter-spacing:0.05pt;"> </font>as part<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>or any accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><a name="INCORPORATION_BY_REFERENCE_1"></a><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INCORPORATION</font><font style="letter-spacing:-0.15pt;"><a name="INCORPORATION_BY_REFERENCE_1"></a> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BY</font><font style="letter-spacing:-0.05pt;"> </font><font style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REFERENCE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC<font style="letter-spacing:-0.05pt;"> </font>allows us to incorporate<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>the information<font style="letter-spacing:0.1pt;"> </font>and reports<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>file<font style="letter-spacing:0.05pt;"> </font>with it, which means<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:0.05pt;"> </font>can disclose<font style="letter-spacing:0.05pt;"> </font>important<font style="letter-spacing:0.1pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>to you by referring<font style="letter-spacing:0.1pt;"> </font>you to these<font style="letter-spacing:0.05pt;"> </font>documents.<font style="letter-spacing:0.05pt;"> </font>The information<font style="letter-spacing:0.1pt;"> </font>incorporated<font style="letter-spacing:0.15pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>is an important<font style="letter-spacing:0.1pt;"> </font>part<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>prospectus,<font style="letter-spacing:0.05pt;"> </font>and information<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>file<font style="letter-spacing:0.05pt;"> </font>later<font style="letter-spacing:0.05pt;"> </font>with the SEC<font style="letter-spacing:-0.05pt;"> </font>will<font style="letter-spacing:0.05pt;"> </font>automatically<font style="letter-spacing:0.15pt;"> </font>update and supersede<font style="letter-spacing:0.05pt;"> </font>the information<font style="letter-spacing:0.1pt;"> </font>already<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>by reference.<font style="letter-spacing:0.1pt;"> </font>We are<font style="letter-spacing:0.05pt;"> </font>incorporating<font style="letter-spacing:0.1pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>reference<font style="letter-spacing:0.1pt;"> </font>the documents<font style="letter-spacing:0.05pt;"> </font>listed<font style="letter-spacing:0.05pt;"> </font>below, which we<font style="letter-spacing:-0.05pt;"> </font>have already<font style="letter-spacing:0.05pt;"> </font>filed<font style="letter-spacing:0.05pt;"> </font>with the SEC<font style="letter-spacing:-0.05pt;"> </font>(SEC<font style="letter-spacing:-0.05pt;"> </font>File No.<font style="letter-spacing:-0.05pt;"> </font>001-39385), and any future<font style="letter-spacing:0.05pt;"> </font>filings<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>make with the SEC<font style="letter-spacing:-0.05pt;"> </font>under Sections<font style="letter-spacing:0.05pt;"> </font>13(a),<font style="letter-spacing:0.05pt;"> </font>13(c),<font style="letter-spacing:0.05pt;"> </font>14 or 15(d) of the Exchange Act, including <font style="letter-spacing:-2.35pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>filings<font style="letter-spacing:0.05pt;"> </font>made after<font style="letter-spacing:0.05pt;"> </font>the date of the filing<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>and prior<font style="letter-spacing:0.05pt;"> </font>to the effectiveness<font style="letter-spacing:0.15pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>statement,<font style="letter-spacing:0.1pt;"> </font>except<font style="letter-spacing:0.05pt;"> </font>as to any portion<font style="letter-spacing:0.05pt;"> </font>of any future<font style="letter-spacing:0.05pt;"> </font>report<font style="letter-spacing:0.05pt;"> </font>or document<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>is not deemed<font style="letter-spacing:0.05pt;"> </font>filed<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:0.05pt;"> </font>such provisions<font style="letter-spacing:0.05pt;"> </font>until<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>sell<font style="letter-spacing:0.05pt;"> </font>all<font style="letter-spacing:0.05pt;"> </font>of the securities:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Annual Report on <a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021015518/rlay-10k_20201231.htm"><font style="text-decoration:underline;color:#000000;">Form 10-K</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the year ended December 31, 2020, filed with the SEC on March 25,</font><font style="letter-spacing:-2.35pt;"> </font>2021;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information specifically incorporated by reference into our Annual Report on <font style="color:#000000;">Form 10-K</font> for the year ended December<font style="letter-spacing:0.05pt;"> </font>31, 2020 from<font style="letter-spacing:0.05pt;"> </font>our definitive<font style="letter-spacing:0.1pt;"> </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021018016/rlay-def14a_20210519.htm"><font style="text-decoration:underline;color:#000000;">proxy statement</font></a><font style="color:#231F20;font-size:10pt;letter-spacing:0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font>on <font style="color:#000000;">Schedule 14A</font><font style="letter-spacing:-0.05pt;"> </font>(other<font style="letter-spacing:0.05pt;"> </font>than<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>furnished<font style="letter-spacing:0.05pt;"> </font>rather<font style="letter-spacing:0.05pt;"> </font>than filed),<font style="letter-spacing:0.05pt;"> </font>which was filed<font style="letter-spacing:0.05pt;"> </font>with the SEC<font style="letter-spacing:-0.05pt;"> </font>on April 7, 2021;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quarterly Reports on Form 10-Q filed with the SEC for the quarters ended March 31, 2021 and <font style="letter-spacing:-2.35pt;"> </font>June 30, 2021, filed<font style="letter-spacing:0.05pt;"> </font>with the SEC<font style="letter-spacing:-0.05pt;"> </font>on <a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021027601/rlay-10q_20210331.htm"><font style="text-decoration:underline;color:#000000;">May 13, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021027601/rlay-10q_20210331.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021043999/rlay-10q_20210630.htm"><font style="text-decoration:underline;color:#000000;">August 12, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Current Reports on Form 8-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312521118438/d110953d8k.htm"><font style="text-decoration:underline;color:#000000;">April 16, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312521118438/d110953d8k.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021028867/rlay-8k_20210519.htm"><font style="text-decoration:underline;color:#000000;">May 19, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312521118438/d110953d8k.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021028867/rlay-8k_20210519.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000156459021030437/rlay-8k_20210518.htm"><font style="text-decoration:underline;color:#000000;">May 27, 2021</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; </font><font style="letter-spacing:-2.35pt;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#231F20;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The description<font style="letter-spacing:0.1pt;"> </font>of our common<font style="letter-spacing:0.05pt;"> </font>stock contained<font style="letter-spacing:0.05pt;"> </font>in our Registration<font style="letter-spacing:0.1pt;"> </font>Statement<font style="letter-spacing:0.1pt;"> </font>on <a href="http://www.sec.gov/Archives/edgar/data/1812364/000119312520191867/d948089d8a12b.htm"><font style="text-decoration:underline;color:#000000;">Form 8-A</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (File No. 001-39385) as filed with the SEC on July 13, 2020, including any amendments or reports filed for </font><font style="letter-spacing:-2.35pt;"> </font>the purpose of updating this description, including <a href="http://www.sec.gov/Archives/edgar/data/1812364/000119312520191867/d948089d8a12b.htm"><a href="http://www.sec.gov/Archives/edgar/data/1812364/000156459021015518/rlay-ex43_903.htm"><font style="text-decoration:underline;color:#000000;">Exhibit 4.3</font></a><font style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Annual Report on </font><font style="color:#000000;">Form 10-K</font> for <font style="letter-spacing:-2.35pt;"> </font>the year ended December<font style="letter-spacing:0.05pt;"> </font>31, 2020, as filed<font style="letter-spacing:0.05pt;"> </font>with the SEC<font style="letter-spacing:-0.05pt;"> </font>on March<font style="letter-spacing:0.05pt;"> </font>25, 2021.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon<font style="letter-spacing:-0.05pt;"> </font>request,<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>will provide,<font style="letter-spacing:0.05pt;"> </font>without charge,<font style="letter-spacing:0.05pt;"> </font>to each person, including<font style="letter-spacing:0.05pt;"> </font>any beneficial<font style="letter-spacing:0.1pt;"> </font>owner, to whom a copy<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>is delivered,<font style="letter-spacing:0.05pt;"> </font>a copy of the documents<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>into this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>but not<font style="letter-spacing:0.05pt;"> </font>delivered<font style="letter-spacing:0.05pt;"> </font>with the prospectus.<font style="letter-spacing:0.05pt;"> </font>You<font style="letter-spacing:-0.05pt;"> </font>may request<font style="letter-spacing:0.05pt;"> </font>a copy of these<font style="letter-spacing:0.05pt;"> </font>filings,<font style="letter-spacing:0.05pt;"> </font>and any exhibits<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>have specifically<font style="letter-spacing:0.05pt;"> </font>incorporated by reference as an exhibit in this prospectus, at no cost by writing or telephoning us at the following <font style="letter-spacing:-2.35pt;"> </font>address: Relay Therapeutics, Inc., 399 Binney Street, 2nd<font style="letter-spacing:0.05pt;"> </font>Floor, Cambridge, Massachusetts 02139, telephone:<font style="letter-spacing:0.05pt;"> </font>(617) 370-8837.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You<font style="letter-spacing:-0.05pt;"> </font>may also access<font style="letter-spacing:0.05pt;"> </font>these<font style="letter-spacing:0.05pt;"> </font>documents,<font style="letter-spacing:0.05pt;"> </font>free<font style="letter-spacing:0.05pt;"> </font>of charge<font style="letter-spacing:0.05pt;"> </font>on the SEC&#8217;s<font style="letter-spacing:-0.05pt;"> </font>website<font style="letter-spacing:0.05pt;"> </font>at <font style="font-style:italic;">www.sec.gov</font><font style="font-style:italic;letter-spacing:-0.05pt;"> </font>or on our website<font style="letter-spacing:0.05pt;"> </font>at<font style="letter-spacing:0.05pt;"> </font><font style="font-style:italic;">www.relaytx.com</font>. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider<font style="letter-spacing:0.05pt;"> </font>any information<font style="letter-spacing:0.1pt;"> </font>on, or that<font style="letter-spacing:0.05pt;"> </font>can be accessed<font style="letter-spacing:0.05pt;"> </font>from,<font style="letter-spacing:0.05pt;"> </font>our website<font style="letter-spacing:0.05pt;"> </font>as part<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>or any accompanying<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding<font style="letter-spacing:0.05pt;"> </font>the foregoing,<font style="letter-spacing:0.05pt;"> </font>unless<font style="letter-spacing:0.05pt;"> </font>specifically<font style="letter-spacing:0.15pt;"> </font>stated<font style="letter-spacing:0.05pt;"> </font>to the contrary,<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>furnish<font style="letter-spacing:0.05pt;"> </font>(and that<font style="letter-spacing:0.05pt;"> </font>is<font style="letter-spacing:0.05pt;"> </font>not deemed<font style="letter-spacing:0.05pt;"> </font>&#8220;filed&#8221;<font style="letter-spacing:0.05pt;"> </font>with the SEC)<font style="letter-spacing:-0.05pt;"> </font>under Items<font style="letter-spacing:0.05pt;"> </font>2.02 and 7.01 of any Current<font style="letter-spacing:0.05pt;"> </font>Report on Form 8-K, including<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>related exhibits under Item 9.01, is<font style="letter-spacing:-0.05pt;"> </font>not incorporated<font style="letter-spacing:0.05pt;"> </font>by reference<font style="letter-spacing:0.05pt;"> </font>into<font style="letter-spacing:-0.05pt;"> </font>this<font style="letter-spacing:0.05pt;"> </font>prospectus or the<font style="letter-spacing:-0.05pt;"> </font>registration<font style="letter-spacing:0.15pt;"> </font>statement <font style="letter-spacing:-2.35pt;"> </font>of which this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>is a part.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This prospectus<font style="letter-spacing:0.05pt;"> </font>is part<font style="letter-spacing:0.05pt;"> </font>of a registration<font style="letter-spacing:0.15pt;"> </font>statement<font style="letter-spacing:0.1pt;"> </font>we<font style="letter-spacing:-0.05pt;"> </font>filed<font style="letter-spacing:0.05pt;"> </font>with the SEC.<font style="letter-spacing:-0.05pt;"> </font>We have<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>exhibits<font style="letter-spacing:0.05pt;"> </font>into this registration<font style="letter-spacing:0.15pt;"> </font>statement.<font style="letter-spacing:0.1pt;"> </font>You<font style="letter-spacing:-0.05pt;"> </font>should read the exhibits<font style="letter-spacing:0.05pt;"> </font>carefully<font style="letter-spacing:0.1pt;"> </font>for provisions<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>may be important<font style="letter-spacing:0.1pt;"> </font>to you.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You<font style="letter-spacing:-0.05pt;"> </font>should rely<font style="letter-spacing:0.05pt;"> </font>only on the information<font style="letter-spacing:0.1pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>or provided<font style="letter-spacing:0.05pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>or any<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>supplement.<font style="letter-spacing:0.05pt;"> </font>We have not authorized<font style="letter-spacing:0.05pt;"> </font>anyone to provide<font style="letter-spacing:0.05pt;"> </font>you with different<font style="letter-spacing:0.1pt;"> </font>information.<font style="letter-spacing:0.1pt;"> </font>We are not<font style="letter-spacing:0.05pt;"> </font>making<font style="letter-spacing:0.05pt;"> </font>an offer<font style="letter-spacing:0.05pt;"> </font>of these<font style="letter-spacing:0.05pt;"> </font>securities<font style="letter-spacing:0.1pt;"> </font>in any state<font style="letter-spacing:0.05pt;"> </font>where the offer<font style="letter-spacing:0.05pt;"> </font>is not permitted.<font style="letter-spacing:0.1pt;"> </font>You<font style="letter-spacing:-0.05pt;"> </font>should not assume<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>information<font style="letter-spacing:0.1pt;"> </font>in this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>or in the documents<font style="letter-spacing:0.05pt;"> </font>incorporated<font style="letter-spacing:0.1pt;"> </font>by reference<font style="letter-spacing:0.1pt;"> </font>is accurate<font style="letter-spacing:0.05pt;"> </font>as of<font style="letter-spacing:0.05pt;"> </font>any date other<font style="letter-spacing:0.05pt;"> </font>than <font style="letter-spacing:-2.35pt;"> </font>the date on the front<font style="letter-spacing:0.05pt;"> </font>of this<font style="letter-spacing:0.05pt;"> </font>prospectus<font style="letter-spacing:0.05pt;"> </font>or those documents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:35pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$350,000,000</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:18pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:18pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:20pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-bottom:8pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:41.54%;margin-right:41.45%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gxr3kcgo1wwv000003.jpg" title="" alt="" style="width:328px;height:127px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:18pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:20pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Prospectus Supplement</p>
<p style="margin-bottom:8pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:41.54%;margin-right:41.45%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:13.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:233.9pt;;">
<tr>
<td style="width:233.9pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Goldman Sachs &amp; Co. LLC</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:16pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">J.P. Morgan</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:16pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cowen</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:16pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guggenheim Securities</p>
<p style="margin-bottom:8pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:41.54%;margin-right:41.45%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:8pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:41.54%;margin-right:41.45%;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>gxr3kcgo1wwv000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gxr3kcgo1wwv000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "  4D# 2(  A$! Q$!_\0
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MZFG:5=WS_=MXFE/X#-"5W83=D?/OCG4/[1\9ZG,IRBR^4GT0;?Z5[7X$T_\
ML[P7ID++AWB\YO7+G=_45\^V%O+JNL6]MDF6ZG5"WNQZ_K7U%$BQ0I&HPJJ
MH]J]#&/EA&FCAPL;S<V2T445YYWA17@WQC\=^)O#GC.&QTC59+6V:R20QK&A
M^8LX)Y4^@KS\?%GQZ1QK\Y_[8Q__ !-.P'US17R/_P +8\>_]!ZX_P"_$?\
M\35FQ^,WCFQN5DEU5;I <F*XMTVM^0!_(T6 ^KZ*Y/P%XTM?''AU=1AB\BXC
M?RKB#=G8_7@]P1R/_K5UE( HKY2UGXJ>-K?7=0@AUV5(X[F1$40Q\*&( ^[5
M3_A;'CW_ *#UQ_WXC_\ B:=@/KBBOD?_ (6QX]_Z#UQ_WXC_ /B:TO#GQ.\<
M7OB?2;6XUJ>2":]ACD0PQ_,I< C[OI18#ZFHHKQ#XT>-?$?ACQ%I]KHVIO:0
MRVGF.JHC9;>PS\P/8"D![?17$_"O6=0\0?#ZQU'5+@W%W(\JM(5 ) =@.@QT
MKMJ "BBB@ HHII(5<DX ZDT .HKY=\5?&+Q-<>);YM$U:2UTQ9"EO&L2'*CC
M=DJ3\W7\:]H^%GB^3QCX/CGNY0^HVKF&Z. -QZJV!ZC]0:=@.ZHHKPSXO:]X
MW\(:['>:=K4T>CWH_=*L49$,@'S)DKW^\/J?2E8#W.BO-OA'X\D\8Z%+:ZE,
M'U>R.)6P 98S]U\#\C^'K7I- !17"_%#QL/!OA=I;=U&I7>8K13@[3W?'HH_
M4BO-_A9XF\=^,O%2)<:Y.=+L\2W9\F/##LF=O\7\@:=M /H*BO,]2U+5)-5O
M)FOI[>&UN"DK([*MHGF%5;:&VME LGS*WW_2JO\ PF_CS_H6_P#R"U(#U:BJ
M5QJ5A9N([J\MX'(R%EE521Z\FH_[>T?_ *"MC_X$)_C19@3:A9Q:A8S6DXS'
M*NT^WO7D=Q:W&EZB\+DI/ _##U'(8?SKU7^WM'_Z"MC_ .!"?XURGB\Z7?)'
M>6E_:27"?(Z).I++VXSSBNC#S<7RO9F-6%]3J="U1=6TN.Y&!)]V11_"PZ_X
M_C6F*\S\+:M_9>H^7*V+:;Y7)/"GLW^?6N\_MW2,?\A2R_\  A/\:BK3<9:;
M%PE=:FC16=_;ND?]!2R_\"$_QH_MS2?^@I9?^!"?XUE9E71H8KB/BEJ'V#P5
M/$.'NY$@'TSN/Z*?SKI_[<TK_H)V?_@0O^->3_&#6X+VZTVQM;B*:.-&F<QN
M&&2=HY'T/YUOAX.51(RK2M!F+\+M/^W^-K>0C*6J/.?RVC]6'Y5]!5Y1\%].
M M-3U)AR[K I^@W'_P!"6O5ZO&3YJK\B<-#E@+1117*=!\R?M ?\E#@_[!\?
M_H;U[+\*40_##0B44GR6[?[;5XU^T!_R4.#_ +!\?_H;UH>$/C=;>&/"FGZ-
M)H<UPUJA4RBX"ALL3TV^]5T$?1/EI_<7\J\F^/UE;/X%MKHPIY\5ZBI(%Y *
MMD9].GY5E_\ #1MG_P!"Y/\ ^!2__$UQ7Q%^+!\<:-!I<&E&R@2<3NSS;V8@
M$ =!@?-22&=/^SE*_P!J\01;OD*0-CWR]>^UXW\ ?#EUINA7^LW431#4718
MPP3&F[YOH2W_ ([7LE# ^+KC_DH$O_84;_T;7V=Y:?W%_*OB?6S(OBK43#N$
MHOI-FS[V[><8KHO[7^)G_/UXH_\ (]-H1];^6G]Q?RI-B9X1?RKY)_M?XF?\
M_7BC_P CUT'@;4OB!+XXT>/4;CQ"UFURHF6?SO+V]]V>,4K#/IFOG+]HC_D;
MM*_Z\/\ VHU?1M?.7[1'_(W:5_UX?^U&H0'I7P2_Y);IO_76;_T:U>AUYY\$
MO^26Z;_UUF_]&M7H=)@%%%% !7G/QE\5?\(YX)EM87VWFIYMH\'E4Q\[?EQ_
MP(5Z-7R7\6?%7_"4^.;@P2;[&Q_T:WQT.#\S?BV?P IH"GX.\!WOB[2]<O+;
M<!I]MOB '^MEZA/^^0WXE:U/@WXJ/ASQM%;3OMLM2Q;2Y/"OGY&_/C_@1KWS
MX;>&/^$3\$V-C(@6[D'GW7'/F-V_ 87\*^=_BIX7/A7QS=1P(4L[L_:K8CL&
M/*_@V1],4]Q'UQ6!XO\ #-MXM\-7>D7.!YJYBD(SY<@^ZWY_IFL_X;^*1XM\
M%V5^[AKN,>1=#_IHO?\ $8;\:Z^I&?'&A:KJ?PY\<K-+$R7%E,8;J#_GHF?F
M7\1R#]#7UO::K97NCQ:M#<H;&2'SQ,3@!,9R?3%>/?'?P1]HMD\5V$7[V$".
M^51]Y.BO^'0^V/2O++7Q]JUIX N?"2/_ *--,&$F>5C.2\8]BV#_ -]>M5N(
ME\=^*+KQ]XT>:V21X2XMK" #G;G X_O,>?QQVKZ3^'_A"+P7X5M]/ 5KM_WM
MW(/XI#U'T'0?3WKR?X$>"/M=X_BN_B_<VY,=D&'WI/XG_P" ]![D^E?0E)L9
M1FTNQN;N.ZGL;:6XC^Y*\2LZ_0XJ]112 ^9_B3?75_XZU W,4D0A80Q)(,?N
MUZ$>QY;_ (%7+V]O/=SI!;0R33/PL<:%F;Z 5],^+O!FG^+K'R[D>5=1C]S<
MH/F3V/JOM7SSKV@:IX5U;[+>HT4JG=%-&3M<#HRM_DBN^A4C*-NIC.+3N,_X
M1CQ!_P! +4__  $D_P *>GAKQ"CJZ:)J:LIR"+23@_E7JG@'XI)>>5I7B"54
MN3\L-X>%D] _HWOT/\_6*B5>4'9H%!/9GBEC]KDL87O;.>UN"/GCFB9#GU /
M:N/UGPQ?_P!INVFV%Q<PR?/B")GV'N#@<5[_ .)-*_M+3RT:YGA^9,=QW%<9
MI-\VFZC'.,E,[9%'=>]7&MS*ZW&Z=]#R4>&-?_Z >I_^ DG^%.'AC7_^@'J7
M_@))_A7U(CI)&KHP*L,J1W%/X]JCZV^PO8KN?+0\,Z__ - 34O\ P%D_PI1X
M9U[_ * FI?\ @+)_A7U)^%'X4UCI=B?JZ[G*_#[3'TCP98P31-%<.&EE5EVL
M&8D\CUQ@?A758H[4=JXY2<I-LW2LK"T444AGS)^T!_R4.#_L'Q_^AO75> _A
M%X6\0^"=+U:_2\^U7,;-(8Y\#.YAP,>U5/C+X)\2>(O&D-[I&DS7=LME'&9$
M9<;@SDCD^XKU'X=:;>:/X TBPU"!H+J&)EDC;&5.]CV^M5T YW_A0_@O^Y?_
M /@3_P#6KP7QAX=G\"^-IK+:)(X)5GM6E0,)(\Y7(/!]#]#7V/7F7QB\"3^+
M="AN],M_-U:Q;Y$! ,L9^\O/IPP^A]:28'8^%->M?$OAFRU:S 6*>/F,?\LV
M'#+^!!K<KQCX+Z1XN\,W=]IFL:1/!ILR^<DCLN(Y1@=C_$/_ $$5[/28'Q=/
M_P E E_["A_]&U]H5\H:U\,?&L^O:A/#H%R\<EU(Z.&3D%B0?O55_P"%9>/_
M /H!WW_?Q?\ XJJ>HCZZS1FOD7_A67C_ /Z =]_W\7_XJKFE?#?QY#K%C+)H
MMZB)<1LS&5> &'/WJ5AGU=7SE^T1_P C=I7_ %X?^U&KZ-KPWXU^#O$/B3Q)
MI]SH^ERW<,=IY;O&5X;>QQR?<4(#K_@G_P DMTW_ *ZS?^C6KT/-?(B_##QZ
MB[5T&\4>@D7_ .*I?^%9>/\ _H!WW_?Q?_BJ=D!]=9HKY%_X5GX__P"@'??]
M_%_^*KZ?\*6MS8^$=&M+Q&2Z@LHHY48Y*L$ (I- 8?Q3\5?\(IX)NIX7*WMU
M_HUJ0>0S Y;_ ("N3]<5\G6DT]M=PW5M_KH761"4# ,#D9!X/XU[=\8/#WC+
MQ9XICCT_1+F;2[&/9 ZLN)&;!=NOT7_@-=O\)/!<WA'PFW]H0^7J=[)YLZ$@
ME%'"+Q[<_P# C36@'B'_  MWXA?]!N3_ ,!(?_B*PO$7BSQ%XJ6#^W+IKK[/
MN\HFW1"N<9Y51Z"OLW:O]T?E4<L4<L3121JR."K C@@]J5P/FGX&^*O[%\7'
M2+B3%IJ@"+GHLP^X?QY7\17TY7ROK?PF\7:3XGN1HNEW$]K#/OM+F)U^[G<O
M?J/YBOI70KB]O-#L;C4K1K6^>(&X@8CY7_BZ=LT,"W<V\-Y:S6MQ&LL$R&.2
M-APRD8(-?%6LV$5CXFU#3H2WDV][) A)R=JN5'Z"OMVOEC7OAGXRN_&.IW4&
M@W#P3:A+(D@9,,ID)!^]Z4(#Z8TG3+71M)M=-LHA';6T8CC4>@_K5^D'04M(
M HHHH *Q]?\ #^G>(].>PU*#S(SRKCAHV]5/8UKCI10FT[H#YA\8>"=1\(WN
M)P9K&1OW-RHX;V/HWM75> ?BA)IGE:3KTC267W8KD\M#[-ZK^H_E[3?V%KJ=
ME+9WL"3VTHP\;C@UX%X[^'-UX8D>^L=]SI3'[W5X?9O;_:KLA.-1<L]S%Q<7
M='T'#+'/"DL3K)&XW*ZG(8>H-<+XDTO[#?F:-<03<C'\+=Q7F7@7XB7GA:9;
M.ZWW.E,?FC_BB]T_^)KW-GL?$VB":SN$F@F7=%*O9OZ>A%9.$J4O(UA-,H>%
M-2WPM8RGYD^:,GNO<?A74"O-(7FL+U9%!26%^A]1U%>AVEREY:QSQ_=<9^GM
M45(V=T:3C;4LT445F0%%%% !1110 E%8^K:Q/IDT073IIXY'2-9$D0#<QP!R
M<UHVTDDL"/+"T#L.8V8$K^(XH:L)23=B>BJ+7Z#6$T[:WF- TV[M@,%Q^M%K
M?QW5U>P(K*UK*(F)_B)16R/^^J+!S(O49K.U34SIL,+"W>>2:584C1E!+'/<
M\=JDLKJXN QN+&2U*] [JV[_ +Y)HMI<.97L7J3BJ&J:C_9MH)O)>9FE2)(T
M(!+,P4<GCJ:@L]8:XOC8W%E-:7'EF9%D96#J" 2"I/0D<>]%F',D[&M12>]9
M5IK=O=ZS=Z8BN);< ER/E?INV_[NY<_6A)L&TC7[T4E<_/XCDB-ZZZ9<R6UG
M(R2S(R<;0"Q"ELG -"5P;L=!14<3K+$DB'<K ,I]165-K$ZZE/96NFS7)A52
M[K(B@;LX^\1Z4)7!R2-JBH(G=XD=T*,P!*$YVGTXJ&.]234Y[+:P:&*.4MV(
M<L /_'#18+EVBJ5C?)?),R(RB*9X3GN5.,U#J^I2:59O=+:2W,<:L\GENJ[5
M49)^8C/X4>07TN:=%4--O)KVV\Z6SDMMV"JNZL6!&<_*32WE\EE+:*Z,WVF<
M0J1V)5FR?^^:+!?2Y>HH[5@-X@=Q+-:Z;>7%I$[(T\6WYMIPQ5<[F .>@[<9
MHM<&[&_130<C-8]SK;QWUQ;6NGW%VULJF8QL@V[AD ;B,G%"0-V-JBJ\$HN+
M>.4*ZB10VUUVL,^H[&K% PHHHH **** "HI(TEC:.1%=&&&4C((]*EHH \/\
M??"Y['S=5\/Q,]K]Z:T'+1^I3U7V[?RXWPCXRU'PC?>9;-YMI(?W]LY^5_<>
MC>]?4->5^/\ X71ZEYNJZ#&L=X?FEM@<+-ZE?1OT-=5.JFN29G*-M4:4VHZ=
MXDLDUO2I-T;X2>,C#Q/_ +0[5J>&;_R)S:2'Y)3E/9O_ *]?/FF:KJ/AS47>
MW9X91F.:&0'##/*LO^<5Z_I.H1ZGI]O?VY(#C<.>58=1^!ISI<J\CJI252/*
M]SU.D/-4-+O?MMDLA^^.&'O5^N2QDU9V%HHHH$%%%% &1KEO+/#9"&-G*WL+
MMCLH<$FM:EHH%8YV_P!+DO?%,$S?:$@6S9?,AE9/FWJ<94^F:DT+3Y+"^UA6
M$WER72O$\KERZ^5&,Y/)Y!'X5NT4^;2PN17N<_XHMY)[2S*PW$RQW<;R"W+!
MPH#9(*D'\JMZ,T9@DCBM]0A56S_IA=B<^A9B>U:IHI7TL'+K<QO$=I->V$$,
M0DW?:X&8Q]542*2?P'-5[73)K+Q,DH>XN(9;-E:69MQC8.N%![9!8_\  170
MT4[]!.";N5KV9[>SFFBA::2-&98TZN<< 5RL&CZOID6G7;2PW$MO,6F2*!A(
MXE/[SYMQ!P3NZ?P"NRI:%*P2A<.U<K!H%S>2ZLES>7EO:W%T^8(Q&%D0JHSN
M*EN>1P:ZNBDG8;C<B2-8XU1  BC  ["N5O;94\27TUQ9ZI)'*D/EO9R2*#@-
MG.QA[=:ZZCO33L#C<BAE\V%'VNFY0=KC!'L?>L:Y>?3=?FO?L=Q<6]Q;1Q;K
M==Y1D9SRO7!#]?:M[M1]:2=@:N9&@P3P6,KW$+0R3W$L_ED@E S$@''?&*EU
MV&2XT#4884+RR6LBHHZLQ4@"M&BB^MPMI8KV2,EC;HXPRQJ"#V.*I:Q;S3W&
ME-%&SB*]5W(_A78XS^9%:U%%]1VTL!Z5RVFW-[HNG_V;_9=U<3PNZPO&!Y<J
MEB5)?/R\'G/OUKJ:*=["<;ZB DJ,]:YG58T.J3/-IM\)"BB&ZL'8,XQ]UMI'
M(.?O9'-=/10G8)1NBCI(O!I5K_:./MGE+YN,?>QSTX_*KW:DI:6XTK(6BBB@
M84444 %%%% !1110!P?CKX=VGBF%KNTVVVK*O$F,++[/_P#%5YEX1NKSP[K\
MWA_58GMVE; 1_P"&3M^##O\ 2OHBN9\6>#M/\5V02?,-Y%_J+M!\\9_J/:MH
M56ERO8(^[)214TB\-E=C<<1OP_MZ&NPSD9'2N$TS3]5,:VU[!B\B^660?ZM_
M1U/H>OYBNSLXWAM4CE;<ZC!.*SE8Z*_*[21:HHHJ3G"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gxr3kcgo1wwv000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gxr3kcgo1wwv000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A /0# 2(  A$! Q$!_\0
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gxr3kcgo1wwv000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gxr3kcgo1wwv000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> /4# 2(  A$! Q$!_\0
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M'  ]S56PUG3=4W_8+ZWN=F-WE2!MN>F<4 7J*** "BBFM(B(SNP55&6)/ %
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MIKJ*JV%A;:78P65G&(K:! D: D[1Z<U:H **** $[4QHPRD%05(P01D&I**
M/'/'_P ,2SSZSH,8Z;IK)%Y)[LG^%9?@/XDS:&5TC7!+):;]JS.?GM_9L\D?
MRKW0KWS7GGC[X;P:]%)J.E1)%JW5AG:L_L>P/O6\*B:Y)D.-M4:/B&TBF\O5
M+.1)8)@,O$<KGUR/6MSP_J/VRQ5'/[Z$;6R>2.QKPGPUXKU'PA>R:-JD<C:=
MO*7-HX^:(G^)?YX[UZ7H>JP"6&_L9_.M7.-X_B7Z=C3G3:5C:'OQMU/0Z6F1
MNLBJZG*L,@T^N<@**** *FH7,EI9R3Q0><T8W%-VWCZTFGW<EY917$D/DF10
MP7?NX/O4US#]HMY(=V/,0KGTS26ML+:TA@!R(D" GOBCH+J95QXCM;=;[>!Y
MEK(L?EF0 OG'(_.M"]O19:?-=LA<1(6V@X)JA-X=@N$O@Y!:ZD$F\J"4QC@?
ME6A?6?VVPFM2Y3S4V[@.E/06I#INHMJ$)D\N-0.GES"3/Y=*JZCKYL+N6 6P
MD,4/G,6F"9&>@SU-6M+L)[&)HYKB.5>-NR()C\NM0WN@VU]=3SSA7,L'D@,N
M=G?(HTN&MC0M[@3P1RA6 D4, PY&?6J-EK45WJEU9+$ZF'[LA^[+ZX^AXJY%
M;M#:)")&++&$#GJ2!C-9=IX:@LI[6XAFE$T)8NQ8D/N^]QT&3SQ0K#U+NIZ@
M;""-UA\UI)5C"[PO)[Y-)I>I?VC#,YB,3PRF)EW!AD>A'6EU32H=6MX[>XYC
M602%<?>QVJQ;6<%G"L-O$L42\A5'%+2P:W,T:WOU>73TACW1N%):=03D9R%Z
MFKU[>"QM?.9&<;U7 ./O$#^M4?[&G36);V&Z15E<,R-"">!CANU7KZQ%]:20
M,Y3<058=5(.0?S%-B5[!'?"34)[0(0855BV>#FJNI:K/87-K#'9&<7#^6K"4
M+@]>]26&FRVLLT]Q=&XN)L!GVA0 .@ J6[T];N>TE+E?LTOF #OQC%'4>MB2
MYN/LUG+<,A/EQER@// SBEBN5>R6Y8%%:,2$'L,9HNK87-I-;EMHD0H2.V11
M%:JEBMLQW(L?EG/<8Q2 H:?JMQ>M"YT^2*VF4LDID!X'3([9J;5-3_LZ*)O)
M+^9)LR6VJONQ/05%I^EW-C(J&_>6UC7;'"4' [9/?%6=0LYKJWV0W'DN#G)0
M,K#T(/44]+AK873[LWMHDSQ&)FS\N\-WZ@CK5RL_2M.73;,0"0N=Q=F(P,DY
M.!V'M6A28(****!A1110 4W;S3J* .0\:^!++Q98Y79;ZBG,5SMZ^S8ZBO+O
M#)OO"OB&?P]J\;0K,W[IVX0L.ZGT->_D9&*P_$OABP\3V M+T.KHP>&=/OQ-
MZ@_TK6%5I<KV'%\LN9#?#][\AM'/S+RN>X]*W@<UQ^@V=P\VV:9/-M7*2.H^
M^1W'UKKU]?6LV:5>6]T.HHHI&04444 &**** "BBB@ I,4M% !1110 F**6B
;@!,48I:* "BBB@!,4M%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
